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Background: MicroRNAs (miRNAs) are short, non-coding RNAs that are involved in 
the post-transcriptional regulation of gene expression. They are important regulators 
of diverse physiological and pathophysiological processes. MiRNA families and 
clusters are two key features in miRNA biology. Previous work on miRNAs in 
abdominal aortic aneurysm has focused on miR-195, a member of the miR-15 family. 
MiR-195 exhibits high homology with the other members of the family and therefore, 
its manipulation, overexpression or inhibition, inevitably affects the expression of 
other miRNAs of the family.  
 
Objective: The current project explores the use of CRISPR/Cas9 as a gene editing 
tool to delineate the expression of miRNA families.  
 
Methods and Results: We employed CRISPR/Cas9, an RNA-guided system able to 
provide highly specific alterations of targeted sequences in the genome of eukaryotic 
cells. We designed RNA guides and validated their efficiency in editing the mir-195 
locus in various cell types while no off-target mutagenesis was observed. 
Quantification of the levels of miR-195 and other members of the miR-15 family, 
revealed a significant decrease of miR-195 and in the expression of the other miRNA 
in the cluster, miR-497. Three more miRNA clusters composed of miRNA members 
of the same or different family were analysed. Although no gene editing was detected 
in the miR-497 genomic locus, computational simulation revealed alteration in the 
three-dimensional structure of the pri-miR-497~195 that may affect its processing. 
RNA pull-down experiments, using wild type and an edited pri-miRNA of shorter 
length, were performed and the eluted proteins were analysed by Mass Spectrometry.  
 
Conclusions: Our findings suggest that CRISPR/Cas9 is a powerful gene editing tool 
able to provide highly specific editing of the genomic locus of miRNAs, resulting in 
decrease of the levels of their mature transcripts. They also highlight different 
regulatory mechanisms in miRNA cluster regulation and function.  
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1 Chapter 1 INTRODUCTION 
 
1.1 MicroRNAs (miRNAs) 
 
1.1.1 MiRNA biogenesis 
 
MicroRNAs (miRNAs) are short, 19-24 nucleotide long, non-coding RNA molecules 
that regulate gene expression post-transcriptionally by binding target transcripts in 
animals through partial complementarity1. They represent the major subgroup of 
small ncRNAs, with more than 2000 miRNAs identified in the human genome2. In 
addition, they are evolutionary conserved and display distinct tissue expression 
profile3. 
 
1.1.1.1 MiRNA transcription and processing 
 
MiRNA genes are transcribed by RNA Polymerase II as long precursor molecules, 
called primary miRNAs (pri-miRNAs), which can encode single or multiple miRNAs, 
forming miRNA clusters4, (Figure 1.1). The pri-miRNAs consist of one or more hairpin-
like structures, ~100nt long, which consist of a long stem with bulges and a terminal 
loop, (Figure 1.2). In a first step, they are processed by RNase III Drosha and its co-
factor, DGCR8, which form the microprocessor complex5, to release a ~65nt long 
hairpin-shaped precursor (pre-miRNA)6. It has been previously shown that a very 
specific and precise recognition of the primary transcript is needed in order for the 
Drosha-DGCR8 complex to recognise and cleave the pri-miRNAs. More specifically, 
basal elements are used as rulers by Drosha while DGCR8 ensures fidelity of the 
processing by interacting with apical elements7, 8. Thus it becomes apparent that 
sequence changes, like the abolition of specific sequence motifs, such as a UG motif 
at the base of the hairpin, a UGU/GUG motif in the apical loop and a CNNC motif 
downstream of the hairpin,  as well as structural alterations in the secondary structure 
of the hairpin of the pri-miRNA, such as a shorter terminal loop, the size and the 
position of the bulge, the apical loop size,  and especially the single stranded state of 




The pre-miRNA is, then, exported to the cytoplasm with the help of the Exportin512 
and is further processed by another RNase III protein, Dicer13, (Figure 1.1). Drosha 
cleavage generates a two-nucleotide-long overhang on the 3’-end of the pre-miRNA 
that is bound by Dicer14. More specifically, the two cleavage sites of Dicer bind to 
the 3’-end of dsRNAs at a fixed distance, of 21–25 nucleotides in length (3’-
counting rule), that is dependable on the type of Dicer15,16,17. In mammals, an 
additional mechanism is employed by Dicer to determine the cleavage site of pre-
miRNA; it binds to the non-stable 5′-phosphorylated end of the pre-miRNA and 
cleaves it, at a distance of 22nt away from the 5′-end (5′-counting rule)18 while a 
strongly paired 5′-end, through G-C base pairing, impairs its binding and further 
processing. Human Dicer shows two basic pockets in its PAZ domain that bind to 
the 5′-end and 3′-end of the pre-miRNA and are spatially arranged to occupy 
simultaneously the 5′-end and 3′-end of the pre-miRNA only in the case that there 
is a two-nucleotide 3′-overhang18,19, (Figure 1.3).  
 
 
Figure 1.1 MiRNA biogenesis. MiRNAs mature through a multistep process. They are transcribed into 
pri-miRNAs and processed to pre-miRNAs by Drosha. The pre-miRNA is exported to the cytoplasm, 
where it is further cleaved to the miRNA:miRNA* duplex by Dicer. Both strands can be loaded to the 






Figure 1.2. Primary miRNA transcript processing. Drosha and DGCR8, the microprocessor 
complex, recognises the single-stranded parts of the transcript, the length of the stem (∼35 bp) and 
the terminal loop of the primary microRNA. Microprocessor measures the distances from the basal 
junction and the apical loop, ∼11 bp and ∼22 bp respectively, and Drosha cleaves the primary 




Figure 1.3. Pre-miRNA processing by Dicer. The PAZ (PIWI –Argonaute (AGO)–ZWILLE) domain of 
the Dicer recognises the ends of pre-miRNA. The two pockets of PAZ interact with the 5′-phosphorylated 
and the 3’-end of the pre-miRNA. Dicer measures a set distance from both termini, since both RNase 
III domains are placed ∼22nt away from the termini. From  Ha M. et al., 2014. 
 
Dicer’s processing results in a short (19-24 nucleotide) miRNA:miRNA* duplex13. In 
most cases, the miRNA strand is selected as the mature miRNA, that then binds the 
Argonaute 2 (Ago2) protein of the RNA induced Silencing Complex (RISC)22, (Figure 
1.1), while the miRNA* strand is degraded. Loaded into the RISC, miRNAs function 
as sequence-specific guides that direct the complex to mRNA transcripts, targeting 
mostly the 3’ untranslated region (UTR) but, in some cases, also the 5’-UTR and the 
coding region. Although the mechanism of miRNA:mRNA interaction is not well 
understood, in mammalian cells this it occurs through incomplete complementarity23. 
Nucleotides 2-8 at the 5’-end of the miRNA constitute its ‘seed region’ that plays a 
critical role in the interaction of miRNA:mRNA. Binding of the miRNA to the miRNA 
Response Elements (MRE) on its targets negatively regulates their expression by 
preventing their translation and triggering transcript degradation mainly through de-
adenylation. Consequently, miRNAs induce post transcriptional gene silencing by 
either the translational repression of the mRNA, its de-adenylation or its degradation, 
process that is influenced by the percentage of complementarity between the miRNA 




Because of the short length of the miRNA seed sequence and the partial 
complementarity that is needed for a miRNA to recognise and bind its corresponding 
targets, single miRNAs can regulate more than one gene. This partial 
complementarity enables miRNAs to target multiple transcripts that, in many cases, 
are effectors of the same signalling pathway thus creating a complex regulatory 
network and eliciting system wide biological responses25. Thus, miRNAs with similar 
seed regions may exert control on set of genes with similar, but not identical sequence 
to differing degrees. 
 
Moreover, miRNAs with similar sequences form families that are comprised of 
multiple members that share a common seed region and often display high homology 
in the rest of their sequence (Figure 1.4). This means that a set of miRNAs can 
suppress the same gene or set of genes. Additionally, the fact that miRNAs are 
organised in families imply important roles for them in regulating the expression levels 
of their mRNA targets with their specific expression further supplementing a flexibility 
in regulating. Furthermore, control on the expression of genes is partial and a single 
mRNA can have multiple binding sites for miRNAs. 
 
 
Figure 1.4. MiR-15 family. The extended miR-15 family is depicted with the aligned sequence of all the 
members and their seed sequence highlighted. From Finnerty et al., 2010.   
 
Overall, miRNAs seem to be an evolutionary tool developed to absorb perturbations, 
reinforce the robustness of biological systems and ensure that gene expression 
occurs both at desirable levels and with appropriate timing. MiRNAs are largely 
considered to be the fine tuners of gene expression that exert mild effects under basal 
conditions and have more pronounced responses after stress. Intriguingly, several 
24 
 
miRNAs may target the same transcript forming a co-targeting network and implying 
redundancy in miRNA function26. 
 
Through regulating the expression of various effectors that function at different steps 
in complex biological pathways, miRNAs can coordinate important cellular processes 
such as cell differentiation, metabolism, and apoptosis23. Thus, miRNAs are able, by 
combining mild effects on multiple individual mRNA targets, to act synergistically 
within a common pathway in order to exert a more pronounced outcome26. Because 
miRNAs contribute to the gene expression in various burdensome diseases like 
cancer and cardiovascular diseases1, they have emerged as an important field of 
study. Nonetheless, taking into consideration the complexity they present, studying 
the functions or manipulating their effects presents great challenges27. 
 
1.1.1.2 RNA Binding Proteins (RBPs) for the processing of miRNAs 
 
RBPs are proteins that are capable of binding double or single stranded RNA in cells 
and participate in forming ribonucleoprotein complexes that are involved in gene 
expression28. They participate in the process of the post transcriptional gene 
regulation of coding and non-coding RNAs involving the transport, maturation and 
stability of the transcripts. RBPs bind RNAs using sequence and/or structural 
motifs in RNA molecules via using RNA-binding domains (RBDs) such as the RNA 
recognition motif (RRM)29, K homology (KH) domain30, DEAD box helicase 
domain31, double-stranded RNA-binding motif (DSRM) or a zinc-finger domain32. 
Different mRNA-binding domain classes of RBPs are found in high frequency either 
in multiple repeats or in combination with other RBDs33. The most prominent 
example is that of ssRBD such as RPMs, KH domains and zinc-finger domains, 
that recognise motifs of 4-6 nucleotides and work in combinations34. Nonetheless, 
recent findings in respect of the structure and the function of the RBPs through the 
study of RNP machines like the spliceosome35,36,37 and the ribosome38,39,40, reveal 
the complexity of unconventional protein-RNA interactions that do not necessitate 
canonical RBDs. 
 
RBPs exert effects on the miRNA biogenesis by interacting with Drosha, Dicer and 
specific miRNAs. RNase III proteins often interact with dsRBD proteins, such as Dcr-
1 in Drosophila spp. that binds one of the two isoforms of Loquacious (Loqs), Loqs-
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PA and Loqs-PB, necessary for the production of most miRNAs, each of which 
contains three dsRBDs41,42. Furthermore, a set of proteins, such as p68 and p72 are 
essential for the processing of a subset of miRNAs by Drosha43 while proteins R-
SMAd, SMAD1–3, SMAD5 and p53 modulate the activity of the Microprocessor 
complex through interaction with p6844,45,46. TDP43 RBP was reported to increase 
Drosha’s stability47 and to promote Drosha and Dicer processing48. It has also been 
demonstrated that human Dicer interacts with TAR RNA-binding protein (TRBP), a 
homologue of Loqs-PB, in a similar way13,49 while cofactor PACT, that harbours a 
dsRBD, has also been shown to associate with mammalian Dicer50. Similarly, TRBP 
regulates the efficiency of processing of certain pre-miRNAs and regulates mature 
miRNA length51. Nonetheless, contrary to Loqs, mammalian TRBP or PACT are not 
essential for the Dicer-mediated processing of the pre-miRNA processing49. 
 
Moreover, various proteins have been reported to selectively bind the terminal loop 
of pri-miRNA. RBPs heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) and 
KH-type splicing regulatory protein (KSRP) facilitate the processing by Drosha via 
binding to the terminal loop of pri-miR-18a and pri-let-752,53. Moreover, pri-let-7 is 
also regulated by LIN28A and its paralogue LIN28B, that bind its terminal loop and 
arrests both Drosha and Dicer-mediated processing. 
 
Additionally, negative feedback loops between miRNAs and RBPs that regulate 
their expression levels have been reported. Human DICER1 mRNA is targeted by 
let-7 miRNA54. RBPs partake in the regulation of the processing of pre-miRNA. 
KSRP, interacts with the terminal loop of various pre-miRNAs and modulates their 
maturation process through affecting the Dicer-mediated processing55 while LIN28 
proteins, through binding to the terminal loop of pre-let-7, regulates the processing 
by Dicer by inducing oligouridylation of the pre-miRNA56. Additionally, modifications 
in the sequence of the stem loop of miRNA, through RNA editing with ADAR1, have 
demonstrated diminished maturation either at the processing by Drosha, as in the 






1.2 Abdominal Aortic Aneurysm (AAA) 
 
AAA is defined as a focal dilation of the wall of the abdominal aorta due to the loss of 
its elasticity,  exceeding 50% of its normal size59. It corresponds to a region of the 
abdominal aorta that has weakened wall and is dilated usually affecting the infra-renal 
segment60, (Figure 1.5). Aneurysmal disease is more common in the elderly 
population (>65 years old) with its prevalence in western populations being 0.4–
0.67%61. Although mortality rate of AAA is improving because of the better 
intervention techniques62, it still is a significant cause of death63,64. 
 
 
Figure 1.5. Angiogram of AAA. 3D MR angiogram with horizontal line demonstrating the location of 
the infrarenal area that present AAA. The distance from the left renal artery is showcased with a double-
headed arrow. From Kramer et al., 2007. 
 
Risk factors for development of AAA include advanced age (>65 years old), gender, 
with males presenting higher prevalence, genetic predilection via family 
history, obesity and smoking66,67. 
 
AAA is an asymptomatic disease68, a characteristic that renders it more dangerous 
since patients are unaware of their condition. A major implication of the disease is the 
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acute rupture of the aneurysm, which leads to heavy bleeding into the abdomen that 
can be fatal and is associated with up to 80% mortality61. Given the burden of AAA 
and the lack of symptoms, that makes the diagnosis more difficult, there is a high 
interest for the discovery of new biomarkers that could indicate AAA development and 
rupture. 
 
1.2.1 AAA pathogenesis 
 
Although aneurysm formation is a complex process multiple histological features, 
important for the development of the disease, have been described such as vascular 
inflammatory processes, extracellular matrix (ECM) degradation and vascular smooth 
muscle cells (VSMCs) apoptosis69. In more detail, chronic infiltration of inflammatory 
cells in the adventitial and medial layers of the aorta, elastin degeneration and medial 
attenuation have been reported to participate in the formation of the disease69. These 
inflammatory stimuli together with mechanical injury that lead to phenotypic changes 
affect the proliferation, migration and apoptosis of the cells70. The infiltration of 
macrophages, leukocytes and lymphocytes71, that lead to a higher production of 
cytokines under the effects of which the inflammatory response progresses further, 
results in neovascularisation, loss of SMCs and matrix degradation72,73,74. Further to 
this, ECM degradation seems to advance due to locally increased levels of matrix 
metalloproteinases (MMPs), cysteine and serine proteases which result in different 
degradation among collagen isoforms (type I and III) and the degradation of elastin 
which affects the elasticity of the aorta75. 
 
Moreover, both T-cells and B lymphocytes have been shown to be abundant in 
aneurysmal tissues and therefore they have been implicated in the progression of 
AAA process while depletion of B-cell has protective effects against the disease71. 
Additionally, regulatory T-cells have a protective effect against the formation of AAA 
with the secretion of IL-10 and TGF-β being implicated by stabilising the aneurysm73 






1.2.2 SMCs in health and in AAA disease 
 
1.2.2.1 SMCs function and biology  
 
VSMCs have been shown to play a major role in the pathogenesis of many disorders 
such as the aortic aneurysm formation, as they are key components of blood 
vessels76. They regulate the diameter of small arteries, controlling blood pressure and 
they are the main cells that constitute the aortic wall able to synthesise ECM proteins, 
participate in the regulation of proteases and protease inhibitors and recruit 
inflammatory cells upon cell injury. VSMCs do not proliferate at high rate, under 
physiological conditions, unless they undergo a phenotypic switch, from contractile to 
proliferating phenotype,  as a response to stimuli like vascular injury and 
hypertension77. Additionally, the ability of VSMCs to contract and proliferate is 
affected by mechanical forces, ROS, ECM components and the TGF-β and SMAD3 
signalling among others, changes that occur during aneurysmal formation78, 79, 80. In 
light of this, the pathophysiology of aortic aneurysms is associated with VSMC 
apoptosis and ECM proteins and elastin degradation, features that distinguish it from 
atherosclerosis albeit the common risk factors81. However, it is not clear how VSMCs 
participate in the formation of AAA. They can contribute to the development of the 
disease through inflammation and production of MMPs82, while a third pathway of 
differential production of ECM has been suggested. It has been reported in mouse 
models that aneurysm formation can be reversed through prevention of VSMC 
apoptosis with caspase inhibitor treatment83, data that support the important role of 
VSMCs in aneurysm pathogenesis. It, therefore, becomes clear that VSMCs can 
exert important control on the homeostasis of the aortic ECM.  
 
Although VSMCs partake in the onset and development of aortic aneurysms through 
loss of synthetic capability, due to cell apoptosis or other mechanisms84, there is 
growing evidence that aortic VSMCs are also capable of participating in the 
degenerative process85. Degradation of the ECM of the aortic wall by elastases has 
been considered to be predominantly due to the infiltration of inflammatory cells86, 
namely macrophages84 as well as neutrophils87 and mast cells88, as it has been 
shown by studies in murine models89. However, it has also been reported that 
apoptosis of aortic VSMCs may contribute to the pathogenesis of AAA via reducing 
the repair rate of the damaged aortic wall90 while AAA-derived cells demonstrated 
increased levels of proteases and cysteine classes that participate in the elastolysis82. 
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More specifically, a lack of upregulation of Tissue Inhibitor of Metalloproteinase 
(TIMP) -1 and -2 was reported while there was considerable upregulation of TIMP-3 
whilst there is an increased MMP activity data that support an imbalanced proteolytic 
state91. 
 
These findings suggest that VSMCs can also participate in the formation of AAA 
through degradation of ECM via elastolytic activity82. In addition, evaluation of 
interactions of VSMC with macrophages demonstrated a significant increase in the 
elastolytic activity of the AAA-derived cells82. Further studies showed that in the case 
of AAA, the protein levels of MMP-9 and MMP-2 protein levels are substantially 
increased compared to non-AAA cells. Elevated levels of MMP-2 and MMP-9 activity 
have been reported in the aneurysmal part of the mouse aorta after AngII 
infusion92. MMP-9 is the most abundant gelatinolytic MMP and is secreted in high 
levels in AAA tissue with MMP-9-deficient mice demonstrating normal levels of the 
elastic lamellae in the aortic wall and, interestingly, resistance to the development of 
aneurysm85. These data suggest a posttranscriptional regulation in normal cells that 
is abrogated in the context of AAA82. A meta-analysis on serum and plasma levels 
has implicated higher levels of circulating MMP-9 to AAA93 while the macrophage 
origin of the MMP-9 was shown when mice were infused with non-MMP9-deficient 
macrophages, reversing the protection effects on AAA94. Taken together, these data 
demonstrate that VSMCs, in the case of AAA, present a pro-elastolytic phenotype 
that is further pronounced in the presence of activated macrophages. This appears 
to be the effect of differentiated post-transcriptional control of MMP-9 synthesis 
resulting in activation of elastolytic MMPs82. 
 
1.2.2.2 MiRNAs and AAA 
 
The maintenance of the physiological function of the cardiovascular system is of high 
importance for mammals while miRNA networks orchestrate cellular homeostasis, 
vascular inflammation, angiogenesis and metabolism and have been implicated in 
the control of important biological processes in the cardiovascular system and in 
many aspects of the development and pathophysiology of cardiovascular diseases95. 
A plethora of miRNAs, from the same or different families, have been implicated in 
various cardiovascular diseases, a feature that demonstrates the significant role the 
miRNA networks play in the physiology of the heart and blood vessels as well as the 
sensitivity they both demonstrate to disease26, 96,97. Studies have reported 
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perturbations in the levels of a vast number of miRNAs in both humans and mice 
models for many cardiovascular diseases such as heart failure, myocardial infarction, 
atherosclerosis and AAA26, 98.  
 
MiRNAs have also been strongly implicated in the formation and development of the 
AAA. Gain- and loss-of-function assays have demonstrated a direct link of specific 
miRNAs with AAA and highlighted the potential they have as novel targets for 
therapeutic applications99,100,101,102. Accumulating data, demonstrate that they are 
important regulators of the function of vascular cell homeostasis in atherosclerotic 
and inflammatory processes. As an example of the role of miRNAs in the function of 
SMCs, postnatal Dicer deletion led to loss of contractile differentiation for VSMCs and 
to lower blood pressure103. A variety of miRNAs have been connected with 
remodelling of vascular cells including miR-126, miR-10a, miR-143~145 and the miR-
15/16 families26, 104. 
 
In more detail, in the vasculature, inhibition of miR-29 has been correlated with the 
reduction of the aortic aneurysm formation105. Additionally, members of the miR-15 
family have been implicated in collagen remodelling and the postnatal silencing of 
elastin in aortas101, 106. Intriguingly, miR-195, a member of the miR-15 family, is known 
to share many of the same targets as miR-29b101 with the seed sequence of miR-15 
miRNAs (5’-AGCAGC-3’) differing only by one nucleotide from that of the miR-29 
family miRNAs (5’-AGCACC-3’). Proteomic analysis of the secretome of murine aortic 
SMCs revealed that miR-195 targets a group of ECM proteins, including elastin, 
collagens and proteoglycans. In mice treated with antagomiR-195, higher aortic 
elastin expression was associated with an increase of MMP-2 and MMP-9 while in 
human plasma the presence of AAA and aortic diameter was inversely correlated to 
the levels of miR-19598. 
 
1.2.2.3 MiR-195 and AAA 
 
MiR-195 is a member of the miR-15 family and is located on chromosome 17 in 
humans and chromosome 11 in mice (Supplementary Table 1). It is transcribed 
together with miR-497 in one primary transcript, forming a homo-cluster since both 
miRNAs are members of the same miRNA family and they share the same seed 
sequence and high homology throughout their sequence (Figure 1.4). Although miR-
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15 family and specifically miR-195 is not studied as intensely as other miRNAs, it is 
known to participate in various disorders like cardiovascular diseases and 
tumorigenesis98, 107. 
 
The ECM is an important component of the structure of aortic wall that determines 
the formation of aneurysm by the dilatation of the aortic wall108. AAAs are 
characterised by decreased levels of elastin and high turnover of collagen. Various 
miRNAs have been implicated in collagen turnover and as a result also in the 
development of the disease, with the members of the miR-15 family participating in 
postnatal silencing of elastin101. The murine miR-15 family consists of 6 highly 
conserved microRNAs (miR-15a, miR-15b, miR-16-1, miR-16-2, miR-195, and miR-
497), which are clustered in 3 separate chromosomes. They have a common seed 
region (AGCAGCA) and varying degrees of sequence homology in the 3′ region of 
the mature microRNA109,98. Expression of miR-195 and miR-497, miRNAs that are 
transcribed in the same primary transcript, is altered in human aortic 
specimens110 while various ECM transcripts have been shown to be directly targeted 
by miR-195 in H4 cancer111 results that were confirmed in vivo in murine models 
where antagomiRs to miR-195 upregulated elastin levels98.  
 
Although miR-195 is not extensively studied in the context of AAA98, data from 
preliminary studies suggest that downregulation of the miRNA lead to de-repression 
of MMP-2 while it is implicated in the downregulation of Smad3 levels by directly 
targeting it, thus leading to decreased proliferation of VSMCs, and increased 
expression of Collagen III112. From the above, it becomes clear that miR-195 is 
strongly correlated with the onset and the development of the disease although 
further studies are needed to conclusively demonstrate the connection. 
 
1.2.2.4 MiR-143~145 in AAA 
 
MiR-143 and miR-145 are two highly conserved miRNAs that form a hetero-cluster 
with their genes located on chromosome 5 in humans and chromosome 18 in mice 
(Supplementary Table 1). They are transcribed as one primary transcript although the 





MiR-145 is highly expressed in VSMCs of healthy rat carotid arteries113 while 
expression of both miRNAs of the cluster are observed during the differentiation of 
stem cells to VSMCs114. The miR-143~145 cluster has been implicated both in the 
differentiation and proliferation of the VSMCs since it has been reported that 
downregulation of their expression leads to higher proliferation of the cells with 
upregulation of their levels having the opposite effect114. ELK1 and KLF4 are among 
the validated targets of miR-143 and miR-145, respectively, and both factors control 
the differentiation of the VSMCs. In more detail, ELK1 promotes the proliferation of 
the cells while KLF4 regulates the contractile phenotype of the cells. Targeting by the 
miR-143~145 cluster modulates the phenotypic switch114, 115. 
 
 
Figure 1.6. Hetero-cluster miR-143~145 controls VSMC differentiation. VSMC differentiation is 
regulated by Myocardin and myocardin-related transcription factors which also regulate the expression 
of miR-143 and miR-145 through a feedback loop. Inhibition of KLF4 miR-145 leads to SMC 
differentiation while targeting of ELK1 by miR-143 inhibits proliferation of SMCs. From Welten et al., 
2016. 
 
Studies in murine models where an IRES-lacZ promoter was fused to the pre-miR-
143 sequence demonstrated that the expression of mmu-miR-143 and mmu-mR-145 
in heterozygous mice was active in the heart in early developmental stages but at 
later stages was exclusively expressed in SMCs in the cardiovascular system, 
bladder and lungs, among other organs, while their expression levels were stable 
across adulthood78. These data unveiled miR-143~145 as a cell-type specific cluster 




Although data from AAA tissues showed that there was no differences in the levels 
of neither miR-143 nor miR-145 when compared to healthy tissue, studies on 
intracranial aneurysm and thoracic aorta aneurysm demonstrated a decrease in the 
levels of both miRNAs116,117,118. Additionally, data from double knock-out mice 
revealed differences both in the structure and the phenotype of the VSMCs of the 
aorta as well as an increase in the migration and proliferation rate of the cells78, 119. 
More specifically, a significant decrease in the numbers of contractile VSMCs were 
observed by electron microscopy and a phenotypic switch to a synthetic phenotype 
was demonstrated together with the decrease in the size of the cells, alterations that 
contributed to a thinner size of the aorta. These data, together with the fact that 
neither the number nor the size of VSMCs were differentiated in other arteries of adult 
knock-out mice, suggest that the differences observed in the aorta were due to the 
phenotypic switch of the cells and to their lack of ability to adjust to the environment78. 
 
In fact, accumulation of synthetic VSMCs in knock-out vessels has been implicated 
in the loss of the vessels’ ability to develop the same contractile forces. Synthetic 
VSMCs, contrary to the proliferative ones, demonstrate contractility defects that 
influence the response of the mutant vessels while various mechanisms have been 
implicated in the development of this phenotype. These suggest that miR-143 and 
miR-145 exert control the phenotypic switch to synthetic cells of smaller size that 
display reduced response to receptor-mediated signals78. 
 
1.2.2.5 MiR-17~92 cluster in cardiovascular diseases 
 
MiR-17~92 is a well-studied cluster that has been implicated in many diseases 
including tumorigenesis, aging, neurodegenerative as well as cardiovascular 
diseases120, 121. It is located on chromosome 13 in humans and chromosome 14 in 
mice (Supplementary Table 1) and is transcribed in one primary transcript, pri-miR-
17~92, harbouring 6 miRNA hairpins, miR-17, miR-18a, miR-19a, miR-19b-1, miR-
20a and miR-92a-1 that comprise four different miRNA families122. 
 
Two paralogues of the main cluster have also been described (Figure 1.7), the miR-
106b~25, located on chromosome 7 in humans, (7q22.1), in the 13th intron of 
the MCM7 gene, and chromosome 5 in mice, and the miR-106a/363 cluster, located 
on chromosome X in both organisms (Supplementary Table 1). In more detail, miR-
106b~25 consists of six miRNAs miR-106a, miR-18b, miR-20b, miR-19b-2, miR-92a-
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2 and miR-363 (Figure 1.7, middle panel) with miR-106b~25 cluster comprising three 
miRNAs, miR-106b, miR-93 and miR-25 (Figure 1.7, lower panel). Both miR-17~92 
and miR-106b~25 are expressed abundantly in multiple tissues although miR-
106a~363 is expressed at lower levels120, 123. MiR-17~92 cluster, together with the 
paralogue ones, presents a combined total of 15 miRNAs that form four miRNA 
families grouped according to their seed sequences, the miR-17 family, the miR-18 
family, the miR-19 family and the miR-92 family. 
 
 
Figure 1.7. Schematic representation of miR-17~92 genomic locus cluster along with the genomic 
loci of its paralogue clusters. MiR-17~92 cluster consists of 6 members that form families with miRNAs 
that belong to paralogue clusters, miR-106a~363 and miR-106b~25. MiRNAs depicted in red rectangular 
belong to the miR-17 family, in blue rectangular to the miR-18 family, green to miR-19 family and orange 
to miR-92a family. From Mogilyansky et al., 2013. 
 
Upregulation of miR-19a, miR-19b and miR-92a is implicated in the development of 
AAA, implying a differential expression for these miRNAs due to post-transcriptional 
regulation124. Additionally, different miRNAs of the cluster show implication in the 
control of different pathways of the pathophysiology of AAA and the development of 
the disease125-127. More specifically, phosphatase and tensin homolog (PTEN) is one 
of the validated targets of the cluster as shown in in vitro experiments128. MREs for 
miR-19a and miR-19b-1 have been reported in the 3’-UTR of PTEN while introduction 
of the two miRNAs in miR-17~92-deficient cells repressed PTEN expression levels120.  
 
However, studies on the vascular expression of miRNAs miR-19a and miR-19b-1 are 
limited and provide controversial results. Although studies in murine endothelial 
differentiation of stem cells have reported increased miR-19 levels, antagomir 
administration did not affect endothelial markers expression129. Additionally, miR-92a 
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is highly expressed in endothelial cells with this overexpression inhibiting 
angiogenesis in ischemic conditions130. Studies in endothelial cells isolated from 
patients with coronary artery disease (CAD) demonstrated elevated levels of both 
miR-17 and miR-92a131 while studies in patients with acute coronary syndrome 
demonstrated increased levels of miR-19a contrary to the results from patients with 
CAD where a decrease in miR-19a levels was observed compared to healthy 
controls132. 
 
TGF-β has been shown by numerous studies to be implicated in every step of the 
development of AAA and TGF-β signaling has been shown to be down-regulated in 
human AAA133 while in murine models it inhibits AAA134. TGF-β  has been implicated 
in the inhibition of infiltration of inflammatory cells135 while it promotes elastin and 
collagen formation136. By doing so, TGF-β hinders the degradation of the ECM of the 
aortic wall by inhibiting the TNF-α-induced MMP-9 expression137. 
 
Interestingly, the miRNAs of the cluster show antagonistic effects with regards to the 
regulation of various targets and pathways. MiR-18a, miR-19a, miR-17 and miR-20 
have been reported to target the TGF-β tumour suppressor pathway, thus facilitating 
tumour angiogenesis, while miR-17 and miR-20 target the E2F transcription factor 
family138-142. In contrast to the effects mentioned above, miR-92a, which resides in the 
same cluster and is transcribed in the same primary transcript, has been shown to 
have antiangiogenic activity130, features that highlight the regulation that the miRNA 
clusters exert in the same pathways and how they can control the equilibrium in these 
pathways by targeting different proteins that have contrasting effects. 
 
With regards to SMCs, studies in mouse models of Pulmonary Hypertension (PH) 
showed that knock out of miR-17~92 cluster in SMCs attenuated hypoxia-induced PH 
whilst reconstitution of the expression of the cluster restored the condition. 
Additionally, it was demonstrated that miR-17~92 regulates SMC phenotype via the 
PDLIM5/transforming growth factor TGF-β 3/Smad3 pathway143. Furthermore, miR-
17~92 is able to act on TGF-β and multiple TGF-β receptors, by inducing TGF-β 3 




Discrepancies in the proliferation of VSMCs result in vascular remodeling and serve 
a key role in several vascular disorders, including atherosclerosis144, pulmonary artery 
hypertension145 and AAA146. However, the molecular mechanism underlying VSMC 
proliferation remains unclear. Studies have indicated that miRNA may also have roles 
in AAA through controlling the physiology and proliferation of VSMCs121. Studies have 
revealed that the miR-17~92 cluster promotes VSMC proliferation in a murine 
model147 and mediates inhibition of VSMC proliferation via bone morphogenetic 
protein receptor type II (BMPR2)148 while overexpression of miR-17 with mimics 
demonstrated that miR-17 stimulates VSMC proliferation. MiR-17 also targets the 3’-
UTR of retinoblastoma (RB) protein, which regulates the proliferation rate of the 
VSMCs149. These results suggested that overexpression of miR-17 stimulated VSMC 
proliferation and enhanced cell cycle progression through promoting G1/S transition 
by increasing the levels of PCNA and E2F1. 
 
Excess proliferation of VSMCs and inflammation have a key role in several vascular 
disorders while proliferation of VSMCs under inflammation is regulated by NF-κB 
p65/microRNA-17/RB pathway activation150. It has been previously shown that NF-
κB regulates miR-143 expression, enhancing the metastasis of hepatocellular 
carcinoma151. The transcription factor NF-κB is activated in and is a master regulator 
of the vascular inflammatory response in many vascular diseases, including AAA 
formation69. NF-κB p65 signalling directly regulates the miR-17 promoter activity, 
through potential p65 binding sites in the upstream regulatory region of the miR-17 
gene, while suppression of RB levels, by activation of p65, was de-repressed when 
miR-17 was downregulated with inhibitors150. NF-κB p65 regulates the expression of 
miR-17, while miR-17 directly targets RB which modulates the proliferation of VSMCs 
through interacting with E2Fs. Taken together, these data support that VSMC 
proliferation is regulated by the NF-κB p65/miR-17/RB pathway150. 
 
1.2.2.6 Limitations in miRNA research 
 
Although, modulating miRNAs expression enables us to elucidate their role in 
disease, the specific inhibition of certain miRNAs can be cumbersome. So far, there 
are two common approaches employed in the research of miRNA inhibition: the 




AntimiRs are chemically modified, single stranded DNA oligonucleotides that are 
used to inhibit miRNAs. They can be partially or fully complementary to their 
corresponding miRNA and they work by hybridising to their target miRNAs, thus 
inhibiting their function152. Nonetheless, due to their small size, the employment of 
antimiRs as a tool in miRNA studies carries the risk of affecting RNA molecules of 
even partial complementarity and miRNAs other than the targeted one, thus inducing 
unwanted inhibition of miRNAs of the same family (Figure 1.8). 
 
Moreover, antagomiRs are synthetic, single-stranded RNA analogues that are used 
in animal models which are fully complementary to miRNAs. They are 3’ cholesterol-
conjugated, to facilitate the uptake by the cells, and they can inhibit miRNAs by 
hybridisation153. Systemic administration of the antagomiRs can effectively reduce the 
levels of the targeted miRNAs for a sufficient amount of time152. However, given that 
miRNAs of the same family share the same seed sequence, it becomes apparent that 
antagomiRs may have adverse effects. They are unable of providing specific 
targeting, and thus inhibition, of only one miRNA but instead they result in inhibition 
of multiple miRNAs of one family. 
 
 
Figure 1.8. Expression levels of 5 members of the miR-15 family upon inhibition mmu-miR-195a. 
The levels of 5 members of the miR-15 family were quantified with qPCR following transfection of mouse 
VSMCs with LNA-195a. Except for mmu-miR-15a, the other miRNAs show a downregulation with mmu-
miR-195a, mmu-miR-16 and mmu-miR-497a showing statistical significance. Lataniotis et al., 2017. 
 
Taking into consideration the short length of the mature miRNAs (19-24 nucleotides) 
and that miRNAs of the same family share the highly homologous 7 nucleotide seed 
38 
 
sequence, it becomes evident that in order to sufficiently inhibit specific miRNAs, 
without affecting miRNAs of the same family, a different approach is needed. Given 
the higher diversity of the genomic loci among different miRNAs, targeting the 
genomic locus of a miRNA gene rather than the mature product seems to be a 
promising alternative. Editing the miRNA genes will subsequently affect the 
maturation process and will result in sufficient inhibition of specific miRNAs. Various 
gene editing platforms have been developed over the past years. Zinc-Finger 
Nucleases (ZFN), Transcription Activator-like Effector Nucleases (TALENs) and 
Clustered Regular Interspaced Short Palindromic Repeats (CRISPR) as well as 
studies in vitro and in multiple organism models have employed the above mentioned 
techniques to specifically inhibit miRNAs154, 155, 156, 157, 158. 
 
1.3 Gene editing 
 
Gene editing is defined as DNA engineering that results in the deletion, insertion or 
insertion of specific sequences. Many platforms have been developed and used over 
the last few decades. 
 
ZFNs was historically the first platform of gene editing of eukaryotic genome to be 
developed. It contains zinc-binding sequences in their DNA-binding domains and can 
provide specific recognition of sequences159, 160. Zinc domains can be modified to 
recognise any triplet of DNA thus being able to target any DNA sequence in 
eukaryotic cells161. Fused to bacterial endonuclease FokI and used in pairs, ZFNs 
can be employed to induce double stranded breaks (DSBs) effectively in any DNA 
sequence.  
 
Alongside, TALENs employ TAL effector DNA-binding domains that is able to 
specifically recognise single nucleotides thus rendering their employment easier and 
faster than ZFNs leading to DSBs in living cells162,. In more detail, TALENs are able 
of being engineered in order to target any DNA sequence in the genome. For a DSB 
to be induced a pair of TALENs is engineered to recognise a 20nt DNA sequence. 
Each TALEN of the pair, fused to FokI, recognises and binds the sequence flanking 




In addition to these techniques, a new and highly versatile RNA guided gene-editing 
technique, CRISPR/Cas, which is able to target DNA or RNA sequences with high 
specificity, has emerged as an attractive platform for specific gene editing. CRISPR 
was first described over 3 decades ago as a locus harbouring high numbers of short 
direct DNA repeats interspaced by short sequences165. A series of publications 
demonstrated that CRISPR is an adaptive immune system that, in nature, is used by 
bacteria as a defence mechanism against phages, upon re-infection166, 167, 168, 169, 170, 
171.  
 
In the current study, the CRISPR/Cas9 platform was assessed as an alternative to 
the traditional miRNA inhibition techniques in order to inhibit specifically miRNAs by 
targeting the miRNA genomic locus rather than the mature RNA sequence. 
 
1.3.1 Clustered Regularly Interspaced Short Palindromic Repeat 
(CRISPR)/ CRISPR associated (Cas) 
 
CRISPR/Cas is an adaptive immune system, naturally found in ~50% of bacteria and 
90% of archaea172 and was firstly described in 1987165. The CRISPR locus consists 
of DNA sequences that encode for proteins and for a series of DNA repeats that are 
interspaced by non-repetitive DNA sequences originating from phages173. According 
to the organisation of their locus and the Cas proteins that are used, CRISPR/Cas 




Figure 1.9 Classification scheme for Cas proteins. Two classes, and five types (the best described 
ones) of Cas proteins are presented along with a schematic representation of the operon and its 
organisation together with the domain architecture. For each type of Cas system the name of the gene 
is indicated for each subunit. Genes that are homologous are colour-coded and identified by a family 
name. Genes and gene regions encoding components of the interference module (crRNA or Cas9 
proteins) are highlighted with a light brown background. The adaptation nucleases (cas1 and cas2) 
and cas6 are dispensable in subtypes III-A and III-B. Also the regions of cas9 that correspond to the 
RuvC-like nuclease (green), HNH nuclease (yellow), recognition lobe (purple) and PAM recognizing 
domain (pink) are depicted. The regions of cpf1 (also known as Cas12a) aside from the RuvC-like 
domain are shown in grey. Makarova et al., 2015. 
 
Although there is a plethora of Cas proteins that are used in CRISPR systems in 
nature, the type II endonuclease Cas9 form Streptococcus pyogenes (SpCas9) is of 
particular interest since it is the Cas protein that is employed in the vast majority of 
studies. The reason for this is that although its relative big size (1,368 amino acids, 
4.10 kbp)175 in type II CRISPR systems only one Cas protein is used, contrary to 
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the other types that utilise multiple proteins to induce the DSB176, (Figure 1.10). 
Regarding the organisation of the locus, viral sequences, that derive from viral 
genome after unsuccessful infection, are incorporated in the CRISPR repeat-




Figure 1.10. CRISPR genomic locus. The type II CRISPR locus from Streptococcus pyogenes is 
shown as an example. The CRISPR genomic locus is comprised of the Cas genes, the tracrRNA and of 
regularly interspaced repetitive sequences (spacers) that are processed to crRNA. The spacer 
sequences are complementary to viral DNA and are used for targeting viruses upon re-infection. From 
Doudna and Charpentier, 2014. 
 
These sequences are transcribed into the precursor CRISPR RNA (pre-crRNA) that 
shares partially complementarity with the trans-activating crRNA (tracrRNA). This 
complementarity is used for the tracrRNA to bind the pre-crRNA in a duplex (pre-
crRNA:tracrRNA) that is then recognised by RNase III and cleaves the pre-crRNA to 
mature crRNA178 (Figure 1.11). The tracrRNA is then bound on the Cas9 protein and 
is used as a tether for the crRNA which guides the endonuclease to target specific 
DNA sequences according to the its sequence179. 
 
Figure 1.11. Precursor crRNA maturation.  In nature, CRISPR locus is transcribed on a regular base 
and subsequently the spacer sequences are transcribed into pre-crRNA. The pre-crRNA shares a partial 
complementarity with the tracRNA and is bound by it. With the help of tracrRNA, the pre-crRNA is 
recognised by RNase III which then cleaves it into a mature crRNA. The functional crRNA:tracrRNA and 
Cas9 complex is then able to target the complementary viral sequence and degrade it by cleaving it. 
From Doudna and Charpentier, 2014. 
 
As immune system, CRISPR/Cas9 in Streptococcus pyogenes functions by 
recognising and binding a tri-nucleotide sequence of the form 5’-NGG-3’, called 
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Protospacer Adjacent Motif (PAM). DNA of the invading virus. Following the PAM 
binding, Cas9, using the crRNA as a guide, interrogates the adjacent sequence, 
through Watson and Crick base pairing, and if there is enough complementarity, it 
induces a blunt-end double stranded break (DSB), using its activated endonuclease 
domains, 3-4 nucleotides upstream of the PAM179. In order for the DSB to happen, 
the first 17-20 nucleotides of the 5’-end of the crRNA need to be complementary to 
the targeted sequence. Two separate endonuclease domains, HNH and RuvC, 




Figure 1.12. CRISPR/Cas9 in nature. The crRNA:tracrRNA duplex is of paramount importance for the 
function of the CRISPR/Cas9 system. By binding to the crRNA through its complementarity, the 
tracrRNA keeps it bound to the Cas9 protein which uses it as a guide to recognise the targeted sequence. 
This targeted sequence needs to be followed by a 5’-NGG-3’sequence for the SpCas9 to induce the 
DSB 3-4nt upstream of the PAM site with the RuvC and HNH domains. Adapted from Doudna and 
Charpentier, 2014. 
 
Furthermore, it has been demonstrated that humanised SpCas9 is still functional in 
eukaryotic cells when the crRNA:tracrRNA is substituted by a chimeric single guide 
RNA (sgRNA) produced by fusing the 3’-end of the crRNA with the 5’-end of the 
tracrRNA (Figure 1.13) 179, 180, paving the way for fast, easy and cheap gene editing. 
SgRNA is an easy to design and fast to produce 20nt long RNA molecule that can be 
designed to target any sequence and is able of guiding SpCas9 to target and cleave 





Figure 1.13. CRISPR/Cas9 with sgRNA. A chimeric sgRNA can be used in the place of 
crRNA:tracrRNA to guide the Cas9 protein to the targeted sequence. Upon recognition, Cas9 unravels 
the dsDNA using the PAM sequence, the first 20nt of the 5’-end of the sgRNA are bound to the targeted 
sequence and the Cas9 cleaves both strands of the DNA with two distinct domains with endonuclease 
activity, RuvC and HNH. From Doudna and Charpentier, 2014. 
 
After the DSB, two different pathways can be employed to repair it: (A) the error prone 
Non Homologous End Joining (NHEJ), which alters the DNA sequence and can lead 
to premature stop codons, and (B) the Homology Directed Repair (HDR), which 
requires a highly homologous DNA template and can be employed for the insertion 
of specific sequences in the edited site (Figure 1.14). 
 
 
Figure 1.14. DSB repair in eukaryotic cells. Upon cleavage from the CRISPR/Cas9, the cell is trying 
to repair the DSB by following two distinct pathways. (A) The first, NHEJ, is an error prone repair which 
can potentially lead to a premature stop codon thus prematurely terminating the mRNA transcription, 
subsequently resulting to a non-functioning protein. (B) The second, less frequent pathway, HDR, can 
be employed for the introduction of specific sequences, such as genes or stop codons. Adapted from 




CRISPR/Cas9, due to its versatility, has emerged as an alternative to Zinc Finger 
Nucleases (ZFNs) and the Transcription Activator-Like Effector Nucleases (TALENs) 
gene editing techniques181. As an RNA-guided system, CRISPR/Cas9 is easier to 
use, faster to design and cheaper to produce compared to ZFNs and TALENs which 
rely on protein-DNA interaction. Moreover, since the 5’-NGG-3’ motif is found in every 
8 nucleotides, on average, in the human genome182, CRISPR/Cas9, employing 
SpCas9, can be used to edit almost every genomic site. Adding to this, the discovery 
of new Cas proteins with different PAM requirements and different ways of inducing 
the DSB, expand the gene editing toolbox with new CRISPR/Cas systems that can 
be used to edit different genetic loci according to individual needs183. 
 
CRISPR’s versatility and ease of use has sparked a series of publications that expand 
on the arsenal of gene editing providing myriad alternative options to SpCas9 
depending on the chemical nature of the molecule (DNA or RNA), the sequence of 
the locus targeted, the nature of the intended induced DSB (staggered or blunt end) 
and the intended editing (gene disruption, DNA base editing, RNA base editing or 
RNA degradation) 183, 184, 185. 
 
1.3.2 Limitations of CRISPR editing 
 
CRISPR/Cas9 technology has revolutionised gene editing providing a highly 
advantageous platform for editing almost any sequence in the genome of multiple 
organisms, including humans and mice. Therefore, it is considered as being a highly 
promising approach to develop therapies against multiple diseases186, 187 as well as 
an alternative to gene therapy, in order to battle a number of genetic diseases188, 189, 
190, 191, 192 . However, there are major innate limitations of the technique that hinder its 
universal application for therapeutic purposes. Namely, two of the most important 
limitations are the possibility of the off-target editing in unwanted loci and the delivery 
of the system, either in in vitro or in vivo models.  
 
1.3.2.1 Off-target editing 
 
Regardless of the advances CRISPR/Cas9 has introduced in the field of gene editing, 
important concerns remain about the possibility of inducing unwanted editing in non-
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targeted sites. Although various, preliminary studies in murine models did not show 
any off-target editing193, 194 the concerns about the precise editing of only the targeted 
sites have not yet convincingly addressed with further studying needed to decipher 
the full impact of CRISPR/Cas9 editing. 
  
As described above, CRISPR/Cas9 employs a 20nt long sgRNA to target and edit 
DNA sequences179. The complementarity between the guide and the targeted 
sequence activates the endonuclease domains of Cas9. Regardless of the high 
specificity of the sgRNA to recognise and bind the targeted sequence, it can tolerate 
a small number (varying from 3 to 5) of mismatches in its sequence195. More 
specifically, the greater the distance of the mismatches from the 3’-end of the sgRNA 
the more tolerable the binding is, with nucleotides 2-8 (from the 3’-end) being the 
least tolerable196. Taken the short length of the sgRNA together with the relative 
tolerance to mismatches Cas9 can withstand into consideration, it becomes apparent 
that is likely that Cas9 is guided to target and induce DSBs in multiple unintended 
sites. 
 
Software employed to design sgRNAs, addressing the problem of off-target 
mutagenesis, provide a list of putative off-target sites according to the tolerance of 
sgRNAs to mismatches. With regards to research and, more importantly, therapeutic 
and clinical applications of the system, off-target editing is a major concern. Although 
initial studies have provided data about the mechanism behind the recognition of off-
target sites196, data that are used for the prediction of sites of unintended editing, 
additional reports in vitro using mouse stem cells and differentiated human stem cells 
support that editing with CRISPR/Cas9 can lead to large deletions and sequence 
rearrangements197. These changes can potentially lead to editing oncogenes and/or 
protein coding genes resulting in severe implications. 
 
Various strategies have been used to address the issue of unwanted editing. These 
include using shorter, 17nt long sgRNA, shortening the guide at its 5’-end which leads 
to a guide less tolerable to mismatches195, the addition of two Guanine nucleotides at 
the 5’-end of the sgRNA198, titrating the concentration of the Cas9 protein used199, 
replacing the WT Cas9 with D10 nickases, where only one of the endonuclease 
domain is active, and using two sgRNAs flanking a specific point thus leading to 
immediate repair of any unintended edited sites200, fusing inactive Cas9 (dCas9) with 
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FokI nuclease201 and using phage-derived anti-Cas9 inhibitors that prevent Cas9 from 
editing the targeted DNA, thus needing higher complementarity to induce editing202. 
However, regardless of the numerous techniques that have been developed, the 
issue of the off-target editing still remains to be resolved. 
 
1.3.2.2 Delivery of the CRISPR/Cas9 system 
 
A second major limitation for the CRISPR/Cas9 platform is the delivery of the system 
to cells or organisms either at the embryo or adult stage. This limitation becomes 
even more prominent in therapeutic applications depending on the gene editing 
approach that is used to change the sequence of the disease-causing gene. As 
explained above, two pathways can be employed to repair the DSB that is induced 
upon editing with Cas9, the NHEJ or the HDR. The former pathway, which leads to 
the disruption of the sequence of the targeted gene, is used when silencing of a 
mutant gene is needed while the latter one is used for correcting a mutant gene back 
to its wild-type sequence. HDR based therapies demonstrate added advantages 
since they can address the off-target problems with the use of nickases as well as 
provide highly specific editing. However, the need to deliver Cas9 proteins, sgRNAs 
and the donor DNA simultaneously and in high efficiency in order for the HDR to 
occur, together with the low editing efficiency the pathway exhibits189, renders this 
approach challenging.  
 
Multiple in vitro techniques have been used with varying efficiencies. These include 
the use of liposomes196, nucleofection203, electroporation204 lentiviral based delivery158 
and microinjections in embryos205. Additionally, ex vivo approaches have been 
studied for the delivery of the system to cells isolated from mice or patients under in 
vitro conditions and the re-introduction of the edited cells to the individuals206. 
Nonetheless, the in vivo delivery still remains the most promising approach for 
therapeutic applications. 
 
One of the first techniques used for gene therapy was the employment of adeno-
associated viruses (AAVs) which is to this day one of the most advanced technologies 
for in vivo editing207. However, this technique presents various limitations since AAV 
vectors are big in size, thus hindering the delivery efficiency, they can induce off-
target editing208 and can trigger immune response due to the bacterial origin of the 
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Cas proteins. A second approach is that of the direct delivery of Cas9/RNP, either in 
vivo or in vitro, with the use of lipoproteins209, 210. The advantages this approach 
presents are the ease at producing high levels of recombinant Cas proteins and the 
track record in protein therapeutics. Moreover, other in vivo deliveries have been 
developed. Hydrodynamic delivery of plasmid DNA, that harbours the sequence for 
Cas9, sgRNAs and donor DNA211, is an alternative to lipoprotein or polyethylenimine 
(PEI) delivery of macromolecules, approaches that have not worked in the past. 
Lastly, two new, highly promising techniques have been described. The first one 
employs gold nanoparticles, conjugated with DNA, complexed with Cas9 RNP and 
donor DNA, entering the cells under in vivo conditions via endocytosis (gold 
nanoparticles) while the second one uses a sialoglycoprotein receptor ligands that 
facilitate the receptor-mediated endocytosis of the system114, 212. 
 
1.3.3 CRISPR/Cas9 and miRNAs 
 
The use of gene editing for inhibition of miRNAs has already been demonstrated in 
various studies213-215. More specifically, with regards to CRISPR/Cas9, it has been 
reported that it can target the expression of miRNAs, although with contradicting 
results about its efficiency202, 216. Moreover, in vivo studies showed that the platform 
can be used for the excision of a 53-kb fragment leading to knock-out mice to study 
the effects of the deletion of the largest miRNA cluster217, the targeting of entire 
families218 while double knock out mice have also been reported219. Further to this, 
CRISPR/Cas9 has also been used to elucidate both the pathway of the miRNA 




2 Chapter 2 AIMS OF THE STUDY 
 
MiRNAs are important and powerful regulators of many cellular processes by 
targeting and modulating the expression levels of multiple mRNA targets that 
participate in various pathways. The study of the miRNAs, though, is hindered by the 
fact that they form families that are comprised of members that share identical seed 
sequences and high homology throughout their sequence. A new approach for the 
study of miRNAs using gene editing has emerged as a promising alternative to 
overcome these limitations.  
 
In the current study CRISPR/Cas9 is employed as a powerful platform to induce 
editing in the miRNA genes in order to elucidate its application in the miRNA study 
and the role of miRNAs. More specifically, the aims of the study are: 
 
1. To study whether gene editing with CRISPR/Cas9 is capable of replacing the 
traditional methods of inhibiting miRNAs, overcoming the non-specific inhibition of the 
miRNAs of the same family. Following this approach, instead of targeting the mature 
miRNAs, editing of their genomic locus was thought to provide specific knock out only 
of the targeted miRNA. 
 
2. To establish a reliable workflow for inhibiting miRNAs. CRISPR/Cas9 is a 
highly versatile and easy to use platform for editing almost any locus in the genome. 
Valuable conclusions reached, through studying its application in the inhibition of 
miRNAs, were postulated to simplify miRNA inhibition with CRISPR/Cas9 and 




3. To study the regulatory mechanisms and function of miRNAs and more 
specifically of miR-195a. Various miRNAs have been implicated in cardiovascular 
diseases with miR-195a being among them. However, it is not as well studied as other 
miRNAs e.g. from the miR-17~92 cluster. The current study aimed to provide a better 
understanding of the maturation process of the primary transcript and more 




3 Chapter 3 MATERIALS AND METHODS 
 
3.1 Cell Culture 
  
Human Embryonic Kidney 293T cells 
 
Human Embryonic Kidney (HEK) 293T cells (HEK293T) were at fetal age, obtained 
from ATCC (CRL-3216) and cultured according to the recommended protocol. The 
cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, ThermoFisher 
Scientific #12491-015), supplemented with 10% heat-inactivated Foetal Bovine 
Serum (FBS) and 1% penicillin/streptomycin (100 U/ml penicillin and 100 µg/ml 
streptomycin) at 37°C in a humidified atmosphere of 95% air/5% CO2. HEK293T cells 
were subcultured with a ratio of 1:3 or 1:4 every 2-3 days up to passage 20. 
 
Human Umbilical Vein Endothelial Cells 
 
Human Umbilical Vein Endothelial Cells (HUVECs) were obtained from Lonza and 
cultured as described previously222. HUVECs were plated on gelatin coated flasks 
(Sigma-Aldrich #9000-70-8, 0.04% in DMEM) and cultured in Medium 199 
(ThermoFisher Scientific #11150059) supplemented with 10% FBS, 1% 
penicillin/streptomycin (100 U/ml penicillin and 100 µg/ml streptomycin) and 3 ng/ml 
endothelial cell growth factor (Sigma, St Louis, Mo # E9640), 1μg/ml endothelial 
growth supplement from bovine neural tissue (Sigma # E2759-5X15MG), 10 U/ml 
heparin (Sigma # E4643), 1.25μg/ml thymidine at 37°C in a humidified atmosphere 
of 95% air / 5% CO2. HUVECs were subcultured at a ratio of 1:3 every other day to 
passage 12. 
 
Human Smooth Muscle Cells 
 
Human Aortic SMCs were obtained from ATCC (PCS-100-012), were of male gender, 
adult age and plated in gelatin coated flasks (0.04% gelatin in DMEM) and cultured 
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in DMEM, supplemented with 15% FBS and 1% penicillin/streptomycin (100 U/ml 
penicillin and 100 µg/ml streptomycin) at 37°C in a humidified atmosphere of 95% 
air/5% CO2. Cells were passaged at a ratio of 1:3 every three days to passage 10. 
 
Mouse Smooth Muscle Cells 
 
VSMCs were isolated by enzymatic digestion of mouse aortas derived from C57BL 
mice (8-10 week old) as described previously222. They were of male gender and 
cultured in Dulbecco’s modifed Eagle’s Medium (DMEM, ThermoFisher Scientific, 
Runcorn, UK, #11965-084) supplemented with 10% heat-inactivated Foetal Bovine 
Serum (FBS, # 16000044), 2mM L-glutamine and 1% penicillin/streptomycin 
(100U/ml penicillin and 100 µg/ml streptomycin, #15240062), at 37°C in a humidified 
atmosphere of 95% air/5% CO2. VSMCs were plated on gelatin coated flasks (0.04% 
in DMEM, ThermoFisher Scientific, Runcorn, UK). Cells were passaged at a ratio of 
1:3 every other day up to passage 30. 
 
3.2 Single Guide RNA Design and Cloning  
 
The CRISPR DESIGN tool (http://crispr.mit.edu, no longer available), provided by the 
Zhang Lab, MIT 2015, was used to design the single guide RNAs. Briefly, the DNA 
sequence of the locus of the miRNA was submitted in FASTA format. After analysing 
the sequence, the tool’s algorithm returned a list of possible guides, ranked according 
to a quality score of inverse likelihood of off-target sites. It also provided information 
about the specific position of the sequence they target in the miR-195 locus, putative 
off-target sites, with their corresponding score, and the number and positions of the 
mismatches between the guides and their off-target sites. Moreover, CRISPR Finder 
on-line tool, provided by Wellcome Trust Sanger Institute, was used to identify 
additional off-target sites for the selected guides in order to eliminate the possibility 
of not detection due to algorithm bias. The highest scoring guides, which targeted 
sequences either in or close to the miRNA stem-loop, were selected. 
 
After choosing the guides to be used, they were synthesized with overhangs which 
would facilitate the cloning into the backbone pX330 plasmid vector (Addgene 
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Figure 3.1 Vectors pX330 and LentiCRISPRv2. (A) Map of vector pX330 with its corresponding 







In detail, to clone the guide sequence into the vectors the two oligos were synthesized 
in the form: 
 
Oligo1:  5’-CACCGNNNNNNNNNNNNNNNNNNN -3’ 
Oligo2:  3’-CNNNNNNNNNNNNNNNNNNNCAAA-5’ 
 
For cloning the oligos into the backbone vector a single step digestion-ligation 
protocol208 was used.  
 
Firstly, the oligos were phosphorylated and annealed. For the reaction, 1μl Oligo1 
(100μM), 1μl Oligo2 (100μM), 1μl 10x T4 Ligation Buffer (NEB #M0308S), 0.5μl T4 
PNK (NEB) and 6.5μl nuclease free H2O were added to a final volume of 10μl. The 
oligos were annealed in a thermocycler at 37°C for 30min, 95°C for 5min and then 
the temperature was ramped down to 25°C at 5°C/min. After the annealing, the oligos 
were diluted 250-fold (1:250) for the pX330 vector or 10-fold (1:10) for the 
LentiCRISPRv2 vector, respectively. 
 
For the single digestion-ligation reaction, 1μl of vector (100ng), 2μl Phosphorylated 
and annealed diluted oligo duplex from the previous step, 2μl 10x Tango Buffer 
(NEB), 1μl FastDigest enzyme, 1μl DTT (10mM) (Sigma #D9779), 1μl ATP (10mM), 
0.5μl T7 DNA ligase (NEB #M0318S) and 11.5μl nuclease free H2O were added to a 
final volume of 20μl. The BbsI enzyme (ThermoFisher Scientific #FD1014) and Esp31 
(ThermoFisher Scientific # ER0451) were used for the pX330 and LentiCRISPRv2 
vectors, respectively. The digestion-ligation reaction was incubated in a thermocycler 
at 37°C for 5 min, 23°C for 5 min, repeated for 6 cycles and 15 cycles for the pX330 
and LentiCRISPRv2 vectors, respectively. 
 
The ligated product was treated with PlasmidSafe exonuclease to remove the un-
ligated linear plasmids. For the PlasmidSafe reaction 11μl Ligation reaction (from the 
previous step), 1.5μl 10x PlasmidSafe Buffer, 1.5μl ATP (10mM) and 1μl PlasmidSafe 
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exonuclease (PlasmidSafeTM ATP-Dependent DNase kit #E3101K) were added to a 
final volume of 15μl. The reaction was incubated at 37°C for 30min. 
 
Next, the ligated vectors were transformed into Stbl3 E. Coli competent cells 
(ThermoFisher Scientific #C7373-03). Briefly, 2μl of the PlasmidSafe treated product 
were added into a shot (20μl) of ice-cold chemically competent Stbl3 cells and 
incubated on ice for 30 min. They were then heat shocked at 42°C for 45sec and 
placed back on ice for 2 min. Next, 240μl of SOC medium was added to the 
transformed bacteria and incubated at 37°C for 40 min. Subsequently, 100μl of 
bacteria were plated on an LB agar petri dish containing ampicillin (50μg/ml) and 
incubated at 37°C overnight. 
 
3.3 In Vitro Transcription (IVT) of sgRNA 
 
For the IVT, the GeneArtTM Precision gRNA Synthesis Kit (Invitrogen #A29377) was 
used to generate single guide RNAs (sgRNAs), according to manufacturer’s 
recommendations. The DNA template of the sgRNA was PCR assembled as shown 
in Figure 3.2. This DNA template was then used to generate the sgRNAs by IVT. All 
IVT Target primer sets are provided in Supplementary Table 2. 
 
 
Figure 3.2. PCR assembly of the gRNA DNA template using the Target F1 and Target R1 oligonucleotides. 
The oligonucleotides were used both as primers and templates together with the T7 primer mix and the tracr fragment 







The following PCR was used for the assembly of the gRNA DNA template: 12.5µl of 
2x PfusionTM High-Fidelity PCR Master Mix, 1µl of Tracr Fragment + T7 Primer Mix, 
1µl of Target F1/R1 oligonucleotide mix (0.3µM) and 10.5µl of nuclease free H2O 
were added to a final volume of 25µl. The following PCR programme was run on a 
Veriti® 60-well Thermal Cycler: initial denaturation at 98°C for 10sec and then 
underwent 32 cycles of 98°C for 5sec, 55°C for 15sec and then a final extension step 




After the DNA template assembly, IVT was used for the generation of the gRNA. The 
reaction mix for each sample contained 8µl of NTP mix (100mM), 6µl of gRNA DNA 
template from the previous step, 4µl of 5x TranscriptAidTM Reaction Buffer and 2µl of 
TranscriptAidTM Enzyme Mix to a final volume of 20µl. The samples were incubated 
on a Veriti® 60-well Thermal Cycler form Thermo Fisher Scientific at 37°C for 3h. As 
a final step, to remove the DNA template, 1µl of DNase I (1U/µl) was added to the 
reaction and was incubated at 37°C for a further 30min. After the DNA template 





For transfection experiments, 293T cells were trypsinised and re-suspended into 
complete medium with no antibiotics. Subsequently, cells were counted using a 
haemocytometer and plated in 24 well plates at a cell density of 240,000 cells/ml. A 
total of 500μl of cell suspension was plated per well.  
 
On the following day, cells were transfected with plasmid vectors using ViaFect™ 
Transfection Reagent by Promega (Catalog No E4981). Two mastermixes (A and B) 
were prepared. For mastermix A, 500ng of the plasmid were mixed with 25μl of 
DMEM per 24 well and for mastermix B, 2μl of ViaFect™ were added to 25μl of DMEM 
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per transfection. After incubating at RT for 5 min the two mastermixes were combined 
and incubated for further 20 min. Afterwards the transfection mastermix was added 
to the corresponding well. All transfection reactions were performed in duplicates. 
 
After 24 hours of the transfection, the conditioned medium was supplemented with 
500μl of complete medium. Two days later, HEK293T cells were detached by 
pipetting and 500μl of the cell suspension was re-plated to a 6 well plate, 
supplemented with 1.5ml of complete media. Cells were returned to the incubator and 
maintained for an additional 3 days. Additional DNA samples were harvested on 
Day5. 
 
3.4 DNA Extraction 
 
For the DNA extraction cells were pelleted and lysed in 300μl of QuickExtract™ DNA 
Extraction Solution 1.0 (Epicentre #QE09050). The samples were heated at 65°C for 
20 min and then at 96°C for 10 min. The DNA concentration was measured using the 
NanoDrop 1000 (ThermoFisher Scientific) device. 
 
3.5 Genomic PCR  
 
For the amplification of the genomic locus of miR-195, primers were designed using 
the online tool OligoPerfect™ Designer by Thermo Fisher Scientific and Kapa HiFi 
PCR Kit Hot Start from Kapa Biosystems (Kapa Biosystems #KK2502) was used. The 
possible editing of the off-target sites, as provided by http://crispr.mit.edu, was also 
tested. The sequences of the genomic locus of the off-target sites were retrieved from 
www.ensebml.org, using the coordinates of the possible off-target sites as provided 
by the CRISPR DESIGN online tool. Details for the primer sequences are provided in 
Supplementary Table 3. 
 
The reaction mix for each sample contained 9μl of 5x Kapa GC Buffer, 1.35μl of 
Forward Primer (10μM), 1.35μl of Reverse Primer (10μM), 1.35μl of dNTPs (10mM), 
6μl of DNA template (50ng/μl), 0.45μl of Kapa Polymerase and 25.5μl of nuclease 




The following PCR programme was run on a Veriti® 60-well Thermal Cycler for the 
miR-195 genomic locus (both human and mouse): initial denaturation and enzyme 
activation at 95°C for 5 min and then 30 cycles of 98°C for 20sec, 62°C for 15sec, 
72°C for 20sec, then were heated at 72°C for 1min. Amplicons were visualized on a 
2% agarose gel in 1xTBE buffer supplemented with Safe-view (10μl/150ml) run at 
200V for 30 min.  
 
3.6 PCR Clean Up 
 
The PCR product was purified using the Thermo Scientific GeneJET Gel Extraction 
and DNA Cleanup Micro Kit (Catalog Number #K0702), following the manufacturer’s 
recommendations. Briefly, the volume of the PCR product was adjusted to 200μl with 
nuclease free H2O. Then, 100μl of binding buffer were added followed by 300μl of 
100% ethanol. The solution was mixed thoroughly by pipetting, transferred to a DNA 
purification Micro Column and centrifuged at 14,000 x g for 1 min. The flow-through 
was discarded and 200μl of Pre-wash Buffer was added to the column before being 
centrifuged at 14,000 x g for 1 min. The flow-through was discarded and 700μl of 
Wash Buffer was added to the column before being centrifuged at 14,000 x g for 
1min, a step that was repeated for a second time. The column was then transferred 
to a clean 1.5ml micro-centrifuge tube and centrifuge at 14,000 x g for 1 min for the 
removal of any residual buffer. The column was then transferred to a clean 1.5ml 
micro-centrifuge tube and 10μl of nuclease free water were added to the column for 
three min incubation. For the elution of the purified DNA product, the column was 
centrifuged at 14,000 x g for 1 min. The DNA concentration of the purified PCR 
product was measured using a NanoDrop 1000.  
 
3.7 T7 Endonuclease I Assay 
 
To assess the gene editing efficiency, the T7 Endonuclease I assay (T7EI) was 
employed as described recently223. Briefly, 90ng of the purified PCR product were 
diluted to a volume of 14μl, in nuclease free H2O, and supplemented with 3.5μl 5x 
KAPA HiFi GC Buffer. PCR products were denatured by heating to 95°C for 10min 
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(Figure 3.3A) and then re-annealed by slowly ramping down the temperature to 25°C 
by a rate of 4.5% per minute (Figure 3.3B). 
 
 
Figure 3.3. T7 Endonuclease I digestion. T7EI recognises and cleaves mismatched DNA. (A) The 
PCR amplicons were denatured and (B) re-annealed randomly. (C) Upon T7 endonuclease I digestion, 
the mismatched strands were cleaved at the edited site (red squares). The fragments were then 
analysed to assess the genome editing efficiency. 
 
After the re-annealing, 2μl of 10x NEB Buffer 2 (NEB #B7002S) and 0.5μl of the T7EI 
(NEB #M0302S) were added to each sample, to a final volume of 20μl for a further 
1h incubation at 37°C. As a final step, 4μl of 6x Purple Loading Buffer (NEB #B7024S) 
were added and the samples were heated to 70°C for 10min (Figure 3.3C). 
 
To visualize the T7EI digestion products, a 2% agarose gel in 1xTBE buffer was 
prepared. The samples were loaded and run at 170V for 50 min alongside a 1kb Plus 
DNA ladder (ThermoFisher Scientific #10787018). After the run, the gel was, rinsed 
twice with 1x TBE Buffer. The gel was subsequently stained with SYBR® Gold 
Nucleic Acid Gel Stain (ThermoFisher Scientific #S-11494) in 1xTBE buffer for 30min, 





For the quantification of the T7EI results, the ImageJ software was used (freely 
available at http://imagej.net). The band intensity of the uncut DNA substrate, the 
cleaved products and background was measured. The values of the band intensities 
were subtracted against the value of the background and the editing efficiency was 
calculated using the following formula: 
 
Indel (%) = (1 - "1− %&'(&%&' ) x 100, 
 
where, A=uncut DNA substrate, B, C= digestion products 
 
3.8 Restriction Enzyme Digestions  
 
The SspI and MwoI digestions were set up in order to detect mutations in the genomic 
loci of mouse miR-195. More specifically, the SspI restriction enzyme identifies the 
sequence 5’-AATATT-3’ and the MwoI identifies the sequences 5’-GCNNNNNNNGC-
3’ (Figure 3.4). Successful gene editing will interrupt these two sites, thus preventing 
the cleavage by the restriction enzymes. For the digestion, 8µl of the PCR reaction 
was used as a template in a digestion that contained 2µl 10x CutSmart (NEB 
#B7204S), 0.5µl of restriction enzyme and 9.5µl of nuclease free H2O to a final volume 
of 20µl. The reaction was incubated in a thermocycler at 37°C for the SspI and at 
60°C for the MwoI for 1h. 
 
Restriction enzymes (all from NEB) were also used to assess gene editing with their 
corresponding sites outlined in Supplementary Table 4. Digestion reactions for all 
other restriction enzymes were incubated at 37 °C for 1 h in CutSmart Buffer with the 
exception of SspI that was incubated in NEB Buffer 2.1. Digestion products were 









Figure 3.4. SspI, MwoI, HinfI, Bsp1286I and MefI restriction sites.  (A) SspI restriction site. (B) MwoI 
restriction site. (C) HinfI restriction site. (D) Bsp1286I restriction site. (E) MfeI restriction site. The black 
arrows indicate the position of the cleavage. The black arrows indicate the position of the cleavage. 
 
3.9 Lentiviral particle transduction 
 
To confer Cas9 expression in VSMCs, we used the LentiCRISPRv2 vector (Addgene, 
#52961) that encodes a Streptococcus pyogenes Cas9 (SpCas9) under the control 
of an elongation 1a short promoter (EFS)224. Lentiviral particles were produced using 
the lentiviral vector LentiCRISPRv2 and packaging plasmids pMD2.G and psPAX2 
(Addgene, #12259, #12260) as described previously225. HEK293T cells were seeded 
in T75 flasks. When they reached a confluency of 70-80%, they were transduced with 
lentiviral vectors for the production of the lentiviral particles. Briefly, two mastermixes 
were prepared. Mastermix A consisted of 590μl of Opti-MEM® I Reduced Serum 
Media (ThermoFisher Scientific #31985070) and 10μg of the lentiCRISPRv2 vector 
harbouring the guide sequence of interest, 5μg of the pMD2.G envelope plasmid 
(Addgene #12259) and 7.5μg of the psPAX2 plasmid (Addgene #12260) and 
Mastermix B consisted of 600μl of Opti-MEM® I Reduced Serum Media and 50μl of 
ViaFect™. The mastermixes were incubated for 5 min at RT and then combined and 
incubated for further 20 min at RT. In the meantime, the medium of the HEK293T 
cells was replaced with 6ml of Opti-MEM® I Reduced Serum Media per flask. The 
transfection complexes were subsequently added to the cells and incubated at 37°C. 
Following a 6h incubation, the medium was replaced with 8ml of DMEM with 10% 
FBS and antibiotics supplemented with 1% Bovine Serum Albumin (Sigma-Aldrich 
#9048-46-8). After 60h, the lentiviral supernatant was collected, centrifuged at 1000 
rpm for 5min and filtered through 0.45µm VWR Syringe Filters #28145481. A p24 




antigen ELISA (Cell Biolabs) was used to determine the viral titer222. The resulting 
solution was either used immediately or stored at -80°C. 
 
3.10 Lentiviral Infection 
 
VSMCs were seeded at T25 flasks at a density of 200,000 cells per flask. The next 
day cells were lentiviral infected using 1.6-2.4 x 107 TU/ml (Table 1). The media were 
supplemented with 8μg/μl of Polybrene (Sigma-Aldrich #28728-55-4) and cells were 
incubated for 24h with the viral suspension. The next day, the lentiviral supernatant 
was removed, discarded and replaced with 5ml of complete medium. 
 
Table 1. List of Lentiviruses used. 
Lentiviruses Titer 
LentiCrisprv2 (Addgene #52961) 1.7-2.3 x 107 TU/ml 
pLKO.1 (Addgene #8453) 1.6-2.4 x 107 TU/m 
 
 
3.11 TA Cloning 
 
PCR amplicons from the edited samples was sequenced to determine mutation 
patterns. Purified, PCR amplified DNA from each sample was ligated to the pGEM®-
T Vector (Promega #A3600). For the ligation reaction 5μl of 2x Rapid Ligation 
Reaction Buffer, 2μl of PCR purified product, 2μl of pGEM®-T vector (Figure 3.5) and 
1μl of T4 DNA ligase (Promega, Catalog No M1801) were used. The reaction was 





Figure 3.5. pGEMâ-T vector.The map of pGEMâ-T with the corresponding restriction sites. 
 
Subsequently, 2.5μl of the ligation product were added to 50μl of JM109™ Chemically 
Competent E. Coli (Promega #L1001) and incubated on ice for 30 min. They were 
then heat shocked at 42°C for 45 sec and placed on ice for 2 min. A total of 240μl of 
SOC medium was added to the transformed bacteria that were incubated at 37°C for 
further 20 min. An ampicillin LB agar petri dish was precoated with 40μl of Xgal 
(50mg/ml) (Promega #V3941) and 40μl of IPTG (100mM) (Promega #V3955) and 
70μl of bacteria culture were subsequently plated. The dish was incubated at 37°C, 
overnight.  
 
Blue and white bacterial colonies were formed overnight, with blue colonies 
corresponding to the bacteria that were transformed with re-ligated, empty vectors. 
White bacterial colonies correspond to bacteria that were transformed with the vector 
conferring the PCR product. Individual bacterial colonies were picked and PCR 
screened as described above. Mutation patterns were identified by Sanger 
sequencing. 
 
3.12 RNA Extraction 
 
RNA was extracted using the miRNAeasy mini kit (Qiagen #74104). Briefly, cells were 
lysed using 700µl of QIAzol® Lysis Reagent. Following a brief incubation at ambient 
temperature, 140µl of chloroform was added to each sample and the solution was 
mixed vigorously for 15 sec. The samples were incubated for 5 min at RT and were 
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then centrifuged for 15 min at 12,000 x rpm at 4°C. Only 280µl of the upper aqueous 
phase were transferred to a new collection tube and 420µl of 100% ethanol were 
added and mixed thoroughly and transferred to an RNeasy® Mini column in a 2ml 
collection tube, washed according to the company’s recommendations. Total RNA 
was eluted using 25µl of nuclease free H2O and the RNA concentration was 
measured using a NanoDrop 1000. 
 
3.13 MiRNA quantification 
 
To assess miRNA expression RNA was reverse transcribed using the Megaplex 
Primer Pools from ThermoFisher (Cat. #4401009) as described previously98. A total 
of 100ng of RNA were reverse transcribed using the Megaplex Rodent Primer Pools 
A. The reaction was performed according to the company’s recommendations (0.8μl 
of Pooled Primers were combined with 0.2μl of 100mM dNTPs with dTTP, 0.8μl of 
10x Reverse-Transcription Buffer, 0.9μl of MgCl2 (25mM), 1.5μl of Multiscribe 
Reverse-Transcriptase and 0.1μl of RNAsin (20U/μl) to a final volume of 7.5μl). The 
RT-PCR reaction was set as follows: 16°C for 2min, 42°C for 1min and 50°C for 1 
sec for 40 cycles and then incubation at 85°C for 5min using a Veriti® thermocycler 
(Life Technologies). The RT reaction products were diluted to 1ng/μl corresponding 
RNA and stored at -20°C. Taqman miRNA assays were used to assess the 
expression of individual miRNAs. For the quantitative Polymerase Chain Reaction 
(qPCR), 2.25ng of Megaplex reverse transcription product were combined with 0.25μl 
of 20x Taqman miRNA Assay (Life Technologies) and 2.5μl of the 2x Taqman 
Universal PCR Master Mix No Amp Erase UNG (ThermoFisher Scientific #4324018) 
to a final volume of 5μl. QPCR was performed on a Viia7 thermocycler at 95°C for 10 
min, followed by 40 cycles of 95°C for 15sec and 60°C for 1min. U6 was used as a 
normalization control. 
 
3.14 MiRNA Overexpression 
 
Cells were plated at 60–70% confluency on the day before transfection. Mouse 
miRNA mimics and a non-targeting control were obtained by ThermoFisher Scientific 
63 
 
and transfected at a final concentration of 20nM using Lipofectamine RMAiMAX 
(ThermoFisher Scientific, Runcorn, UK) as described previously98.  
 
3.15 Gene expression 
 
QPCR was used to assess the gene expression levels. In these studies, 1μg of RNA 
was reversed transcribed into cDNA using the High Capacity Reverse Transcriptase 
kit (ThermoFisher Scientific, Runcorn, UK). Prior to pri-miRNA assessment RNA 
samples were treated with DNAse for 30min at 37°C, to remove any genomic DNA 
contamination in the preparations. For all genes, Taqman Assays were used with the 
exception of Carmn that was assessed using specific primers226 (Supplementary 
Table 3) and SyBr Select Mastermix (TermoFisher Scientifc, Runcorn, UK). Beta 
Actin was used as a normalisation control.  
 
3.16 Computational analysis 
 
Secondary structures without pseudoknots were generated by RNAfold (Vienna RNA 
tools, http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi) using the Turner 
model (Standard settings), while secondary structures with pseudoknots were 
generated by vsfold5227 (Chiba Institute of Technology, Japan, http://www.rna.it-
chiba.ac.jp/~vsfold/vsfold5/) and Settings: 37°C temperature; Kuhn length 6; 
Jacobson-Stockmayer gamma=1.75 and contiguous stems=6. Visualisation of the 
secondary structures with pseudoknots was performed using the Pseudoviewer 
software (Inha University, S Korea http://wilab.inha.ac.kr/ pseudoviewer/). The 
RNAComposer228 (Poland, http://rnacomposer.cs.put.poznan.pl/) was used to 
generate the pbd-files through molecular RNA simulation from vsfold5 output. The 
RNAComposer output pdb-fles were then input to pyMOL to generate high quality 3D 
images. MiR-497a stem loop is depicted in green and its terminal loop in magenta. 





3.17  pLKO.1 cloning 
 
The pLKO.1229 vector  was used for pri-miRNA overexpression experiments, since it 
is the recommended vector for expression of shRNAs under a T7 promoter (Figure 
3.6). 
 
Figure 3.6. Vector pLKO.1-puro cloning vector. Map of vector pLKO.1 with its corresponding 
elements. 
 
For the cloning of the DNA sequence of mmu-miR-497~195, pGEM®-T vectors 
harbouring WT or mutant sequences were used as template. These sequences were 
resulted from editing of the genomic locus of the primary transcript. For cloning 
purposes, new guides harbouring sequences corresponding to the restriction sites of 
AgeI and EcorI were designed (Supplementary Table 3). For the PCR amplification 
of the DNA sequence of the primary transcript, a specific programme was used on a 
Veriti® 60-well Thermal Cycler. 
 
More specifically, two PCR reactions were prepared for each transcript (WT and 
mutants) to final volume of 45µl. The reaction mix for each sample contained 9μl of 
5x Kapa GC Buffer, 1.35μl of Forward Primer (10μM), 1.35μl of Reverse Primer 
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(10μM), 1.35μl of dNTPs (10mM), 2μl of DNA template (50ng/μl), 0.45μl of Kapa 
Polymerase and 29.5μl of nuclease free H2O to a final volume of 45μl. 
 
The following PCR programme was run on a Veriti® 60-well Thermal Cycler for the 
miR-195 genomic locus (both human and mouse): initial denaturation and enzyme 
activation at 95°C for 5 min and then 5 cycles of 98°C for 20sec, 57°C for 20sec, 72°C 
for 40sec, followed by 30 cycles of 98°C for 20sec, 62°C for 20sec, 72°C for 40sec 
then were heated at 72°C for 1min. Next, the two reactions were combined and 
cleaned-up, following the same protocol as explained above, with the final elution 
being in15µl of H2O. Then, the eluted DNA was run on a 0.8% agarose gel in 1xTBE 
buffer supplemented with Safeview (10μl/150ml) at 170V for 50 min. Following this, 
gel purification of the amplicons was performed using the Thermo Scientific GeneJET 
Gel Extraction and DNA Cleanup Micro Kit (Catalog Number #K0702) following the 
company’s recommendations. In brief, the part of the gel that engulfed the DNA band 
of the correct size was excised using a scalpel and was transferred to a 1.5mL 
Eppendorf tube. Next, 200µl of Extraction Buffer were added and the gel mixture was 
incubated at 58°C for 10min. Then, 200µl of ethanol were added to the tube and 
mixed by pipetting. The mixture was afterwards transferred to a DNA purification 
Micro Column and was centrifuged for 60sec at 14,000 x g. Next, the column was 
washed with 200µl of Prewash Buffer and centrifuged for 60sec at 14,000 x g. Then, 
700µl of Wash Buffer was added and centrifuged twice. The empty column was then 
centrifuged and then transfer to an empty microcentrifuge tube. In a final step, 15µl 
were added to the empty column to elute the DNA.  
 
Following the clean-up, two digestions were set up with AgeI restriction enzyme. In 
more detail, a reaction with 5µl of Buffer O, 2µl of AgeI, with 15µl of PCR product and 
28µl of H2O was set-up for the gel purified PCR product. A second reaction with 5µl 
of Buffer O, 2µl of AgeI, 9.09µl of pLKO.1 vector (a total amount of 5000ng) and 
33.91µl of H2O was set-up and they were both incubated at 37°C for 2 hours. 
 
Following these digestions, the products were cleaned-up as per standard protocol 
eluting in 15μl of H2O. A second step of digestions was set-up with 5µl of CutSmart, 
2µl of EcoRI, 15µl of PCR clean-up product and 28µl of H2O and were incubated at 




As a last step, the digested products were cleaned-up as per standard protocol and 
the final concentration was measured using the NanoDrop 1000. 
 
For the ligation reaction, 1µl of 10x T4 ligase buffer, 240ng of pLKO.1, 420ng of PCR 
clean-up and 1µl of T4 ligase were added to a final volume of 10µl and they were 
incubated at RT overnight. 
 
3.18 RNA Pull-down assay 
 
Cell lysate preparation 
 
RNA Pull-down experiments were conducted to assess how changes in the tertiary 
structure of the pri-miR-497~195, due to CRISPR/Cas9 editing, might affect its 
recognition and binding from RNA binding proteins. For the RNA Pull-down 
experiment, VSMC were cultured in T175 flasks to a confluency of 90% before they 
were harvested. In more detail, the culture medium was removed from the flasks and 
the flasks were washed off with 4ml of phosphate-buffered saline (PBS; Sigma, cat. 
no. D8537). Next, the cells were scraped, and the cell suspension was placed in a 
50ml falcon tube before it was centrifuged at 1,000 rpm for 5min. After spinning, the 
supernatant was removed and 800μl of Pierce IP Lysis buffer (ThermoFisher #87787) 
supplemented with protease inhibitor (Roche Complete Mini, EDTA-free, cat. no. 
11836170), phosphatase and RNAse inhibitors (Life Technologies) were added and 
the solution was incubated on ice for 30min while mixing occasionally. After the 30min 
had elapsed, the lysate was centrifuged at 13,000 rpm for 20min at 4°C, the 
supernatant was removed and stored at -20°C. 
 
IVT of primary transcript  
 
For the RNA Pull-down experiments, primary transcripts corresponding to the wild 
type or the mutated sequences conferring a 16-nucleotide deletion, were PCR 
amplified with the use of forward primers containing the T7 promoter. Afterwards, the 
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PCR products were run on a 0.8% agarose gel in 1xTBE buffer (ThermoFisher 
#15581-028), stained with Safe-view 10µl/150ml (NBS Biologicals, NBS-SV5), at 
170V for 50min. The products were then gel purified using the GeneJET Genomic 
DNA Purification Kit (#K0721). The DNA concentration of the gel purified 
products was measured using the NanoDrop 1000 (ThermoFisher Scientific) device 
and 400ng of DNA were used for the IVT reaction to a final volume of 20µl as 
described above in Chapter 3.3. The samples were incubated on a Veriti® 60-well 
Thermal Cycler form ThermoFisher Scientific at 37°C for 2h. Finally, 1µl of DNase I 
(1U/µl) was added to the reaction and was incubated at 37°C for a further 30min to 
remove the DNA template. Afterwards, the RNA was purified using the RNA Clean 
Up Kit following the manufacturer’s recommendations (ThermoFisher Scientific). 
Briefly, after adjusting the volume to 200μl with nuclease-free water, 100μl of Binding 
Buffer were added and mixed thoroughly. Then 300μl of of ethanol were added before 
the mixture was transferred to a GeneJetä RNA Purification Micro Column and 
centrifuged at 14,000 x g for 60 seconds. After discarding the flow through, 700μl of 
Wash Buffer 1 was added and the column was centrifuged at 14,000 x g for 60 
seconds. Next, 700μl of Wash Buffer 2 was added and the column was centrifuged 
again at 14,000 x g for 60 seconds. The empty purification column was centrifuged 
to remove any residual Buffer and 10μl of nuclease-free water was used to elute the 
RAN. After the clean-up, the concentration was measured with the NanoDrop 1000 
(ThermoFisher Scientific) and 50pmol of cleaned-up RNA was used for labeling in a 




For the RNA labeling the Pierce RNA 3' End Desthiobiotinylation Kit (#20163) was 
used. In more detail, the RNA was supplemented to a final volume of 6.25μl, 0.5 μl of 
DMSO were added and it was incubated on a Veriti® 60-well Thermal Cycler form 
Thermo Fisher Scientific at 85°C for 10min and then reannealed by ramping down 
the temperature to 10°C. 
 
For the labelling reaction 1.75μl of nuclease-free water, 3μl of 10x RNA Ligase 
Reaction Buffer, 1μl of RNAse inhibitor, 6.25μl of 50pmol of reannealed RNA, 1μl of 
Biotinylated Cytidine Bisphosphate, 2μl of T4 RNA ligase and 15μl of PEG 30% were 
mixed in the above order to a final volume of 30μl. The reaction was carefully mixed 
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and incubated on a Veriti® 60-well Thermal Cycler from ThermoFisher Scientific at 
16°C overnight. 
 
After the overnight incubation, 70µl of nuclease-free water were added to the ligation 
reaction. As a next step, 100μl of chloroform were added in order to extract the RNA. 
The mixture was vortexed briefly and then centrifuged for 5min at 12,000 rpm to 
separate the phases. The aqueous phase was carefully removed and transferred to 
a 1.5ml Eppendorf tube. Then, 10μl of 5M NaCl, 1µl of glycogen and 300μl of ice-cold 
100% ethanol were added before RNA being precipitated at -20°C for 2h. In the 
meantime, the cell lysate was precleared. In detail, 200μl (4ng/μl) of cell lysate per 
sample was used and 20μl of Pierce™ Streptavidin Magnetic Beads (1:10 of the 
lysate volume). A magnetic rack was used to gather the magnetic beads against the 
wall of the tube and washed twice with Tris-buffered saline (TBS, Product No. 28379, 
containing 0.05% Tween-20 Detergent). The beads were then re-suspended in 20μl 
of Tris and applied to the lysate. They were put in the cold room (4°C) at rotation for 
2h. After the 2h had elapsed for the RNA precipitation, it was centrifuged at 13,000 × 
g for 15 minutes at 4°C. The supernatant was carefully removed and the pellet was 
washed with 300µl of ice-cold 70% ethanol carefully not to detach the pellet. The 
ethanol was carefully removed and the tubes flipped upside down for 5min to air-dry 
the pellet. Afterwards, the pellet was re-suspended in 20µl of re-suspension buffer 
(490μl of 20mM Tris-buffered saline supplemented with 10μl of 5M NaCl). They were 
incubated on a Veriti® 60-well Thermal Cycler from Thermo Fisher Scientific at 65°C 
for 10min before the temperature was ramped down to 4°C by 1.5% rate. 
 
In the meantime, the RNA binding mastermix was prepared. In more detail, 20μl of 
Protein-RNA Binding Buffer, 60μl of 50% Glycerol, 1μl of 5M NaCl, 100μl of pre-
cleared lysate and 19μl of nuclease-free water were mixed per sample. In a 1.5ml 
Eppendorf tubes, 200μl of the mastermix and 10μl of the labelled RNA were added 
and incubated at 4°C with rotation for 2h. In the meantime, 20μl of beads per sample 
were pre-cleared. In detail, a magnetic rack was used to gather the beads against the 
wall of the tube and they were washed twice with Tris. They were then re-suspended 
in 20μl of Tris and added to the RNA-protein samples and incubated for 2h at 4°C 
with rotation. Afterwards, a magnetic rack was used to gather the beads against the 
wall of the tube, the depleted supernatant was removed and kept at -20°C and the 
beads were washed off with 250μl of wash buffer for three times. Then, 40μl of elution 
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buffer was added, mixed well by vortexing and incubated at 37°C with mild agitation. 
With the help of a magnetic rack the beads were gathered against the wall of the tube 
and the eluate was removed and stored at -20°C. 
 
3.19 In-gel digestion and HPLC-MS/MS analysis 
 
To analyse the RNA Pull-down eluate, 20µl of each sample were loaded on to pre-
cast 10-well NuPAGE Novex 4-12% gradient Bis-Tris polyacrylamide gels (Life 
Technologies), with 7µl of Novex Sharp Pre-stained Protein Standard (Invitrogen, Life 
Technologies) loaded as marker. Separation was achieved by electrophoresis for 
approximately 90min at 180V. Protein profiles of the gels were visualised by silver 
staining. All steps were performed with gentle shaking. After the electrophoresis, the 
gel was rinsed with ddH2O and was incubated in fixing solution of 5% acetic acid and 
50% methanol solution for 30min, at room temperature, followed by three brief 
washes in ddH2O, and rehydration in ultrapure H2O overnight at 4°C. The next day, 
gels were incubated in sensitising solution (1.25 mM sodium thiosulphate 5-hydrate) 
for 1min, washed for 1min with H2O for three times and stained in 6mM silver nitrate 
solution for 30min at 4°C. After three brief washes in H2O, gels were incubated in 
developing solution (280mM sodium carbonate, 5% formaldehyde) for approximately 
5min until the protein bands are clearly discernable. Gels were washed in 5% acetic 
acid for 10min to stop the developing, followed by three washes in H2O and placed in 
clear plastic bags to be scanned using a calibrated scanner (GS-800, Bio-Rad). Each 
gel lane was divided in twelve sections of various sizes, according to the amount of 
protein as judged by Silver staining, using a scalpel, and transferred to a 96-well plate 
for automated de-staining and tryptic digestion, using an Investigator ProGest 
(Digilab) robotic digestion system according to the manufacturer’s protocol. The 
obtained peptide solution was frozen at - 80°C for at least 2 h and lyophilised under 
vacuum at -55°C for approximately 5h in a Christ Alpha 1-2 LD Freeze Dryer. The 
lyophilised peptides were re-suspended in 40 µl of 2% acetonitrile, 0.05% 






3.20 In-solution digestion and HPLC-MS/MS analysis 
 
After the preliminary results of the in-gel digestion were assessed an in-solution 
digestion was used due to the low number of proteins that were pulled-down. The 
eluates were denatured by the addition of 9M urea, 2M thiourea in a 1:2 ratio (final 
concentration 6M urea, 2M thiourea) and were vortexed briefly. Samples were then 
reduced by adding 100mM dithiothreitol (DTT; final concentration 10mM) followed by 
incubation at 37°C for 1 hour shaking at 600rpm. The samples were then cooled down 
to room temperature before alkylation of proteins using 500mM iodoacetamide (IAA, 
final concentration 50mM) followed by incubation in the dark for 1h at room 
temperature. Proteins were then precipitated using pre-chilled (-20°C) acetone in a 
6:1 volume ratio, overnight. The next day, samples were briefly vortexed and 
centrifuged at 0°C for 40min. the protein pellets were fully dried using a SpeedVac 
Concentrator (ThermoFisher Scientific, Savant SPD131DDA) for approximately 
30min. For protein digestion, samples were re-suspended in 40µl trypsin solution, 
containing 0.01µg/µl trypsin in 0.1 M triethylammonium bicarbonate (TEAB), pH 8.5, 
assuming 20μl, before briefly vortexing and centrifuging them. Proteins were digested 
overnight at 37°C under agitation (240rpm). The digestion was stopped by 
acidification of the samples with 10% v/v trifluoroacetic acid (TFA; final concentration 
1%). Peptide samples were purified using a 96-well C18 spin plate (MicroSpin, 
Harvard Apparatus, cat. no. 745617). The resin was activated using 200 µl methanol 
and centrifuged at 1000 x g for 1 minute. Wash steps included 200 µl of 80% 
acetonitrile (ACN), 0.1% TFA in H2O, and three equilibration steps using 200µl of 1% 
ACN, 0.1% TFA in H2O with centrifugation (1000 x g for 1 minute) after each step. 
Samples were loaded onto the resin and centrifuged at 2250 x g for 1 minute; the flow 
through was reloaded onto the resin a second time and centrifugation repeated. The 
resin was then washed three times with 200µl 1% acetonitrile (ACN), 0.1% TFA in 
H2O (centrifugation at 2250 x g for 1 minute). Finally, the samples were eluted with 
170 µl of 50% acetonitrile, 0.1% TFA in H2O (centrifugation at 1000 x g for 1 minute); 
this step was repeated, combining the collected eluate. Samples were then dried 
down using the SpeedVac Concentrator for approximately 5 hours. Dried peptide 
samples were reconstituted with TFA (0.05%) in ACN (2%) (Thermo Scientific, 
51101) and separated by a nanoflow LC system (Dionex UltiMate 3000 RSLC nano). 
Samples were injected onto a nano-trap column (EASY-Spray PepMap® RSLC C18, 
2μm 100Å, 75μm x 50cm) (Thermo Scientific, ES803), at a flow rate of 25 µL/min for 




The following nano-LC gradient was then used to separate the peptides at 0.25 
µL/min: 0−5min, 4-10% B; 5−75min, 10-30% B; 78−80min, 30−40% B; 85-89min, 
99%B, 90-120min 4%B, where A=0.1% formic acid (FA) in H2O, B=80% ACN, 
0.1%FA in H2O. The nano column (Acclaim® PepMap100 C18, 50 cm x 75 µm, 3µm, 
100 Å) was set at 45°C and coupled to a nanospray source (Picoview, New Objective, 
US). The temperature of the analytical column was set at 45°C and connected to an 
EASY-Spray ion source (Thermo Scientific, ES081). Spectra were collected from an 
Orbitrap mass analyser (Q Exactive HF, Thermo Scientific) using full Mass 
Spectrometry (MS) mode (resolution of 60,000 at 200 m/z) over the range 350–1600 
m/z. Data-dependent MS2 scan was performed using Quadrupole isolation in Top15 
mode using higher energy collision dissociation (HCD) fragmentation in each full MS 
scan (resolution of 15,000 at 200m/z) with dynamic exclusion enabled. Data-
dependent MS2 scan was performed using the top fifteen ions in each full MS scan 
(resolution of 17,500 at 200 m/z) with dynamic exclusion enabled. Proteome 
Discoverer software (Thermo Scientific, version 2.2.0.388) was used to search the 
raw data files against the mouse database (mouseSP201701, 16,844 protein entries) 
using Mascot (version 2.6.0, Matrix Science). 
 
The mass tolerance for precursor ions and fragment ions was set at 10 ppm and 20 
mmu, respectively. Trypsin was used as the digestion enzyme with up to two missed 
cleavages allowed. Variable modifications included acetylation of N-terminus, 
oxidation of methionine residues and deamination of asparagine in the presence of 
O18 water. MS/MS-based peptide and protein identifications were validated after 
filtering for a peptide probability of greater than 95%, a protein probability of greater 
than 99% and at least two proteins per  sample group. Data was normalised to the 
total peptide amount to take into account inter-sample variations in abundances and 




3.21 Software analysis of proteomic data 
 
For the analysis of the interactions of the proteins that were identified with Mass 




STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) software 
provides information on known and predicted protein-protein interactions based on 
experimental evidences and multiple other sources. An additional advantage is that 
the interactions are presented according their confidence following statistical 
advantage. 
 
Cytoscape, an open source software, employs protein-protein interaction data from 
large databases and provides information on the functionality of the proteins, their 
interaction networks and link the networks to databases of functional annotations. 
Moreover, Cytoscape offers a comprehensive visualisation of the interactions. 
 
Lastly, Reactome, an open-source and curated database of pathways, integrates 
user-supplied data as well as data from a set of databases to perform a pathway and 




Western Blot analysis was used for the validation of the Mass Spectrometry data. 
Eluate from RNA Pull-down was separated on a pre-cast 10-well NuPAGE Novex 4-
12% gradient Bis-Tris polyacrylamide gels (Life Technologies) as described above in 
3.18. For immunoblotting, proteins were transferred from the polyacrylamide gel to a 
nitrocellulose membrane in ice-cold transfer buffer (25mM Tris base and 200mM 
glycine dissolved in 20% methanol) for 2h at 350mA. Proteins were then stained with 
Ponceau S solution (SIGMA, cat. no. P7170) to confirm adequate transfer. After 
washing in TBS with 0.1% Tween-20 (TBS-T), membranes were blocked with 5% milk 
in TBS-T for 1h at room temperature. Membranes were washed briefly in TBS-T and 
incubated overnight in primary antibody solution (see list below, Table 2) at a 1:1000 
dilution in 5% bovine serum albumin (BSA; Sigma, cat. no. A9418) in TBS-T at 4 °C 
while rotating. Membranes were then washed thrice for 10min in TBS-T, followed by 
incubation with a light chain specific horseradish peroxidase (HRP)-conjugated 
secondary antibody (Dako) to detect the primary antibody, in a 1:5000 dilution in 5% 
fat-free milk in TBS-T for 1h at room temperature. After three washes in TBS-T (10min 
each), membranes were developed using enhanced chemiluminescence (ECL, GE 
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Healthcare) on a Xograph processor with exposure time dependent on signal 
intensity. 
 
Table 2. Primary antibodies used for immunoblotting. 
 
Primary antibody (species) Company, catalogue no. 
Larp1 (Rabbit) Proteintech 13708-1-AP 
IGF2BP2 (Rabbit) Proteintech 11601-1-AP 
hnRNPE1 (Rabbit) Proteintech 145231-AP 
DHX9 (Rabbit) Proteintech 177211-AP 
EIF2AK2 (Rabbit) Proteintech 182441-AP 
ILF3 (Rabbit) Proteintech 198871-AP 
Tra2b (Rabbit) Abcam ab31353 
 
3.23 Statistical analysis 
 
Statistical analyses of the levels of the miRNAs of different clusters upon editing were 
performed with the ANOVA test with Dunnett post hoc test. Results are given as 
mean±SD. A value of P<0.05 was considered significant. Microsoft® Excel® (version 
14.0.7208.5000) and GraphPad Prism (version 7.00) were used for statistical 
calculations. MS data were quantified using normalised total intensities and analysed 
as described previously. All other statistical analyses were performed with Microsoft® 
Excel® (version 14.0.7208.5000) and GraphPad Prism (version 7.00). FDR 
correction was used to correct for multiple testing for the statistical analysis of the 
Mass Spectrometry data. P-values<0.05 were considered significant with * signifying 




4 Chapter 4 EVALUATION OF THE DELIVERY 
METHOD FOR CRISPR/Cas9 AND ITS EFFICIENCY 




The extended miR-15 family comprises of 10 members (miR-107, miR-103, miR-15a, 
miR-15b, miR-16, miR-195, miR-497, miR-503, miR-424 and miR-646) of miRNAs 
which share an identical seed sequence (Figure 1.4).  
 
The members of the family are clustered in three separate chromosomes, with miR-
195, the miRNA of interest of the current study, being clustered together with miR-
497. The inhibition of miR-195, with the use of antimiRs/antagomiRs, is not precise, 
due to the high homology of sequence that the two miRNAs of the same family share 
and their identical seed sequence, a feature that leads to the non-specific 
downregulation of multiple members of the same family. 
 
In this project, CRISPR/Cas9 system was employed to edit the genomic locus of miR-
195 to assess whether genome editing can result in specific inhibition of the miRNA 
without affecting the levels of the other members of the family. CRISPR/Cas9 has 
emerged as a fast, easy-to-use and highly specific method for editing DNA in 
eukaryotic cells179, 196 although there are limitations, concerning the delivery of the 
system to cells, that need to be overcome230. The objective of the study was to take 
advantage of the CRISPR/Cas9 system to target the miR-195 genomic locus in 
primary cells with high specificity. By using sgRNAs designed to target specific sites 
in the stem loop of miR-195, a part of the genomic locus of the miR-195 was edited, 
a change that was expected to impair Drosha’s ability to process the stem loop. In 
more detail, the aims were to: 
 
• Establish a reliable workflow for miRNA inhibition using genome editing by: 
 
Ø Designing in silico and testing sgRNAs that target and edit miRNA genes, 








• To genetically engineer, with the use of CRISPR/Cas9, stable cell lines of SMCs 
that harbour deletions of miR-195 and 
 
• To assess putative off target mutagenesis of the guides tested. 
 
The results presented in this chapter demonstrated that transfection of mouse 
VSMCs stably expressing Cas9 with IVT guides lead to efficient editing of the mmu-




4.2 Experimental Design 
 
The present study aimed to explore the use of CRISPR/Cas9 in editing miRNA genes 
in primary cells in order to investigate their regulation and function. The focus of it 
was miR-195, a miRNA previously shown to participate in the onset and development 
of AAA98. As an initial step, different strategies were tested to generate genetically 
engineered SMCs that harboured a deletion for miR-195. To achieve sufficient editing 
efficiency and take advantage of the latest technological developments in the field, a 
total of four experimental strategies were employed: 
 
(A) Plasmid delivery of the CRISPR/Cas9 system,  
 
(B) Lentiviral delivery of the CRISPR/Cas9 system, 
 
(C) Cas9 ribonucleoproteins (Cas9/RNPs) and 
 
(D) Transfection of VSMCs stably expressing Cas9, with IVT sgRNAs. 
 
Firstly, after designing guides targeting the desired sites in silico, the plasmid delivery 
was assessed in human cells. By using plasmids, which harboured the corresponding 
guide sequences and the Cas9 gene, we tested their ability to edit the targeted site 
and their efficiency. The efficiency of editing was also assessed at different time 
points. By doing so, potential effects on the viability of the cells, as a result of the 
transfection or the editing, were assessed. Genomic DNA was also sequenced to 
identify the mutation patterns. However, the obtained results suggested a rather low 
efficiency and led to undertaking a different delivery technique. 
 
As a second strategy, lentiviral particles were used to infect primary cells. Since the 
lentiviral infection results in the integration of the sequence of interest into the 
genome, we expected to have more efficient gene editing of the miR-195 locus. The 
second strategy was assessed in two different human cell types, HUVECs and human 
SMCs, with the results suggesting a substantial editing efficiency, and mouse VSMCs 
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with the efficiency reaching significant levels. However, the strategy was deemed as 
non-optimal because of the potential high off-target mutagenesis, due to the 
continuous presence of Cas9/RNP complexes in the cells, as well as due to the 
limitations of the lentiviral delivery. 
 
To address these issues, a third strategy was employed. Transient transfection of 
cells with Cas9/RNPs was performed. Commercially available recombinant Cas9 
proteins were used along with IVT sgRNA designed to target the human miR-195 and 
assessed in in vitro experiments. Additionally, HEK293T cells were transfected with 
Cas9/RNP complexes with the editing efficiency not reaching sufficient levels. 
 
Furthermore, mouse VSMCs were infected with lentiviral particles that harboured only 
the Cas9 gene, thus generating stable cell lines that were stably expressing the Cas9 
protein. The cells were then transfected with IVT guides. The approach was thought 
as the most suitable to overcome the limitations of transfecting cells, an approach 
that led to low efficiency of editing. After concluding to our approach of choice, the 
levels of the mature miRNA were assessed in mouse VSMCs to determine the impact 
of gene editing in the mmu-miR-195 inhibition. The effect on the expression levels of 
other members of the miR-15 family was also evaluated. 
 
Finally, possible off-target mutagenesis was studied, with the experiments showing 







4.3.1 Gene Editing in Human Cells 
 
4.3.1.1 In Silico sgRNA Design for hsa-miR-195 and cloning 
 
The CRISPR DESIGN Tool (http://crispr.mit.edu, Zhang Lab, MIT) was used to 
design the guides for the genomic locus of miR-195 (Figure 4.1). The DNA sequence 
corresponding to the locus of the miRNA gene was used as input sequence to the 
software. The following oligos, which targeted sites in the miR-195 stem loop (Figure 














Figure 4.1 In silico design of the single-guide RNA for hsa-miR-195 locus. The guides used for the 
human miR-195 locus were designed with the help of the CRISPR DESIGN Tool (http://crispr.mit.edu, 
Zhang Lab, MIT). The guide sequence is depicted, with the corresponding score and the 5 most likely 









Figure 4.2 Schematic representation of the editing of the hsa-miR-195 genomic locus. (A) The 
hsa-miR-195 genomic locus with the corresponding elements. The location of the 5p arm of the miRNA 
is highlighted in red and the location of the 3p arm of the miRNA is highlighted in blue. The SspI restriction 
enzyme sites are depicted as squares. (B) Schematic of the miR-195~497 cluster and the location of 
the DSBs. (C) The genomic DNA sequence of the miR-195 locus. The mature miR-195 is underlined 
and the seed sequence is highlighted with a red rectangular. The target sites of the two guides are shown 
with their corresponding PAM sequences highlighted in green. The positions, where the DSB occurred, 







4.3.1.2 Strategy A: Plasmid Delivery 
 
 
To determine the efficiency of the selected guides, HEK293T cells were transfected 
with pX330 plasmids harbouring the sgRNAs (pX330G1 and pX330G2). PCR 
amplification of the genomic locus revealed two bands in the samples that were 
transfected with both plasmids (Figure 4.3A), a long one corresponding to the full size 
and a shorter one corresponding to a truncated product. The latter was a result of the 
simultaneous editing of the locus by both guides and the perfect re-ligation of the 
strands which resulted in the deletion of a 105bp long fragment as confirmed by 
sequencing. The gene editing efficiency of each treatment was assessed with the 
T7EI assay (Figure 4.3B). Each of the single guides demonstrated an efficiency which 
varied from 24-27% while the combination of both guides showed an efficiency of 
34%. Editing efficiency did not change between Day2 and Day5 post transfection. 
Sanger sequencing was used to identify the mutation patterns. In total, a variety of 
patterns were observed: (i) DNA that was not edited, (ii) DNA that had a deletion of a 
105bp long sequence upon editing from both guides and perfect re-ligation of the 
DNA strands, (iii) DNA with short indels at the site where the DSB occurred and (iv) 








Figure 4.3 Gene editing of the miR-195 genomic locus using plasmid vectors. (A) HEK293T cells 
were transfected with the pX330 plasmid harbouring Cas9 and sgRNA1 or sgRNA2 (pX330G1 and 
pX330G2, respectively). On Day 2 (D2) and Day 5 (D5) post transfection, DNA was harvested and the 
genomic locus of miR-195 was PCR amplified. Agarose gel electrophoresis revealed two amplicons of 
different size in the cells that were transfected with both guides simultaneously, one corresponding to 
the full-size product (577bp) and one to the truncated product (471bp). (B) T7EI assay was used for 
assessing the gene editing efficiency that ranged from 18-34%. (C) Blue and white colony screening 
was used to pick the colonies that were successfully transformed with the PCR amplicons. (D) PCR 
amplification of the isolated plasmids indicated the differences in the size of the cloned sequences. (E) 
Nine colonies were selected according to the size of the PCR amplicon and were Sanger sequenced. 









4.3.1.3  Strategy B: Lentiviral Delivery in Human Primary Cells 
 
 Gene Editing in HUVECs 
 
To facilitate the delivery of the CRISPR/Cas9 system to primary cells lentiviral particles 
were used. HUVECs were infected simultaneously with lentiviral particles harbouring both 
sgRNAs (LEG1 and LEG2). 
 
Titration experiments with PLUS™ Reagent, a reagent that enhances cationic lipid-
mediated transfection of DNA into cultured eukaryotic cells, were conducted. Indeed, high 
editing efficiency was observed based on the intensity of the bands that corresponded to 
the truncated product (Figure 4.4, lanes denoted with asterisks). The T7EI confirmed the 
high editing efficiency. Moreover, the fact that, after the T7EI only 4 distinct bands were 
observed indicates perfect re-ligation of the DNA bands while, the marginally higher 
editing efficiency in the case PLUS™ Reagent was not used, demonstrated the efficient 
delivery of the system (Figure 4.4). 
 
Next, in three independent experiments PCR amplification of the locus revealed two 
bands for the edited cells with the shorter one corresponding to the truncated product in 
accordance with the results for the plasmid delivery (Figure 4.5A). The T7EI assay 
revealed editing efficiency varying from 81-96% (Figure 4.5B). Sanger sequencing 
revealed 3 different mutation patterns: (i) DNA that had a deletion of a 105bp long 
sequence upon editing from both guides and perfect re-ligation of the two strands and (ii) 
DNA with short indels at only one or (iii) both sites of the DSB (Figure 4.5C). 
 
The pattern of the DNA bands, after the T7EI digestion, differs among the samples 
infected with only one of the two guides and those infected with both guides. In the latter 
occasion, only four bands are observed: (i) the band corresponding to the full sequence, 
(ii) the band of the truncated sequence, (iii) the band corresponding to a 359bp long 
sequence and (iv) the band of the 112bp long sequence while the 465bp and 218bp long 
bands, which are noticed in the treatments with either LEG1 or LEG2, are not detected. 
These differences are due to the simultaneous cleavage of the sequence by the two 




Figure 4.4 T7 Endonuclease I assay for HUVECs upon lentiviral infection. HUVECs were infected 
with lentiviral particles harbouring Cas9 and sg195g1 or sg195g2 (LEG1 and LEG2, respectively). On 
Day 3 post infection, DNA was harvested and the genomic locus of miR-195 was PCR amplified. In the 
cells that were infected with both guides simultaneously PCR revealed two bands, one corresponding to 
the full-size product (577bp) and one to the truncated product (471bp), derived from perfect re-ligation 





Figure 4.5 Lentiviral delivery of Cas9 and sgRNA. (A) HUVECs were infected with lentiviral particles 
harbouring Cas9 and sg195g1 or sg195g2 (LEG1 and LEG2, respectively). On Day 3 post infection, 
DNA was harvested and the genomic locus of miR-195 was PCR amplified. In the cells infected with 
both guides simultaneously PCR revealed two bands, one corresponding to the full-size product (577bp) 
and one to the truncated product (471bp). (B) The T7EI assay revealed an edited efficiency of 81-96%, 
in three independent experiments. (C) Mutation screening was assessed using Sanger sequencing. 









Figure 4.6 Schematic representation of the digestion products upon editing with guides sg195g1 
and sg195g2. Upon T7EI digestion of the miR-195 amplicon (A) gene editing using the LEG2 is 
predicted to generate two fragments of 112bp and 465bp, (B) gene editing using the LEG1 is predicted 
to generate two fragments of 218bp and 395bp and (C) gene editing using the LEG12 and LEG2 followed 





 Gene Editing in human SMCs 
 
Human SMCs were infected with lentiviral particles harbouring the designed sgRNAs 
(LEG1 and LEG2). PCR amplification of the locus revealed two bands. Based on T7EI 




Figure 4.7 T7 Endonuclease I assay for hSMCs upon lentiviral infection. Human SMCs were 
infected with lentiviral particles harbouring Cas9 and sg195g1 or sg195g2 (LEG1 and LEG2, 
respectively). On Day 3 post infection, DNA was harvested and the genomic locus of miR-195 was PCR 
amplified. The cells infected with both guides simultaneously revealed, after PCR amplification, two 





4.3.1.4 Strategy C: Cas9/RNPs in HEK293T cells 
 
 
As a third approach, Cas9/RNPs were used. In vitro transcribed guide G2 was used 
to form Cas9/RNP complexes. In order to test for the ability of the Cas9/RNP complex 
to cleave the targeted DNA sequence, an in vitro Cas9 digestion was performed which 
showed that Cas9 is able to cleave the PCR template when in complex with guide 
G2. The sizes of the two observed bands corresponded to the position of the cleavage 
by guide G2 and the digestion was complete (Figure 4.8A). Additionally, HEK293T 
cells were transfected with Cas9/RNPs to study the complexes’ ability to recognise 




Figure 4.8 Assessment of Cas9/RNPs approach in HEK293T cells. (A) Cas9/RNPs complexes were 
generated by incubating Cas9 protein (0.5μg) with in vitro transcribed guide sg195g2 (G2), (125ng). The 
Cas9/RNPs were tested in vitro for their ability to recognise and cut the targeted DNA. (B) HEK293T 
cells were transfected with Cas9/G2 RNP complexes and the editing efficiency was assessed using T7EI 





4.3.1.5  Off-target Mutagenesis 
 
Mutagenesis, in the most likely off-target sites (OFT), was assessed using the T7EI 
assay. DNA from lentiviral infected HUVECs that showed the highest editing 
efficiency was used. T7EI assay did not show any off-target editing. The non-specific 
bands, of shorter length, that were observed in some of the samples (Figure 4.9), did 
not result from gene editing, since they were observed in both the edited and unedited 
cells and their sizes did not correspond to the off-target cleavage of the LEGuides. 
OFT 2-5 for guide LEG1 and OFT 1, 2 and 4 for guide LEG2 were tested.  
 
 
Figure 4.9 Assessment of possible off-target mutagenesis upon lentiviral infection of HUVECs. 
The most likely off-target sites for both guides (OFT 1-5), as suggested by the CRISPR DESIGN Tool 
(http://crispr.mit.edu, Zhang Lab, MIT), were assessed by T7EI assay. No off-target mutagenesis was 




4.3.2 Gene Editing in Mouse Cells 
 
4.3.2.1 In Silico sgRNA Design for mmu-miR-195 and cloning 
 
The CRISPR DESIGN Tool (http://crispr.mit.edu, Zhang Lab, MIT) was used to 
design the guides targeting the mmu-miR-195 genomic locus (Figure 4.10). As an 
input, the DNA sequence of the locus of the miRNA was used. Three oligos, which 
targeted sites within the miRNA sequence (Figure 4.11 and Figure 4.12), with the 
highest scores, were selected: 
 
 
sg195m2 (Gm2): 5’-TGGAGCAGCACAGCCAATAT-3’ 
 
sg195m4 (Gm4): 5’-CAGCACAGAAATATTGGCAT-3’ 
 





Figure 4.10 In silico design of the single-guide RNA for the mmu-miR-195a locus. The guides used 
for editing the mouse miR-195 locus were designed with the help of the CRISPR DESIGN Tool 
(http://crispr.mit.edu, Zhang Lab, MIT) on-line tool. The guide sequence is depicted, with the 









Figure 4.11 Schematic representation of the editing of the mmu-miR-195 genomic locus. (A) The 
mmu-miR-195 genomic locus. The location of the 5p arm of the miRNA is highlighted in red and the 
location of the 3p arm of the miRNA is highlighted in blue. DSBs are depicted as purple triangles and 
SspI and MwoI restriction sites are depicted as squares. (B) Schematic of the mmu-miR-195~497 
cluster. (C) Part of the DNA sequence of the miR-195 locus. The DNA sequence of the mature mmu-
miR-195 is underlined. The target sites of the guides are shown with their corresponding PAM sequences 
highlighted in green. The positions where the DSB occurs are depicted as purple triangles. Gm2: 


























Figure 4.12 Schematic representation of the secondary structure of the mmu-miR-195a stem loop 
with guides. Representation of the mmu-miR-195a stem loop with the detailed sequence, bulges, 
mismatches and apical loop along with the targeted DNA sequence and the PAM sequence for (A) 
sg195m2, (B) sg195m4 and (C) sg195mA. PAM sequence is highlighted in blue. The mature miRNA 
sequence is highlighted in purple and grey arrows indicate the corresponding position of the DSB on the 
stem loop which is the site of mutations induced by random indels following editing of the genomic locus 







4.3.2.2 Strategy B: Lentiviral delivery in mouse VSMCs 
 
 Lentiviral particles Gm2 and Gm4 
 
Mouse VSMCs were infected with lentiviral particles harbouring the designed guides 
Gm2 and Gm4 (LEGm2 and LEGm4). On Day 3 after the infection, gene editing 




Figure 4.13 T7 Endonuclease I assay for mouse SMCs upon lentiviral infection with guides Gm2 
and Gm4. Mouse SMCs were infected with lentiviral particles harbouring Cas9 and sg195m2 or 
sg195m4 (LEGm2 and LEGm4, respectively). On Day 3 post infection, DNA was harvested and the 
genomic locus of mmu-miR-195 was PCR amplified. T7EI assay was used to assess the efficiency of 





Figure 4.14 Schematic representation of the sizes of T7EI digestion products upon editing with 
guide Gm4 and Gm2. T7EI digestion of the mmu-miR-195 amplicon upon editing with (A) guide LEGm4 
is predicted to generate two fragments of 204bp and 326bp, (B) guide LEGm2 is predicted to generate 
two fragments of 228bp and 302bp and (C) both guides simultaneously, followed by perfect re-ligation, 






 Lentiviral particles Gm2 and GmA 
 
Mouse VSMCs were infected with lentiviral particles harbouring the designed sgRNAs 
(LEGm2 and LEGmA). PCR amplification of the DNA harvested from the cells 
revealed two bands for the infected mouse VSMCs while T7EI assay showed a gene 
editing efficiency of 32% and 26% for LEGm2 and LEGmA respectively and 48-51% 
for cells infected with both guides simultaneously (Figure 4.15). The pattern of the 
DNA bands, after the T7EI digestion, differs according to the treatment. When mouse 
SMCs were infected with both guides at the same time, four bands can be observed: 
(i) a band of the full sequence (530bp), (ii) a band of the truncated sequence (484bp), 
(iii) a band corresponding to a 302bp long sequence and (iv) a band of the 182bp 
long sequence. These differences in the pattern between the single use of the guides 
and the infection with both together are the result of the simultaneous cleavage of the 




Figure 4.15 T7 Endonuclease I assay for mouse VSMCs upon lentiviral infection with guides Gm2 
and GmA. Mouse VSMCs were infected with lentiviral particles harbouring Cas9 and guides sg195m2 
or sg195mA expression (LEGm2 and LEGmA, respectively). On Day 3 post infection, DNA was 
harvested and the genomic locus of mmu-miR-195 was PCR amplified. The T7EI assay was used for 




Figure 4.16 Schematic representation of the T7EI digestion products upon editing with guide 
GmA and Gm2. Upon T7EI digestion of the mmu-miR-195 amplicon (A) gene editing using the LEGmA 
is predicted to generate two fragments of 182bp and 348bp, (B) gene editing using the LEGm2 is 
predicted to generate two fragments of 228bp and 302bp and (C) gene editing using the LEGmA and 
LEGm2 followed by perfect re-ligation will generate a truncated product consisting of two fragments of 






4.3.2.3 Strategy D: Transfection of mouse VSMCs stably expressing Cas9 with 
sgRNAs 
 
Mouse VSMCs stably expressing Cas9 were generated by infecting cells with 
lentiviral particles harbouring Cas9. Following infection, cells were selected with 
Puromycin treatment (2µg/ml) for 48h, (Figure 4.17). 
 
 
Figure 4.17 Cas9 expression in VSMCs infected with LentiCRISPRv2 lentiviral particles. Lysates 
from mouse VSMCs infected with lentiviral particels harbouring Cas9 were harvested and blotted with 
antibody against the protein (TherrmoFisher Scientific, #MA5-23519. Four different lines are presented. 
B-actin was used as a normalisation control. For comparison, a similar exposure time was applied.  
 
Next, the ability of the Cas9/RNP complexes to form and cleave the targeted DNA 
sequence was tested by an in vitro Cas9 digestion. In vitro transcribed guides were 
used to form Cas9/RNP complexes with the digestion showing that Cas9 is able to 
cleave the PCR template when in complex with either Gm2 or GmA. The sizes of the 
observed bands corresponded to the position of the cleavage by the Gm2 or GmA 
and the digestion was nearly complete (Figure 4.18A).  Additionally, mouse VSMCs 
infected with lentiviral particles harbouring Cas9, were transfected with IVT guides to 
assess the ability of the single guide RNAs to form complexes with the Cas9, 
recognise and cleave the targeted DNA in cells. Two conditions were tested, cells 
infected with lentiviral particles harbouring Cas9 but not treated with puromycin and 
selected cells. T7EI showed that only the selected cells had successful editing of the 





Figure 4.18 Assessment of gene editing in mouse VSMCs stably expressing Cas9. (A) Cas9/RNPs 
complexes were generated by incubating Cas9 protein (0.5μg) with in vitro transcribed guide (125ng). 
The Cas9/RNPs were tested in vitro for their ability to recognise and cut the targeted DNA. (B) Mouse 
VSMCs, stably expressing Cas9, were transfected with IVT guides GmA or Gm2. Two days post 
transfection, DNA was harvested and the genomic locus of mmu-miR-195 was PCR amplified. The T7EI 
assay was used for assessing the efficiency of the editing of 22%. The digested products corresponded 
to the expected sizes as described above. Gm2: sg195m2 and GmA: sg195mA, (n=3). Represantative 
results from only one experiment are shown. 
 
Selected mouse VSMCs were then transfected simultaneously with IVT guides GmA 
and Gm2. DNA was extracted on two different days, Day2 (D2) and Day7 (D7) and 
the editing efficiency showing levels that were stable across the two timepoints (Figure 
4.19). 
 
Figure 4.19. T7EI assay for mouse VSMCs stably expressing Cas9 after transfection with IVT 
guides. Mouse VSMCs that were infected with lentiviral particles harbouring Cas9 were selected with 
puromycin treatment and compared to non-selected cells. Gm2: sg195m2 and GmA: sg195mA. n=3, 
represantative results from only one experiment are shown. 
 
The mmu-miR-195 locus has two SspI restriction sites (5’-AATATT-3’) with single 
guide Gm2 disrupting one of them and 3 MwoI restriction sites (5’-GCNNNNNNNGC-




expressing Cas9 were transfected with IVT guides and SspI and MwoI restriction 
digestions were performed for rapid assessment of gene editing. After the 
simultaneous or single transfection of mouse VSMCs stably expressing Cas9 with 
single guides Gm2 and GmA, digestion with SspI or MwoI restriction enzymes were 
used to rapidly assess the success of the editing. According to the disruption of the 
digestion sites that each guide conferred, different patterns were observed. 
Transfection solely with single guide Gm2 and digestion with SspI resulted in three 
bands corresponding to 331bp and 199bp after the successful editing of the targeted 
site and the disruption of the one of the two SspI sites (as depicted above in Figure 
4.11), and bands of 303bp and 199bp after no editing of the two sites resulting in 
digestion of both of them. In the latter case, the digestion resulted in a third band of 
28bp which diffused in the agarose gel and is non-discernible. Upon transfection with 
single guide GmA, no SspI site got disrupted. Simultaneous transfection with both 
guides and digestion with SspI showed the same pattern as previously described 
(Figure 4.20A). The 530bp corresponded to non-complete digestion of the full-length 
PCR product. Upon digestion with MwoI restriction enzyme, multiple bands for the 
non-edited PCR product were observed, corresponding to 184bp, 177bp, 102bp and 
a band of shorter length of 67bp. After, transfection with single guide GmA, only one 
MwoI got disrupted upon successful editing, resulting in the presence of a band 286bp 
long. Upon editing with both guides simultaneously, the pattern changed as a result 
of the perfect re-ligation of the DNA and the digestion of a shorter PCR product which 
resulted to a 244bp (Figure 4.20B). In both cases, editing with both guides but not 
digestion with either restriction enzyme, revealed a 484bp long band, which 
corresponded to the perfect re-ligation of the DNA after editing with the guides (right 









Figure 4.20 Restriction enzyme digestion with SspI and MwoI. Mouse VSMCs stably expressing 
Cas9 were transfected with IVT Gm2 or GmA. On Day3 post transfection, DNA was harvested and the 
genomic locus of miR-195 was PCR amplified. (A) Upon SspI digestion, only cells transfected with both 
guides (denoted with two asterisks) showed an undigested product of 484bp. Cells transfected only with 
Gm2 had a disruption of one of the SspI sites (one asterisk). (B) MwoI digestion showed a different 
pattern for transfection with Gm2 together with GmA and Gm2 only transfected cells (denoted with 






4.3.2.4  Off-target mutagenesis in mouse VSMCs 
 
 Off-target mutagenesis upon lentiviral infection 
 
Mutagenesis, in the most likely off-target sites (OFT) as returned by the CRISPR 
online tool, was assessed using the T7EI assay. DNA from lentiviral infected mouse 
VSMCs did not show any off-target editing. The non-specific bands, of shorter length, 
that were observed in some of the samples (Figure 4.21), did not result from gene 
editing, since they were observed in both the edited and unedited cells and their sizes 
did not correspond to the predicted site of off-target cleavage of the LEGuides. The 
five most likely off-targets were tested for each guide (Figure 4.21). 
 
 
Figure 4.21 Assessment of possible off-target mutagenesis upon lentiviral infection of mouse 
SMCs. The five most likely off-target (OFT 1-5) for both guides (A) Gm2 and (B) GmA, as suggested by 
the CRISPR DESIGN Tool (http://crispr.mit.edu, Zhang Lab, MIT), were assessed by T7EI assay. No 
off-target mutagenesis was detected for neither of the LEGm2 and LEGmA. OFT.:Off-target, ND: Non 






 Off-target mutagenesis upon transfection of mouse VSMCs stably 
expressing Cas9 with IVT guides 
 
For the assessment of putative off-target mutagenesis the 7 most likely off-target sites 
(OFT) as returned by the CRISPR DESIGN Tool (http://crispr.mit.edu, Zhang Lab, 
MIT) and CRISPR Finder (Wellcome Trust Sanger Institute), was assessed using the 
T7EI assay. DNA from mouse VSMCs stably expressing Cas9 were transfected with 
IVT single guide Gm2 and did not show any off-target editing. The digested observed 
bands, of shorter length (Figure 4.22), did not result from gene editing, since they 
were observed in both the edited and unedited cells and their sizes did not correspond 
to the predicted site of off-target cleavage of the guides. 
 
 
Figure 4.22 Assessment of possible off-target mutagenesis upon editing with IVT Gm2. T7EI 
assessment of gene editing in the loci of putative off-target sites for Gm2 as predicted by the CRISPR 
DESIGN Tool (http://cripsr.mit.edu, Zhang Lab, MIT) and CRISPR Finder (Wellcome Trust Sanger 
Institute). OFT; Off-Target, ND: Non-Detectable, NS: Non Specific. Gm2: sg195m2, n=1. 
 





CRISPR/Cas9 is a novel, versatile gene editing technique that appears to be able to 
overcome the problem of the unspecific miRNA inhibition, a limitation that hinders the 
study of miRNAs. In the present study, we investigated whether genome editing, with 
the use of CRISPR/Cas9, can be employed for specifically inhibiting miR-195 in 
primary cells by testing four different approaches. Although gene editing has been 
used in the past for the knock-out of miRNAs157, 231, 232, to the best of my knowledge, 
this is the first time the CRISPR/Cas9 is used in primary cells to inhibit miR-195.  
 
4.4.1 Gene Editing in Human Cells 
  
For the current project, the first step undertaken was to design guides to edit the miR-
195 genomic locus. The objective was to target two sites in the genomic locus of the 
hsa-miR-195 stem loop, one close to the seed sequence and one further upstream 
of the stem loop of the miRNA. It has already been shown that a combination of 
sgRNAs can be used for editing a locus more effectively233. However, the short length 
of the DNA sequence corresponding to the stem loop together with the PAM 
requirements of the CRISPR/Cas9 was an important limiting factor since the chances 
of finding 5’-NGG-3’ sequences in such a short sequence were poor. Moreover, 
although it has been shown that Cas9 is able to induce DSBs in different sites in short 
distances within the same genomic locus and lead to the deletion of the flanked 
sequence,233, 234 the short distance between putative targeted sites can interfere with 
the ability of Cas9 protein to physically approach the sequences. Considering results 
reported in previous studies along with the CRISPR requirements, the guides were 
designed accordingly. A sequence of a total length of 250nt, flanking the hsa-miR-
195 gene, was used as an input to the CRISPR Design Tool and because of the need 
to target specific sites in the miRNA stem loop, the guides were chosen primarily 
based on the position of the site they targeted and not necessarily on their ranking 
score (Figure 4.1, Figure 4.2).  Four different delivery strategies with different 




Figure 4.23. A comprehensive summary of the experimental approaches and their effects. 
 
4.4.1.1 Strategy A: Plasmid Delivery 
 
Plasmid delivery to HEK293T cells was used to induce gene editing to the hsa-miR-
195 locus. Plasmid delivery would have only transient expression of the Cas9 protein 
thus minimising the effects of the protein accumulation that could possibly lead to off-
target effects235. Nevertheless, according to our results, the efficiency of the gene 
editing, as the T7EI assay revealed, was rather modest. The highest percentage of 
indels was achieved after transfection with plasmids harbouring both guides, 
simultaneously, reaching a 34% on Day2. These results come in accordance with 
previous studies reporting higher efficiency upon editing with two guides233, 236. 
Although T7EI assay is a quantitative technique used for assessing successful editing 
that cannot provide qualitative information and is thought to marginally underestimate 
its efficiency due to innate limitations of the assay, it is regarded as the gold standard 
assay. The sizes of the bands after the T7EI indicated the sites where editing was 
induced. In more detail, T7EI is an in vitro assay that is used to assess the editing by 
employing the T7 endonuclease which is able to recognise and cleave mismatches 
in double stranded DNA. The digestion products have sizes that correspond to the 
site of the edit (Figure 3.3). Formation of homoduplexes between edited strands or 
incomplete digestion by T7 endonuclease underestimate the editing efficiency and 
limit the assay208.  
 
Next, the results from T7EI were confirmed by DNA sequencing, which showed that 
the editing occurred specifically in the sites targeted by the designed guides. In line 
with published results237, editing of the hsa-miR-195 genomic locus resulted in the 
formation mainly of deletions, rather than insertions, while, in the case of transfection 
with both guides simultaneously, either the formation of indels in both targeted sites 
106 
 
or the excision of the sequence flanked by the designed guides and perfect re-ligation 
of the DNA strands (Figure 4.3E). Further to this, it has already been reported that 
two guides can be used for the excision of DNA sequences as was observed in the 
current project200. Of note is the fact that although the predicted length of the excised 
sequence was 106bp, Sanger sequencing revealed that in 50% of the blue and white 
colonies screened (data not shown) the length of the excised sequence was in fact 
105bp. Although it could be the result of an insertion of an adenine following the 
editing, it seems more likely to be the result of Cas9 cutting 4nt upstream of the PAM 
sequence instead of 3nt, as was expected, in either of the two targeted sites. Although 
this discrepancy has been reported179, due to sequencing limitations, there was not a 
way of deciphering at which site that discrepancy occurred. In more detail, both of the 
two trinucleotide sequences upstream of the PAM sequences of the two guides used 
are followed by an adenine. In both cases the expected outcome would have been 
the adenine to be excised although sequencing data did not confirm that. A single 
unexpected adenine was identified in all of the sequences where the 105nt excision 
occurred although, based on these results, we can conclude in which case DSB 
happened 4nt upstream of the PAM sequence. However, taking into consideration 
the high percentage of the transfection (data not shown), that was observed and the 
relatively modest percentage of the gene editing, the plasmid delivery did not appear 
as a favourable delivery system in primary cells. Nevertheless, plasmid delivery was 
confirmed as a suitable delivery approach to quickly test for the ability of the designed 
guides to edit the sequence of choice in human cells. 
 
4.4.1.2 Strategy B: Lentiviral Delivery 
 
In order to address the low efficiency of the plasmid delivery, lentiviral delivery of the 
CRISPR/Cas9 was chosen as an alternative approach and it was tested in primary 
human cells. Previous studies on HUVECs, using lentiviral particles, demonstrated 
that it is a powerful method238 and taking advantage of the high proliferation rate of 
the cells, preliminary experiments were conducted. It has been reported that 
CRIPSR/Cas9 leads to higher editing efficiency in dividing cells203. Upon division and 
more specifically during the mitotic (M) phase of the cell cycle, the nuclear envelope 
breaks down due to the karyokinesis. During this, the CRISPR/Cas9 system can more 
easily access the DNA and edit it. Since initial experiments were conducted in human 
cells, there was no need to design new guides. Firstly, optimisation experiments were 
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used to identify the optimal conditions of infection (Figure 4.4) and results from three 
independent experiments suggested that infection with lentiviral particles resulted in 
almost complete gene editing as shown in Figure 4.5. PCR amplification showed two 
bands of different sizes with the intensity of the shorter one, corresponding to the size 
of the truncated DNA upon successful editing, indicating high efficiency (Figure 4.5A). 
Indeed, T7EI confirmed that lentiviral infection had high levels of editing with the 
efficiency reaching a 98% occurrence (Figure 4.5B). These results can be attributed 
to both the high proliferation rate of the cells as well as the efficacy of the delivery. 
DNA sequencing established that editing occurred in the targeted sites while the cells 
showed the same editing patterns as with plasmid delivery (Figure 4.5C). According 
to our results, we observed a high percentage of targeted genomic deletions, while in 
the instances when the flanked sequence was not excised, indels were observed in 
the cleaved sites, in agreement with previous findings239. Interesting are the changes 
of the pattern of the digested bands following T7EI digestion with the sizes of the 
bands showing as a mix following the editing with the two guides alone (Figure 4.5B). 
This can be explained by the fact that when editing with both guides occurred, a DNA 
sequence is excised and the DNA strands are perfectly re-ligated, not leading to any 
cleavage by T7EI, while editing at the corresponding sites with the two guides at 
different timepoints induce the formation of indels that upon cleavage resulted in 
fragments of different lengths, unique to this treatment (Figure 4.6). 
 
Following the preliminary results on HUVECs and given that the study aimed at using 
human SMCs, since the apoptosis of SMCs is a key component in triggering the AAA, 
the system’s efficiency was investigated in human SMCs. Although lentiviral infection 
confirmed the high editing efficiency, with a percentage of 80% (Figure 4.7), miRNA 
quantification (data not shown) showed that the levels of the miR-195 in prolonged 
cell culture conditions were extremely low, thus leading to the conclusion that the 
human SMCs would not be an appropriate model for the study. Therefore, mouse 











4.4.1.3 Strategy C: Cas9/RNPs 
  
In a third approach, the use of Cas9/RNPs appeared as a favourable alternative to 
the previous strategies deployed because of its transient effects and to its quick 
turnover240. Taking advantage of the latest developments in the CRISPR/Cas 
research and the reagents that became widely commercially available, such as 
recombinant Cas9 protein and IVT and synthetic sgRNAs, a new set of experiments 
was conducted. In order to test the ability of the Cas9 recombinant protein to bind the 
IVT guides and form RNP complexes and to recognise the targeted DNA, in vitro 
experiments were conducted. Guide G2 was used because of the high editing 
efficiency it showed in preliminary experiments (Figure 4.3). Following IVT and 
purification of the guide, it was added to recombinant Cas9 in vitro and was incubated 
with the corresponding DNA template leading to its cleavage at the targeted site, as 
the length of the digested bands indicated (Figure 4.8A). Next, HEK293T cells were 
transfected with Cas9/RNPs complexes with IVT guide G2, showed an efficiency of 
25% (Figure 4.8B). The fact that the editing efficiency was similar to the one observed 
after plasmid transfection with the same guide, suggested that for the hsa-miR-195 
locus and the specific guide it was not possible to obtain a higher efficiency for 
Cas9/RNPs compared to plasmid delivery as described in the literature208. 
 
4.4.1.4 Off-target mutagenesis 
 
One of CRISPR’s major limitation is the putative off-target mutagenesis as a result of 
the tolerance the guide shows in mismatches in their complementarity with the 
targeted DNA235. In more detail, the sgRNA can recognise and bind DNA sequences 
that show up to 3nt differences in their complementarity, leading Cas9 to edit the off-
target sites. This activity occurs more easily in the 5’-end of the guide, which is its 
distal end from the endonuclease domains of Cas9. This off-target activity can result 
in unwanted editing of the DNA sequence, although with lower efficiency203. Given 
the importance of the gene editing to be specific together with the possibility of the 
off-target sites to be in onco-suppressor genes, the need to test for possible off-target 
mutagenesis becomes vital. An increasing number of studies suggest that 
CRISPR/Cas9 is likely to induce high off-target mutagenesis in multiple sites although 
with no conclusive data241. To address this issue, the CRISPR design software 
provide a list of possible off-target sites as predicted by an algorithm that penalises 
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the suggested guides according to the number of mismatches between the guide and 
the putatively recognised DNA sequence, ranking them in an inverse order of off-
target likelihood (Figure 4.1). To assess the off-target mutagenesis, primers flanking 
the 7 most likely off-target sites for guides G1 and G2, as predicted by CRISPR Online 
tool, were designed (Supplementary Table 5), with T7EI showing no editing at said 
sites (Figure 4.9). Taking into consideration the high efficiency of the guides used 
together with the fact that no off-target editing was detected, we can securely 
conclude in that guides G1 and G2 did not induce any off-target editing in these sites, 
although the possibility that the guides can have other sites cannot be excluded. 
Whole genome sequencing is the technique of choice for assessing possible off-
target mutagenesis by scanning the whole genome for discrepancies in the 
sequence242 although, even in this case, no definitive results can be obtained due to 
the presence of SNPs243. 
 
4.4.2 Gene Editing in Mouse Cells 
 
Mouse VSMCs appeared as a favourable alternative to human SMCs. As in human 
cells, the first step undertaken was the design of guides. Although human miR-195 
genomic locus shares high sequence similarity with the corresponding mouse one, 
the prerequisite for the guides to be fully complementary to the targeted sequence 
meant that new guides needed to be designed. For the mouse VSMCs three guides 
were designed since PAM sequences were more common in the mouse genomic 
locus of miR-195a compared to the human one. However, due to the need of the 
guides to target sites in the stem loop of miR-195a, guides that did not have the 
highest score were selected (Figure 4.10, Figure 4.11 and Figure 4.12).  
 
4.4.2.1 Strategy B: Lentiviral delivery 
 
Lentiviral delivery of the system was tested and editing efficiency in two independent 
experiments with guides Gm2 and Gm4 reached 31% when both guides were used 
simultaneously (Figure 4.13). Of interest is the fact that the pattern of the edited bands 
changed according to the guides used (Figure 4.14).  A second set of experiments 
with guides Gm2 and GmA showed that they were more efficient when used together 
(Figure 4.15). In more detail, although guide GmA showed lower efficiency compared 
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to Gm4 (26% and 48%, respectively), infection of mouse VSMCs together with 
lentiviral particles conferring Gm2 resulted in editing of 51% efficiency, higher than 
the one observed when Gm2 and Gm4 guides were used simultaneously. The 
difference between the efficiency when targeting with both guides and with each 
guide alone can possibly be explained by the fact that guides Gm2 and Gm4 target 
sites that are located closer together (24nt apart), thus hampering the accessibility of 
the sequence by the Cas9/RNP complexes. The observed differences in the editing 
efficiency between the two guides for mouse VSMCs and between the two species 
(human and mouse) SMCs can be explained by the fact that different guides were 
employed targeting the same or different genomic loci, respectively. Discrepancies 
among the efficiency of different guides, targeting the same locus, have been 
reported previously for experiments in the same cell type with some guides failing to 
induce any editing190 while it has also been illustrated that the gene editing efficiency 
can vary greatly among different loci 180, 208. These observations can be possibly 
explained by the different organisation and accessibility of the various loci or by 
possible instability or secondary structures of the sgRNAs196. Since lentiviral delivery 
was deemed to be the most effective, it was concluded that no significantly higher 
editing efficiency could be induced in mouse VSMCs. 
 
4.4.2.2 Strategy D: Transfection of mouse VSMCs stably expressing Cas9 with 
IVT guides 
 
Although lentiviral delivery of the system to mouse VSMCs was shown to be highly 
effective, the constant expression of Cas9 together with the guides was deemed to 
be a non-favourable feature. Moreover, lentiviral infection also presents substantial 
limitations and risks. Considering these, in order to circumvent the difficulties raised, 
a different approach was followed. Cells stably expressing Cas9 were generated by 
infecting mouse VSMCs with lentiviral particles harbouring only the gene for Cas9. 
Next, IVT sgRNAs GmA and Gm2 was used to test their ability to form Cas9/RNP 
complexes to form and cleave the targeted sequence in vitro, showing a successful 
and almost complete digestion with the sizes of the resulting bands corresponding to 
the sites of cleavage (Figure 4.18A). Following these results, optimisation of the 
infection showed that selection of the infected cells with the use of Puromycin resulted 
in successful editing compared to no selection (Figure 4.18B). Following these 
results, newly engineered and selected cells were transfected with IVT guides Gm2 
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and GmA, simultaneously, with T7EI showing a similar efficiency with that achieved 
with lentiviral infection (54% on Day 2, Figure 4.19), results indicative of the efficacy 
of this approach. In addition, the editing efficiency on two different timepoints (Day2 
and Day7) indicated the viability of the edited cells. 
 
In addition, the guides selected for editing mmu-miR-195a interrupted different 
restriction sites upon successful editing (Figure 4.11). That provided the opportunity 
to test, in a fast and easy way, with the use of restriction enzymes, the editing 
efficiency. In detail, since editing interrupted the restriction sites restriction enzymes 
recognised, formation of any indel would result in the corresponding site to stay intact 
upon digestion (Figure 4.20). Furthermore, the T7EI assay was employed to evaluate 
the level of efficiency. 
 
All in all, by using this approach no off-target editing was expected to occur since the 
accumulation of the Cas9 was not expected to result in any off-target editing. The 
presence of sgRNAs, that could potentially form a complex with the stably expressed 
Cas9 and guide it to edit off-target sites, was transient179. Not only Cas9 is incapable 
to target any sequence without the help of the sgRNA but, further to this, it is the 
interrogation of the targeted sequence and its binding by the sgRNA, that activates 
the endonuclease domains of the protein244. In more detail, Cas9 endonuclease 
scans the genome for PAM sequences which it binds and releases rapidly if no 
complementarity is recognised between the sgRNAs and the adjacent to the PAM 
genomic DNA. Upon recognition of a highly complementary sequence, the 
conformation of the Cas9 changes, because of the DNA binding by the sgRNA, an 
alteration that brings the two nuclease domains of Cas9 (HNH and RuvC) closer 
together and activates them. Therefore, the transient presence of IVT guides in the 
cells would mean that the accumulated Cas9 would stay inactive. Thus, with this 
approach, gene editing occurs only upon transfection with the guides while their 
presence in the cells is transient. Taken together the above, transfecting VSMCs 
stably expressing Cas9 with IVT guides was concluded to be the most favourable 
delivery approach for the aim of the current study. 
4.4.2.3 Off-target mutagenesis 
 
To address the limitation of the unintended mutagenesis, the same approach, as 
previously described, was followed. Moreover, since a new delivery system was 
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tested, that of the transfection of mouse VSMCs stably expressing Cas9 with 
transiently present IVT sgRNA, the need to test for off-target editing was high. Firstly, 
the 5 most likely off-target sites for either guides, as returned by the CRISPR Design 
Tool (Figure 4.10), were tested in cells infected with lentiviral particles with no 
mutagenesis being detected (Figure 4.21). Furthermore, new guides were identified 
and tested for guide Gm2. Various software, freely available online, can be employed 
for the design of guides with different software using different algorithms to predict 
possible off-target sites. These algorithms penalise mismatches between the DNA 
sequence scanned and the suggested guides in a different way resulting in a list of 
possible off-target sites that vary among the different software. To address this, a set 
of 7 possible off-target sites was tested consisting of sites that were returned both by 
CRISPR Online Tool and CRISPR Finder, provided by Sanger Institute (Figure 4.22). 
By testing sites that appeared in both software the chances of false positive sites 
were eliminated. T7EI results in Cas9 expressing mouse VSMCs demonstrated that 




5 Chapter 5 INVESTIGATION OF THE REGULATION 





MiRNAs provide rapid responses in physiological and non-physiological conditions to 
counteract rapid and variable fluctuations and safeguard the robustness of biological 
systems245.  
 
MiRNA biogenesis is a multistep process that starts with the miRNAs being 
transcribed by RNA polymerase II as pri-miRNAs which encode for either single or 
multiple miRNAs4, 246. A large portion of miRNAs organise in miRNA clusters while 
computational analysis suggests that the existence of miRNA clusters is much higher 
than expected by chance247. MiRNAs being transcribed in the same primary transcript 
are organised in homo-clusters, that consist of members of the same family, and 
hetero-clusters, that consist of miRNA from different families248. Pri-miRNAs present 
a very specific secondary structure by folding into hairpins, that contain imperfectly 
base-paired stems. They are then processed via a two-step, sequential maturation 
process during which they get cleaved by two RNA III nucleases. During the canonical 
pathway, they are cleaved, in a first step in the nucleus by Drosha and DGCR8, 
resulting in the release of a premature miRNA and its export to the cytoplasm. In a 
second step the pre-miRNA is cleaved by Dicer, leading to a miRNA duplex and 
subsequently to a mature miRNA5. A precise recognition of the pri-miRNA by the 
microprocessor have emerged as important for the fidelity of processing5. Several 
determinants, such as the secondary structure of the stem loop and sequence motifs, 
need to interact in a co-ordinated response for pri-miRNA recognition and cleavage7, 
8, 11, 249. These findings imply that CRISPR/Cas9 gene editing of miRNA genes can 
affect processing of the hairpin in a dual manner either through the alteration of its 
sequence or of its secondary structure. 
In this chapter, the use of gene editing as a tool to understand the clustered miRNA 
regulation was examined. Previous experiments, outlined in Chapter 4, demonstrated 
that CRISPR/Cas9 system is a very precise tool, inducing indel formation only in the 
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vicinity of DSB. Intriguingly, it was shown that in mmu-miR-497~195 cluster mutations 
in the mmu-miR-195a stem loop can affect the expression of mmu-miR-497a that 
resides in the other hairpin of the cluster. It was hypothesised that the editing of the 
mmu-miR-195a exerts an effect on the maturation of mmu-miR-497a by affecting its 
processing by Drosha. 
 
Following the literature and the results outlined in Chapter 4, the study focused on 
four clusters, the homo-cluster mmu-miR-497~195, the hetero-clusters mmu-miR-
143~145 and mmu-miR-17~92 and cluster mmu-miR-106b~25, a paralogue of cluster 
miR-17~92. The objective was to determine whether editing the sequence of one 
miRNA of the cluster is able to affect the expression levels of the other clustered 
miRNAs by influencing their maturation. 
 
The results presented in this Chapter demonstrated diverse regulatory mechanisms 
of expression for clustered miRNAs. Firstly, they confirmed that mutations in the 
genomic locus of mmu-miR-497~195, induced by CRISPR/Cas9 editing affect the 
expression levels of the mature mmu-miR-497a that resides in the other hairpin of the 
same cluster. Secondly, experiments in different clusters showed that although 
editing of clustered miRNAs is capable of affecting the expression levels of the other 
miRNAs of the cluster, these results cannot be extrapolated to all of the clusters. In 





5.2 Experimental Design 
 
The aim of the experiments presented in the current chapter was to elaborate on the 
findings outlined in Chapter 4, on editing of mmu-miR-195a, and to elucidate whether 
editing of clustered miRNAs can affect the expression levels of the other miRNAs of 
the cluster. Four different clusters were chosen to be studied. 
 
Firstly, cluster mmu-miR-497~195 was further studied in more detail and a new guide 
was designed and used to confirm that the observed results were not guide specific. 
Next, the effects of editing were evaluated in the hetero-cluster mmu-miR-143~145114 
which consists of two miRNAs, mmu-miR-143 and mmu-miR-145a, that are not 
members of the same miRNA family and do not share seed sequence similarities. 
The objective was to overcome the limitations in studying possible autoregulatory 
effects of miRNAs of homo-clusters and to assess whether editing of hetero-clusters 
shows different effects. Guides editing different sites in or close to the stem loop of 
mmu-miR-145a were designed while changes in its secondary structure upon editing 
was also evaluated. In addition, clusters mmu-miR-17~92 and mmu-miR-106b-25 
were studied. Guides targeting mmu-miR-18 were designed and used and it was 
hypothesised that the abolition of its hairpin would affect the maturation only of the 
flanking miRNA hairpins as was the expected outcome of editing mmu-miR-25. 






5.3.1 Regulation of mmu-miR-195~497 cluster in VSMCs 
 
5.3.1.1 Editing of mmu-miR-195 locus with sg195m2 
 
Mmu-miR-195a forms a homo-cluster together with mmu-miR-497 as they are 
member of the same miR-15 family and get transcribed in one primary transcript with 
the stem loops located within 500bp. For the editing of mmu-miR-195a locus, mouse 
VSMCs stably expressing Cas9 were transfected with guide sg195m2 targeting a site 
in the stem loop of the miRNA disrupting one of the two SspI sites located in the 
sequence of mmu-miR-195a (Figure 5.1A). Digestion with SspI restriction enzyme 
showed successful editing (Figure 5.1C) while T7EI confirmed the editing with the 
efficiency varying from 28-30% (Figure 5.1D). Sanger sequencing demonstrated the 
formation of a panel of indels, mainly deletions flanking the targeted area (Figure 
5.1E). QPCR quantification showed a reduction in the expression levels of mmu-miR-
195a by 55% and of mmu-miR-497a by 62%, with the levels of mmu-miR-15a, mmu-







Figure 5.1 Gene editing of the miR-195a locus using IVT sgRNA195m2. (A) Schematic 
representation of the genomic locus of the mmu-miR-497~195 cluster with the two stem loops of mmu-
miR-497a and mmu-miR-195a being depicted as empty rectangular. The corresponding site of editing 
is depicted as a grey triangle and the position of the guide upon editing as a grey line. (B) The T-Coffee 
multiple sequence alignment programme was used to compare the mouse miR-15 family members. 
Bottom Panel: mmu-miR-497a displays high homology with mmu-miR-497b. Mmu-miR-497b is encoded 
by the antisense strand of the mmu-miR-497a~195 cluster and does not harbour the same seed 
sequence. (C) SspI digestion results upon editing of mmu-miR-195a with sg195m2 (D) T7EI assay for 
the mmu-miR-195a locus following editing with sg195m2. ND: Non-detectable. P1 and P2: Genomic 
PCR primers. (E) Sanger sequencing showing the editing of the mmu-miR-195 locus. The presence of 
random indels, mainly deletions was detected and represented as dashes. The PAM sequence is 
highlighted in grey. Insertions are shown in bold small case fonts. N/A: Not Applicable. (F) Gene editing 
of the mmu-miR-195a locus resulted in the down-regulation of both mmu-miR-195a and mmu-miR-497a 
without affecting the expression of other members of the miR-15 family as assessed by qPCR. U6 was 
used as a normalization control. n=4, * p<0.05. Assessment of the levels of miR-497b showed that it is 






5.3.1.2 Possible gene editing of miR-497a locus with sg195m2 
 
Following the assessment of the levels of miR-497a miRNAs upon editing of the miR-
195 with the sg195m2, T7EI and Sanger sequencing was used to investigate putative 
editing and formation of indels in the genomic locus of mmu-miR-497a with neither of 
the assays showing any editing (Figure 5.2). 
 
Figure 5.2 Investigation of editing in the miR-497a locus with sg195m2. (A) T7EI assay showed no 
editing at the locus of mmu-miR-497a upon editing with sg195m2. (B) Clustal alignment of Sanger 
sequencing data of the genomic locus of the mmu-miR-497a stem loop following sg195m2 editing in 
VSMCs. Wt: unedited cells, 1-10 randomly picked individual colonies harbouring genomic PCR 






5.3.1.3 Editing of mmu-miR-195a locus with sg195m3 
 
Editing of mmu-miR-195a locus was induced with transfection with guide sg195m3 of 
mouse VSMCs stably expressing Cas9. The newly designed guide targeted a site in 
the stem loop of the miRNA disrupting an SspI site (Figure 5.3A and B). T7EI showed 
efficient editing with the efficiency varying from 24-33% (Figure 5.3C). Sanger 
sequencing demonstrated the formation of indels, mainly deletions (Figure 5.3D), 
while qPCR quantification showed a reduction in the expression levels of both mmu-
miR-195a and of mmu-miR-497a, without affecting the levels of mmu-miR-15a, mmu-
miR-15b and mmu-miR-16 (Figure 5.3E), as previously shown (Figure 5.1). Off-target 
mutagenesis assessment did not show any editing in the six most likely off-target 
sites (Figure 5.4) with Sanger sequencing data of the mmu-miR-497a locus not 






Figure 5.3 Gene editing of the mmu-miR-195a locus using sgRNA195m3. (A) Schematic 
representation of the genomic locus of the mmu-miR-497~195 cluster with the two stem loops of mmu-
miR-497 and mmu-miR-195 being depicted as an empty rectangular. The corresponding site of editing 
with sg195m3 is depicted as a grey triangle. (B) Representation of the mmu-miR-195a stem loop with 
the detailed sequence along with the targeted DNA sequence and the PAM sequence for sg195m3. (C) 
T7EI assay for the miR-195a locus following editing with sg195m3. ND: Non-detectable. P1 and P2: 
Genomic PCR primers. (D) Sanger sequencing showing the editing of the mmu-miR-195a locus. The 
presence of random indels, mainly deletions was detected and represented as dashes. The PAM 
sequence is highlighted in grey. Insertions are shown in bold small case fonts. N/A: Not Applicable. (E) 
Gene editing of the mmu-miR-195a locus resulted in the down-regulation of both mmu-miR-195a and 
mmu-miR-497a without affecting the expression of other members of the miR-15 family as assessed by 







Figure 5.4 Assessment of off-target editing with sg195m3. T7EI did not show any gene editing in the 
loci of the 6 most likely putative off-target sites for sg195m3 as predicted by the CRISPR DESIGN Tool 
(http://cripsr.mit.edu, Zhang Lab, MIT) and the CRISPR Finder (Wellcome Trust Sanger Institute). OFT; 






Figure 5.5 Investigation of editing in the miR-497a locus with sg195m3. Clustal alignment of Sanger 
sequencing data of the miR-497a stem loop locus following sg195m3 editing in VSMCs. Wt: unedited 
cells, 1-10 randomly picked individual colonies harbouring genomic PCR amplicons from sg195m3 





5.3.1.4 Regulation of the mmu-miR-497a expression 
 
In order to determine whether the downregulation of mmu-miR-497a occurred as a 
secondary effect due to the downregulation of mmu-miR-195a, gain of function 
experiments were conducted. Overexpression of mmu-miR-195a in mouse VSMCs 
with the use of miRNA mimics demonstrated no increase in the levels of mmu-miR-
497a (Figure 5.6). 
 
 
Figure 5.6. Overexpression of miR-195a. QPCR quantification of the levels of mature mmu-miR-195a 
and mmu-miR-497a, following overexpression of miR-195a using miRNA mimics. U6 was used as a 





5.3.1.5 Secondary structure of mmu-miR-195a stem loop upon editing 
 
Computational analysis was performed in collaboration with Dr Kathleen Steinhofel 
and Prof Andreas Albrecht. Analysis with RNAfold prediction programme was used 
to determine the secondary structure of the stem loop upon editing with guide 
sg195m2 (Figure 5.7A) and sg195m3 (Figure 5.7B). The structure of the wild-type 
mmu-miR-195a stem loop presented the expected bulges and apical loop while one 
nucleotide deletion with either guide resulted in a predicted formation with a more 
pronounced bulge. A 18nt deletion with guide sg195m2 (Figure 5.7A, Left Panel) 
resulted in a shorter stem and a bigger apical loop while a 16nt deletion with guide 
sg195m3 (Figure 5.7B, Right Panel) resulted in a predicted secondary structure with 
no evident stem and apical loop. 
 
 
Figure 5.7 Predicted secondary structure of the mmu-miR-195a stem loop upon editing. Minimum 
free energy structure of the mmu-miR-195a stem loop following editing with (A) sg195m2 and (B) 
sg195m3, as assessed by the structure prediction software RNAfold. The base pairing probability, as 
indication of structural remodelling or dynamics, was used for colour-coding. 
 
 
5.3.1.6 Tertiary structure of mmu-miR-497~195 primary transcript upon editing 
 
For the investigation of the effects of editing with guide sg195m2 on the tertiary 




RNA structure modelling server was used. The secondary structure without 
pseudoknots, as returned by vsfold5 was used as an input for the unedited transcript 
(wt, Figure 5.8A), after a 1nt mutation (mut1, Figure 5.8B) and an 18nt deletion (mut5, 
Figure 5.8C). The three 3D simulations appear different with the wild type showing a 
prominent mmu-miR-195a stem loop and a compressed but still accessible miR-497a 
stem loop (Figure 5.8A) while the conformation of the 1nt deletion (mut1) had no effect 
on mmu-miR-195a stem loop but led to a mmu-miR-497a stem loop strongly attached 
to the main core of the primary transcript (Figure 5.8B). In the case of the 18nt deletion 
(mut5), profound differences were observed as no typical hairpin for pri-miR-195a 
could be detected and the whole structure was more strongly entangled with the main 
core. The miR-497a stem loop displayed a compact shape in closer proximity with 




Figure 5.8 Effect of CRISPR/Cas9 editing in the tertiary structure of mmu-miR-497~195 cluster. 
Computational simulation of the 3D structure (generated by vsfold5 - with pseudoknots – as input to 
RNAComposer, pdb-fle visualised by PyMOL) of the pri-miR-497~195 in (A) unedited WT, (B) mutant 
harbouring a deletion of 1nt (mut1) and (C) a mutant harbouring a deletion of 18nt (mut5). Mmu-miR-
497a stem loop is depicted in green and its terminal loop in magenta. Mmu-miR-195a stem loop is 
depicted in red and its terminal loop in yellow. A full movie of the 3D structure of the different transcripts 







5.3.2 Gene editing in different miRNA clusters 
 
5.3.2.1 Gene editing in mmu-miR-143~145 cluster 
 
 In silico design of guides 
 
To design the guides targeting the genomic locus of mmu-miR-145, the CRISPR 
DESIGN Tool (http://crispr.mit.edu, Zhang Lab, MIT) was employed (Figure 5.9). The 
DNA sequence, corresponding to the transcript annotated as miRNA stem loop in 
miRBasev21, was uploaded to the software. The two following oligos, which targeted 
sites upstream of the stem loop and in the mmu-miR-145 stem loop (Figure 5.10), 











Figure 5.9 In silico design of the sgRNAs for mmu-miR-145a locus. The CRISPR DESIGN Tool 
(http://crispr.mit.edu, Zhang Lab, MIT) was used to design the guides for editing the mmu-miR-145 locus. 
In the above figures, the sequences of the two guides, their corresponding score and the 5 most likely 







Figure 5.10 Schematic representation of the secondary structure of the mmu-miR-145a stem loop 
with guides. Representation of the mmu-miR-145a stem loop with the detailed sequence for (A) 
sg145m1 and (B) sg195m2. PAM sequence is highlighted in blue. The mature miRNA sequence is 
highlighted in purple and grey arrows indicate the corresponding position of the DSB on the stem loop 
which is the site of mutations induced by random indels following editing of the genomic locus in mutant 
cells. 
 
 Editing of the mmu-miR-145a locus 
 
Mmu-miR-145a is transcribed in one primary transcript together with mmu-miR-143 
forming a hetero-cluster, since the two miRNAs are not members of the same miRNA 
family. For the editing of mmu-miR-145a locus, two guides were designed, sg145m1 
and sg145m2 with the former one targeting a site 30bp upstream of the mmu-miR-
145a stem loop and the latter one disrupting a HinfI site in the mmu-miR-145a stem 
loop (Figure 5.11A). The two miRNAs do not share the same seed sequence neither 
any sequence homology (Figure 5.11B). T7EI results indicate successful editing with 
guide sg145m1 demonstrating editing efficiency varying from 47-57% while guide 
sg145m2 showed an efficiency of 24-29% (Figure 5.11C). HinfI restriction digestion 
enzyme confirmed the editing with guide sg145m2 (Figure 5.11D) and Sanger 
sequencing demonstrated the formation of small indels, mainly deletions with either 





Figure 5.11 Gene editing of the mmu-miR-145a locus. (A) The genomic locus of the miR-143~145 
cluster with the corresponding sites of the DSBs induced by sg145m1 and sg145m2. (B) MiRNAs miR-
145a and miR-143 do not share a common seed region or any sequence homology, as the T-Coffee 
multiple sequence alignment programme indicates. (C) T7EI assay in three independent experiments 
for the miR-145a locus after editing with either guide. ND: non-detectable, (n=3). (D) The sg145m2 
targets the miR-145 genomic locus and disrupts a HinfI restriction site. Asterisks (*) indicate differential 
digestion products. (E) Sanger sequencing data for the edited mmu-miR-145a genomic locus using 
guides sg145m1 and sg145m2, respectively. The PAM sequence is highlighted in grey. Deletions are 
represented as dashes, insertions are shown in bold small case fonts. N/A: Not Applicable. P7 and P8: 







The assessment of the effect of editing on the levels of the miRNAs with qPCR 
revealed a downregulation of both mmu-miR143 and mmu-miR-145a upon editing 
with either guide although guide sg145m2 showed a sharper effect (Figure 5.12). In 
more detail, guide sg145m1 resulted in a 28% downregulation of miR-143 and 33% 
downregulation of miR-145 while guide sg145m2 showed a downregulation of 50% 
and 89% for miR-143 and miR-145a, respectively.  
 
 
Figure 5.12 Assessment of the levels of mmu-miR-143 and mmu-miR-145a upon editing. QPCR 
quantifcation of the primiR-143~145 expression in sg145m2 edited cells. Pri-miRNA Taqman assays 
that are specifcally designed to amplify fanking sequences within 500 base pairs on either side of the 
stem loop were used. Beta actin was used as a normalization control. n=3, *p<0.05 (ANOVA with 





T7EI did not reveal any off-target effect in the mmu-miR-143 locus with either guide 
(Figure 5.13A), results that were confirmed by Sanger sequencing (Figure 5.13B). 
 
Figure 5.13 Off-target editing in miR-143 locus. (A) T7EI assay showed no editing at the locus of 
mmu-miR-143 upon editing with sg145m1 or sg145m2. The asterisk (*) depicts a non-specific band as 
a result of the T7EI digestion that is not due to editing, (n=3). (B) Clustal alignment of Sanger sequencing 
data for the mmu-miR-143 stem loop locus following sg145m1 and sg145m2 editing, respectively. Wt: 
unedited cells, 1-10 randomly picked individual colonies harbouring genomic PCR amplicons from edited 
VSMCs. P5, P6: Genomic PCR primers as depicted in Figure 5.11. 
 
The expression levels of pri-miR-143 and pri-miR-145a were quantified with qPCR in 





of both pri-miR-143 and pri-miR-145a (Figure 5.14A) while transfection of mouse 
VSMCs with miR-145a mimics resulted in a significant increase in the expression of 
mmu-miR-143 (250%) accompanied by an increase in pri-miR-143 and pri-miR-145a 
of 162% and 165%, respectively. The levels of KLF4, as a validated target of miR-
145a, were subsequently downregulated by 40% (Figure 5.14B). 
 
 
Figure 5.14 Assessment of the levels of pri-miR-143 and pri-miR-145a. (A) QPCR quantification of 
the pri-miR-143~145 expression in sg145m2 edited cells. Pri-miRNA Taqman assays that are 
specifically designed to amplify flanking sequences within 500 base pairs on either side of the stem loop 
were used. Beta actin was used as a normalisation control. n=3, *p <0.05 (ANOVA with Dunnett post 
hoc test). (B) The expression of the mature mmu-miR-143 and pri-miR-143~145, following mmu-miR-
145a overexpression with mmu-miR-145a mimics, was quantified by qPCR. Kruppel Like Factor 4 
(KLF4), a validated target of miR-145a was also assessed. Beta actin was used as a normalization 
control. n=3, *p<0.05 (ANOVA with Dunnett post hoc test). 
 
RNAfold prediction programme demonstrated changes in the secondary structure of 
the stem loop upon editing with guide sg145m2 (Figure 5.15). The structure of the 
WT mmu-miR-145a stem loop presented the expected bulges and apical loop while 
1nt deletion did not lead to any significant changes. On the other hand, a 12nt deletion 






Figure 5.15 Predicted secondary structure of mmu-miR-145a stem loop. Minimum free energy 
structure of the mmu-miR145a stem loop as assessed by the structure prediction software RNAfold after 
editing with sg145m2. The base-pairing probability, as indication of structural remodelling or dynamics, 
was used for colour-coding. 
 
The expression of the long non-coding RNA Carmn, that overlaps the miR-143~145a 
cluster and constitutes an independent transcription unit (Figure 5.16B), did not differ 




Figure 5.16 Expression of long non-coding RNA Carmn. (A) QPCR quantification of Carmn in 
sg145m2 edited cells. Beta actin was used as a normalisation control, (n=3), (ANOVA with Dunnett post 
hoc test). (B) Snapshot obtained from NCBI database (https://www.ncbi.nlm.nih.gov/gene/328968) 








5.3.3 Gene editing of mmu-miR-17~92 cluster 
 
5.3.3.1 In silico design of the guide 
 
CRISPR DESIGN Tool (http://crispr.mit.edu, Zhang Lab, MIT) was used to design the 
guides for the genomic locus of miR-18a, the (Figure 5.17). The DNA sequence 
corresponding to the transcript annotated in miRBasev21 was used as input 
sequence to the software. The following oligo, targeting a site in the stem loop of miR-






Figure 5.17 In silico design of the single-guide RNAs for mmu-miR-18 locus. The CRISPR DESIGN 
Tool (http://crispr.mit.edu, Zhang Lab, MIT) was used to design the guide for editing the mmu-miR-18 
locus. In the figure, the sequence of the guide, the corresponding score and the 5 most likely off-target 




Figure 5.18 Schematic representation of the secondary structure of the miR-18a stem loop with 
guides. Representation of the miR-18a stem loop with the detailed sequence and the corresponding 
site of the DSB with sg18. PAM sequence is highlighted in blue, the mature miRNA sequence is 
highlighted in purple and grey arrow indicates the corresponding position of the DSB on the stem loop 




5.3.3.2 Editing of miR-18a 
 
Cluster mmu-miR-17~92 consists of 6 miRNAs (Figure 5.19A) that do not share the 
same seed sequence and any sequence homology (Figure 5.19B). Gene editing of 
miR-18a with guide sg18 resulted in an efficiency varying from 32-37%, as shown by 
T7EI (Figure 5.19C), while digestion with restriction enzyme Bsp1286I confirmed the 
editing (Figure 5.19D). Sanger sequencing demonstrated the formation of small 
indels (Figure 5.19E) and qPCR revealed the robust downregulation only of miR-18a 
levels by 88% (Figure 5.19F). 
 
Figure 5.19 Gene editing of the miR-18a locus. (A) The genomic locus of the miR-17~92 cluster with 
the corresponding sites of the DSB induced by sg18. (B) T-Coffee multiple sequence alignment 
programme indicates that the miRNAs of the cluster do not share a common seed region or any 
sequence homology. (C) T7EI assay in three independent experiments for the miR-18a locus after 
editing. ND: non-detectable (D) The sg18 disrupts a Bsp1286I restriction site. Asterisks (*) indicate 
differential digestion products. (E) Sanger sequencing of the edited miR-18a genomic locus. The PAM 
sequence is highlighted in grey, deletions are represented as dashes, insertions are shown in bold small 
case fonts. N/A: Not Applicable. P9 and P10: Genomic PCR primers. (F) Gene editing of the miR-18a 
locus resulted in the down-regulation only of mmu-miR-18a without affecting the expression of other 






Sanger sequencing did not reveal any off-target formation of indels in the loci of either 
mmu-miR-17, miR-19a or miR-20a (Figure 5.20). 
 
 
Figure 5.20 Off-target editing in mmu-miR-17~92 locus. Clustal alignment of Sanger sequencing data 
for the mmu-miR-17~92 cluster following editing. Top Panel: miR-17 locus, Middle Panel: miR-19a locus 
and Bottom Panel: miR-20a locus Wt: unedited cells, randomly picked individual colonies harbouring 





Computational analysis with RNAfold prediction programme was used for assessing 
the secondary structure of the stem loop upon editing with guide sg18 (Figure 5.21). 
The structure of the wild-type miR-18a stem loop presented the expected bulges and 
apical loop while neither a 2nt nor a 14nt deletion led to significant changes with the 
latter resulting in an apical loop of smaller size. 
 
 
Figure 5.21 Predicted secondary structure of miR-18a stem loop. Minimum free energy structure of 
the miR-18a stem loop as assessed by the structure prediction software RNAfold upon editing. The 
base-pairing probability, as indication of structural remodelling or dynamics, was used for colour-coding.  
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5.3.4  Gene editing of mmu-miR-106b~25 cluster 
 
5.3.4.1 In silico design of the guide 
 
The guide targeting the genomic locus of mmu-miR-25 was designed in CRISPR 
DESIGN Tool (http://crispr.mit.edu, Zhang Lab, MIT), (Figure 5.22) by using the DNA 
sequence corresponding to the transcript annotated in miRBasev21 as the miRNA 
stem loop. The highest scoring oligo, targeting the stem of the mmu-miR-25 hairpin 
(Figure 5.23), was selected as the most suitable one: 
 
 
Figure 5.22 In silico design of the single-guide RNAs for mmu-miR-25 locus. The guide for editing 
the mmu-miR-25 locus was designed with the help of the CRISPR DESIGN Tool (http://crispr.mit.edu, 
Zhang Lab, MIT). In the figure, the sequence of the guide, the corresponding score and the 5 most likely 









Figure 5.23 Schematic representation of the secondary structure of the mmu-miR-25 stem loop 
with the designed guide. Representation of the mmu-miR-25 stem loop with the detailed sequence 
and the corresponding site of the DSB with sg25. PAM sequence is highlighted in blue, the mature 
miRNA sequence is highlighted in purple and grey arrow indicate the corresponding position of the DSB 
on the stem loop which is the site of the formation of random indels following editing of the genomic 
locus. 
 
MiR-25 is part of the miR-106b~25 cluster and is transcribed in one primary transcript 
together with mmu-miR-106b and mmu-miR-93. For the editing of mmu-miR-25, 
guide sg25 was designed, targeting a site in the mmu-miR-25 stem loop disrupting 
an MfeI site (Figure 5.24A). The two miRNAs do not share the same seed sequence 
neither any sequence homology (Figure 5.24B). T7EI results indicate successful 
editing with an indel formation efficiency varying from 20-27% (Figure 5.24C). MfeI 
restriction digestion enzyme confirmed the editing (Figure 5.24D) and Sanger 
sequencing demonstrated the formation of small indels, mainly deletions (Figure 
5.24E). Assessment of the levels of expression of miR-25 showed a significant 





Figure 5.24 Gene editing of the miR-25 locus. (A) The genomic locus of the miR-106b~25 cluster with 
the corresponding sites of the DSB induced by sg25. (B) T-Coffee multiple sequence alignment program 
indicates that miRNAs miR-106b, miR-25 and miR-93 that form the cluster do not share a common seed 
region or any sequence homology. (C) T7EI assay in three independent experiments for the miR-25 
locus after editing. ND: non-detectable (D) The sg25 disrupts an MfeI restriction site. Asterisks (*) 
indicate differential digestion products. (E) Sanger sequencing of the edited miR-25 genomic locus. The 
PAM sequence is highlighted in grey, deletions are represented as dashes, and insertions are shown in 
bold small case fonts. N/A: Not Applicable. P11 and P12: Genomic PCR primers. (F) Gene editing of the 
miR-25 locus resulted in the down-regulation only of miR-25 without affecting the expression of other 
members of the cluster as assessed by qPCR. U6 was used as a normalization control. n=4, * p<0.05. 
Assessment of the levels of miR-497b showed that it is not expressed in mouse VSMCs. 
 
Sanger sequencing did not reveal any off-target formation of indels in the loci of either 








Figure 5.25 Off-target editing in mmu-miR-106b~25 locus. Clustal alignment of Sanger sequencing 
of the mmu-miR-106b~25 cluster following editing. Top Panel: miR-93 locus and Bottom Panel: miR-
106b locus Wt: unedited cells, randomly picked individual colonies harbouring genomic PCR amplicons 
from edited VSMCs. P9 and P10: Genomic PCR primers as depicted above in Figure 5.24. 
 
RNAfold prediction programme revealed a secondary structure of the stem loop upon 
editing with guide sg25 with the 1nt deletion not conferring any important changes in 
contrast to the 6nt deletion that resulted to a short stem loop and a significant change 





Figure 5.26 Predicted secondary structure of mmu-miR-25 stem loop. Minimum free energy 
structure of the miR-25 stem loop as assessed by the structure prediction software RNAfold upon editing. 









MiRNA maturation is a complex process which asserts the fidelity of the biogenesis 
of miRNAs. In an initial step the miRNA genes are transcribed to a pri-miRNA before 
getting cleaved by Drosha. The fidelity of the processing is ensured by a very specific 
and precise recognition of the pri-miRNA by the microprocessor. During the 
microprocessor recognition of the primary transcript a trimeric complex is formed 
including one Drosha, that recognises basal elements of the transcript, thus serving 
as a ruler, and two DGCR8 adaptors that interact with the apical elements5. This 
modular model predicts varying contributions of several determinants that need to 
interact in a coordinated response for pri-miRNA recognition7. Elegant experimental 
approaches have identified additional recognition and processing features8, 11. 
Secondary structures such as stem length, hairpin pairing, bulge size and position 
and apical loop size has been shown to contribute to effective miRNA biogenesis. 
Moreover, sequence motifs, such as a UG motif at the base of the hairpin, a 
UGU/GUG motif in the apical loop and a CNNC motif downstream of the hairpin, can 
enhance processing7, 8, 249. Importantly, these primary sequence motifs exert their 
effects in some pri-miRNAs but not in others and are thought to have an additive 
effect in pri-miRNA processing. An intricate set of rules and modifications that are 
preferentially utilised in miRNAs over non-miRNA hairpins were also uncovered11. 
These findings led to the prediction and experimental validation for a significant role 
of single-nucleotide polymorphisms (SNPs) in altering pri-miRNA processing and 
miRNA biogenesis in several occasions11. Intriguingly they also imply that 
CRISPR/Cas9 gene editing of miRNA genes can affect processing of the hairpin in a 
dual manner either by altering the sequences or the tertiary structure.  
 
Adding to the complexity of miRNA biogenesis, RBPs can also modify various steps 
of the processing post-transcriptionally thus affecting the miRNA maturation21. 
Additionally, an optimal length for the stem of the hairpin and two bulge-depleted 
regions in the stem, regions that may function as protein-interacting surfaces, were 
proposed as necessary for the RBP:miRNA interactions.  
 
MiRNA clusters, based on their genomic locus organisation and regulation, can be 
divided into homo-clusters, that are composed of members of the same miRNA family 
and get transcribed together as one primary transcript, and hetero-clusters that are 
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comprised of miRNAs that belong to different families. In regarding how they exert 
their regulation, homo-clusters are capable of controlling their targets in a single step 
thus resulting in a rapid regulation, contrary to hetero-clusters that typically control 
their targets in multiple steps or targets and in a more delayed response248. Thus, 
miRNAs are able to control the expression of multiple proteins, by binding their 
corresponding mRNAs, that function at different steps in various complex biological 
pathways. Through this, miRNAs can exert powerful effects on important processes 
of cell growth, differentiation, and apoptosis7, 23, 250 . Therefore, albeit the minor effects 
that an individual miRNA may have on a specific target, the combined effects of 
clustered miRNAs on multiple mRNA targets, of a common pathway, can be more 
pronounced and efficient. 
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Downregulation of the levels of mature mmu-miR-497a 
 
In the current chapter, gene editing with CRISPR/Cas9 was assessed as a tool to 
understand the regulation of clustered miRNAs. Preliminary results demonstrated the 
effectiveness of CRISPR/Cas9 for the precise editing of the DNA sequence of 
miRNAs inducing indel formation in the vicinity of the DSB. As discussed previously, 
editing of mmu-miR-195a led to the downregulation of the expression levels of the 
edited miRNA as well as those of mmu-miR-497a, the miRNA that resides on the 
other hairpin of the same cluster. 
 
After establishing the most effective delivery approach to edit the genomic loci of 
miRNAs, additional experiments were conducted in mouse VSMCs to edit mmu-miR-
195a to decipher whether the downregulation was either the direct result of the editing 
or of the impaired processing of the pri-miRNA. The experiments focused on the 
genomic locus of the pri-miR-497~195 (Figure 5.1A). Guide sg195m2 was selected 
for the new set of experiments since it had previously shown the highest efficiency of 
the set of guides tested and Sanger sequencing had shown that the use of one guide 
resulted in the formation of various indels. Furthermore, compared to other guides 
tested, sg195m2 targeted a site in the stem loop of the miRNA but did not change the 
sequence of the mature miRNA and offered a better insight in the processing of the 
primary transcript of mmu-miR-195a. By not disrupting the sequence of the mature 
miRNA but, in contrast, by inducing indels in the stem loop, editing with sg195m2 can 
lead to an altered primary transcript with an intact mature sequence. Thus, the editing 
would lead to differential processing of the primary transcript and downregulation of 
the levels of mature mmu-miR-195a while in the case the maturation was not hindered 
the processing would result in a mature mmu-miR-195a with the WT sequence able 
to function physiologically. 
 
Newly edited mouse VSMCs with guide sg195m2 were generated and restriction 
digestion showed successful editing (Figure 5.1C, D). Sanger sequencing confirmed 
the formation of indels (Figure 5.1D) and qPCR quantification, with more replicates 
than previously shown (n=4,) demonstrated the statistically significant downregulation 
of the levels of both the mature mmu-miR-195a and mmu-miR-497a (Figure 5.1E.), 
without affecting the levels of the other members of the miR-15 family, results that 




Nonetheless, the above results are not indicative of the mechanism that led to the 
downregulation of the levels of the mature mmu-miR-497a. Despite computational 
analysis not showing any complementarity between the DNA sequence of the 
genomic locus of mmu-miR-497a and sg195m2, the possibility of off-target 
mutagenesis could not be excluded, especially in light of the published studies 
reporting editing in off-target sites that were not predicted by online software251. 
Moreover, the off-target editing of mmu-miR-497a due to the proximal editing by Cas9 
of the targeted sites in mmu-miR-195a, could not be excluded. Although sequencing 
data showed precise editing in the vicinity of the DSBs induced by the designed 
guides due to innate PCR limitations and its incapability of amplifying long stretches 
of DNA with high fidelity, the genomic locus of the pri-miR-497~195 was tested in two 
independent sequencing experiments. Following the sequencing of the genomic 
locus of mmu-miR-195a, -PCR primers designed to amplify the genomic locus of 
mmu-miR-497a (Figure 5.1A) were used and T7EI showed no specific editing (Figure 
5.2A) with Sanger sequencing confirming its absence (Figure 5.2B). 
 
Further to this, sg195m3, as a newly designed guide with no sequence homology with 
sg195m2, induced gene editing with an overall efficiency that approximated that of 
sg195m2 (Figure 5.3C) resulting in statistically significant downregulation only of the 
levels of both the mature mmu-miR-195a and mmu-miR-497a (Figure 5.3D) with 
Sanger sequencing revealing the formation of indels in the vicinity of the induced DSB 
in the genomic locus of mmu-miR-195a. Noteworthy, no editing in a panel of off-target 
sites, predicted by both the CRISPR Online Tool and the CRISPR Finder was 
detected (Figure 5.4). Following the same approach, as outlined above, T7EI was 
used to assess unexpected off-target mutagenesis in the genomic locus of the mmu-
miR-497a, with the results showing no editing (Figure 5.5). 
 
Mmu-miR-195a and mmu-miR-497a form a cluster on chromosome 11 (Figure 5.1A 
and Figure 5.3A) and are transcribed as one primary transcript, with both stem loops 
located within 500bp114. While no editing was detected in the genomic locus of mmu-
miR-497a, the downregulation of the miRNAs needed to be further investigated. Gain 
and loss of function experiments could be employed in order to determine whether 
the mature downregulation of mmu-miR-497a may occur as a secondary effect due 
to reduced levels of mature mmu-miR-195a. In the case of the mmu-miR-497~195 
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cluster however, the sequence similarities between the two miRNAs indicate that the 
inhibitor can effectively silence both miRNAs and thus no conclusive data could be 
obtained. Overexpression of a miRNA can be achieved using short synthetic 
oligonucleotides that function as mature miRNA without requiring any processing by 
the Drosha or Dicer complexes. Following mmu-miR-195a overexpression using 
miRNA mimics, no differences on the expression of the mature miR-497a were 
observed (Figure 5.6), suggesting that the mmu-miR-497a expression is not 
controlled by miR-195a. 
 
The tertiary structure of the primary miRNA transcripts can affect the accessibility of 
the stem loops by RNase III RBPs Drosha and Dicer and thus miRNA biogenesis may 
depend on this structure252. Therefore, a computational analysis was conducted to 
assess whether structural constraints could hinder the processing of the mutant pri-
miRNAs. The analysis for mmu-miR-195a focused on mutant 1 that harboured a 
deletion of 1 nucleotide (mut1), mutant 5 that harboured a deletion of 18 nucleotides 
(mut5) and the unedited transcript (WT). Three software prediction programmes 
(RNAfold, Sfold, Co-fold) were used and all of them returned identical results (Figure 
5.7). Despite 1nt deletion not demonstrating any prominent changes in the secondary 
structure of the mmu-miR-195a hairpin, the 18nt deletion resulted in a wider apical 
loop and the abolition of a bulge in the stem of the hairpin (Figure 5.7A). Similarly, in 
the case of editing with sg195m3, 1nt deletion resulted in subtle changes whereas a 
16nt deletion in the DNA sequence of the mature mmu-miR-195a led to substantial 
changes in the structure of the hairpin, with the elimination of the apical loop and the 
severe shortening of the stem (Figure 5.7B).  
 
Furthermore, the 3D simulation highlighted even more pronounced differences. In the 
wt, the mmu-miR-195a stem loop was prominent while the mmu-miR-497a stem loop 
more compressed but clearly accessible. In the mut1, the conformation of mmu-miR-
195a stem loop was similar although the single nucleotide mutation had an effect 
leading to a mmu-miR-497a stem loop strongly attached to the main core and not as 
accessible as in WT. Nevertheless, profound differences were observed in the 
conformation of mut5. No typical hairpin for pri-miR-195a could be detected and the 
structure was more strongly entangled with the main core. The mmu-miR-497a stem 
loop displayed a compact shape in close proximity with the mmu-miR-195a stem loop 
but relatively distal from the main core and with no clear accessibility to the hairpin 
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(Figure 5.8). Overall, the 3D remodelling indicated a clear difference between the 
entire structure of wt and mut5 and to a lesser extent also between wt and mut1 with 
accessibility of the mmu-miR-497a stem loop being affected in both mutants. These 
results suggested that extensive deletions (in this case 18nt) in the genomics locus 
of mmu-miR-195 stem loop can alter the tertiary structure of the entire mmu-miR-
497~195 transcript. 
 
Although these results cannot safely lead to definitive conclusions about the 
mechanism through which the editing of the mmu-miR-195a gene can affect the 
levels of the mature mmu-miR-497a, the possibility of impairing the maturation in a 
dual manner directly through sequence and structural alterations and disruptions 
cannot be excluded. Computational analysis showed that disrupting the mmu-miR-
195a stem loop can impose tertiary constraints that influence the processing of the 
entire pri-miR-497~195 resulting in downregulation of the expression levels of both 
miRNAs. 
 
In the case of the mmu-miR-195a stem loop, the UGU/GUG motif in the apical loop 
is not present implying that the sequence is not important for the maturation of the 
hairpin. Nonetheless, editing with CRISPR/Cas9 led to the direct deletion of the 
terminal loop of the hairpin affecting its secondary and tertiary structure (Figure 5.7). 
These findings are in line with the literature that reports that mutations in the apical 
loop of miRNA hairpins lead to less effective processing and an autoregulatory role 
of the tertiary structure252, 253. 
 
5.4.1 Editing of mmu-miR-143~145 cluster 
 
Next, to determine the effect of gene editing in a hetero-cluster the study focused on 
the mmu-miR-143~145 cluster114. This locus spans approximately 1400bp in mice 
and harbours mmu-miR-143 and mmu-miR-145a, two miRNAs that do not share 
sequence similarities (Figure 5.11A and B) but regulate essential functions for 
VSMCs growth, differentiation, and contractility78, 254. 
 
Following the same rationale presented previously, two sgRNAs targeting the mmu-
miR-145a locus were designed using the CRISPR Online Tool (Figure 5.9). The 
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guides used were selected according to the site they targeted with guide sg145m1 
generating a DSB 30bp upstream of the stem loop of mmu-miR-145a and guide 
sg145m2 targeting directly the stem loop, disrupting a HinfI restriction site, (Figure 
5.10 and Figure 5.11A). T7EI results indicated that sgRNA145m1 was more efficient 
in inducing gene editing (Figure 5.11C) while digestion with HinfI confirmed the editing 
(Figure 5.11D). Sanger sequencing demonstrated small indel formation (1–40bp) with 
either sgRNA (Figure 5.11E), in accordance with previous results from mmu-miR-
497~195 cluster. 
 
QPCR quantification showed that the gene editing had a robust effect on miRNA 
expression. Editing with guide sg145m1 led to largely similar and significant 
downregulation of the levels of both the mmu-miR-143 (28%) and mmu-miR-145a 
(33%). A strong inhibition of mature mmu-miR-145a and mmu-miR-143 (89% and 
50%, respectively) expression was observed following sg145m2 application (Figure 
5.12). Interestingly, despite the high levels of gene editing induced by the sgRNAm1 
guide the downregulation in mature mmu-miR-145a and mmu-miR-143 expression 
was significant but lower than when guide sgRNA145m2 was used, suggesting that 
targeting directly the stem loop is a more efficient strategy for inhibiting miRNA 
expression (Figure 5.12). Further support to this notion was provided by Sanger 
sequencing. The sg145m1 guide led to indels that did not disrupt the mmu-miR-145a 
stem loop sequence, while sg145m2 guide resulted in mutations within the hairpin. 
These results showed that the effects of targeting directly the stem loop of the miRNA 
is a more effective strategy of downregulating its expression since a DSB induced 
within the miRNA sequence can result in the formation of indels and the direct 
disruption of its secondary structure contrary to the effects of sg145m1 which induced 
a DSB in a substantial distance from the stem loop.  
 
Despite the significant decrease in mmu-miR-143 expression, no editing of the mmu-
miR-143 genomic locus was observed with either guide (Figure 5.13A), as was 
expected. Mutation screening revealed no indels in the mmu-miR-143 locus in edited 
cells with either guide (Figure 5.13B).  
 
Two different approaches, previously reported, have shown that mutations in the pri-
miRNA sequence of mmu-miR-143~145 can be tolerated provided that they do not 
disrupt critical structural elements. In more detail, introducing loxP sites for Cre-
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mediated recombination in the genomic loci of mmu-miR-143 or mmu-miR-145a 
resulted in mutant mice that do not exhibit any effect on the expression of any of the 
two miRNAs in either case254. This approach deleted the stem–loop sequence of the 
pre-miRNA for each of the miRNAs, or the genomic sequence for both miRNAs, and 
replaced it an exogenous DNA. Interestingly though, replacing the genomic region of 
mmu-miR-143 with the exogenous sequence of the LacZ reporter not only disrupted 
the expression of mmu-miR-143 but also led to effective silencing of the mmu-miR-
145a expression118. This construct permitted the cells that produced miR-143 and 
miR-145 to be visualised through staining with b-galactosidase. From these 
experiments, it becomes apparent that while both approaches disrupt the miRNA 
gene, the introduction of a reporter in the DNA sequence of the primary transcript 
renders it unsuitable for downstream processing and hinders the maturation of mmu-
miR145a despite the presence of an intact mmu-miR-145a stem loop. Although not 
conclusive, these reports imply a critical role of the tertiary structure as a critical 
determinant in the maturation of clustered miRNAs. Furthermore, they indicate that 
the introduction of mutations in the pri-miR-143~145 sequence per se does not 
hamper miRNA maturation254. This is in line with findings presented in the current 
study that sg145m1, which induces sequence changes upstream of the mmu-miR-
145a stem loop, had not but a minimal effect on the expression of the clustered 
miRNAs inducing effective editing of the locus, a conclusion that becomes even more 
evident when the indel efficiency of the two guides are compared to their final effects 
on the expression of the miRNAs.  
To elaborate on the regulatory mechanisms involved, the expression of pri-miR-143 
and pri-miR-145a in sg145m2 edited cells was quantified. To this end, commercially 
available assays, designed to target the flanking sequences on either side of the 
miRNA stem loop, were used. Effectively, the assays employed to quantify the pri-
miR-143 and pri-miR-145a targeted the hairpin of mmu-miR-143 and mmu-miR-145a, 
respectively. A sharp decrease was observed indicating that targeting mmu-miR-
145a affects the expression of the entire pri-miR-143~145 (Figure 5.14A), in line with 
the results for homo-cluster mmu-miR-497~195. 
 
In order to determine whether mature miR-145a expression exerts transcriptional 
control on the miR-143~145 cluster, mmu-miR-145a was overexpressed in VSMCs 
using miRNA mimics. These are short synthetic oligonucleotides that function as 
mature miRNA without requiring any processing by the Drosha or Dicer complexes. 
High levels of mmu-miR-145a led to increased miR-143 expression (250%) that was 
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accompanied by a coordinated increase in pri-miR-143 and miR-145a expression 
(162% and 165% respectively), indicating transcriptional regulation. As expected the 
levels of KLF4, a validated target of miR-145a114 were significantly downregulated 
(40%) following miR-145a overexpression (Figure 5.14B).  
 
These findings provide a helpful insight in the co-ordination in the maturation of 
clustered miRNAs. In the case of the mmu-miR-143~145 cluster an interdependency 
in the mature miRNA expression was demonstrated. The results outlined above were 
indicative of a transcriptional regulation of mmu-miR-145a on mmu-miR-143 and a 
feed-forward loop that reinforces the expression of the entire cluster. Gene editing of 
the mmu-miR-145a stem loop led to decreased expression of both the miRNAs of the 
cluster while mmu-miR-145a mimics led to increased levels of pri-miR-143 and 
mature mmu-miR-143. Thus, a direct evidence for the role of mature mmu-miR-145a 
in triggering the expression of the cluster mmu-miR-143~145 is provided. Although it 
is difficult to dissect whether the differences in mmu-miR-143 expression are due to 
structural changes or due to transcriptional regulation triggered by the reduced mmu-
miR-145a levels, the two possibilities are not mutually exclusive. It is important to 
point out that mmu-miR-143 and mmu-miR-145a show no sequence homology 
suggesting that they do not have common targets114. Nonetheless, the two miRNAs 
participate in a regulatory network that controls cytoskeletal remodelling and 
phenotypic switching of VSMCs under pathological conditions254. This underlines the 
added value of miRNA clusters that provide an effective mechanism of cellular 
response and may explain the evolutionary pressure for their sequence conservation. 
 
Next, RNAfold revealed that induction of 1nt deletion in the hairpin of mmu-miR-145a 
with sg145m2 did not change the secondary structure while a 12nt deletion changed 
the structure significantly (Figure 5.15). Intriguingly, the expression of Carmn (cardiac 
mesoderm enhancer-associated non-coding RNA), a long non-coding RNA 
overlapping the mmu-miR-143~145 cluster that constitutes an independent 
transcription unit226 did not differ in mmu-miR-145a edited cells (Figure 5.16), 
confirming that only the primary transcript (pri-miR-143~145) and not the wider locus 
is affected. 
 
With regards to the tertiary structure of the cluster miR-143~145, as its length is about 
1400bp, it cannot be analysed using the algorithms currently available for the 
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computational simulation. The development of more elegant tools to predict the 
tertiary structure of longer sequences will provide further insights. 
 
Although not adequate results that support the notion were obtained, it is tempting to 
speculate that the downregulation of the clustered miRNA is due to both a disruption 
of a feed-forward loop as well as of the hindering of the processing of the primary 




5.4.2 Editing of mmu-miR-17~92 cluster 
 
Next, the study focused on a highly studied miRNA clusters in the mouse genome, 
the miR-17~92, spanning 800 bp. The miR-17~92 cluster plays a pivotal role in the 
cardiovascular system and in cancer and mediates processes such as 
angiogenesis120, 122. This cluster consists of six miRNAs that can be grouped in four 
families based on their seed sequence (Figure 5.19A and B). Intriguingly, two 
paralogs, the miR-106a~363 and miR-106b~25 clusters are believed to be derived 
from a series of duplication and deletion events during vertebrate evolution have been 
identifed255.  
 
Gene editing using sg18 that targets the miR-18a stem loop (Figure 5.19A) was 
efficient (32–37%) as assessed by T7EI assay (Figure 5.19B) and disrupted the 
Bsp1286I restriction site (Figure 5.19D). Sanger sequencing revealed the presence 
of small deletions in the miR-18a stem loop (Figure 5.19E) that were predicted to 
induce a differential secondary conformation (Figure 5.21). As previously, these 
deletions were very specific and occurred only in the vicinity of the DSB. No mutations 
were identified in a 1 kb region that encodes the cluster (Figure 5.20). Interestingly, 
in contrast to the results presented for clusters mmu-miR-497~195 and mmu-miR-
143~145, in the case of mmu-miR-17~92 cluster, although the expression of miR-18a 
diminished significantly (88%) there was no impact on miR-17, miR-19a and miR-20a 
levels, miRNAs that are all located on the same cluster (Figure 5.19F). Additionally, 
discrepancies between the editing efficiency as evaluated by T7EI and the levels of 
downregulation of mmu-miR-18 showcased the limitations of the assay for assessing 
the impact of editing. Although underestimation of the indel efficiency is expected 
these results demonstrate that T7EI is not as sensitive as a technique. The 
expression of miR-19b-1 and miR-92a-1 could not be assessed as they are also 
encoded by a second miRNA cluster on chromosome X (Supplementary Table 1).  
 
Intriguingly, analysing Sanger sequencing data with RNAfold did not show any 
significant secondary structure alterations despite the deletion of a long sequence, 
although these results are not conclusive. Thus, in the case of mmu-miR-18 it is 
tempting to speculate that is neither the structural changes of the targeted hairpin nor 
the deletion of sequence motifs but, possibly, the deletion of miRNA specific 
sequences that led to the downregulation of the levels of the mature miRNA. 
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Nonetheless, there is also the possibility that the 6nt deletion that was chosen to be 
assessed with RNAfold had no effect neither on the structure nor on the expression 
levels of the miRNA.  
 
In agreement with the results shown above, it has been reported that pri-miR-17~92 
shows a highly specific globular, tertiary structure that affects the processing of the 
transcript by Drosha252, 253. More specifically, Chaulk et al have demonstrated that pri-
miR-17~92 takes a folded structure of globular shape that results in the internalisation 
of the 3’-end of the transcript while the 5’-end of the cluster folds on top of it, leading 
to a less efficient processing of the internalised miRNAs253, 256. Moreover, a non-
miRNA containing stem loop in the core of the primary transcript, showing a high 
sequence conservation, has been reported 256. This stem loop interacts with other 
hairpins in the transcript, namely miR-19b, and affects the processing of the whole 
structure. Interestingly, physiological interactions of the two hairpins lead to low levels 
of miR-92a while disruption of the primary transcript's structure, due to mutations, 
leads to enhanced expression252, 256. In addition, this structure affects the maturation 
of other miRNAs of the 3' core suppressing the expression of miR-19b and miR-18a256 
while removal of miR-19b resulted in the upregulation of miR-92a and, to a lesser 
extent, of miR-18a. These data also indicate that miR-18a hairpin, although not part 
of the 3' core, is internalised upon folding of the primary transcript. 
 
These data further support the notion that miRNA processing is complex and highly 
sensitive in tertiary structure changes and showcase how sequence alterations, with 
the subsequent disruption of the structure, can affect miRNA maturation. Taken 
together, with the data outlined above, they show how CRISPR/Cas9 editing can be 
employed for the downregulation of different miRNAs of the same cluster with the use 
of specific guides depending on the intended result. Nonetheless, editing of the 
cluster's DNA sequence although successful, was shown not to exert any effects on 
the maturation of the clustered miRNAs in contrast to previous results, highlighting 
that the processing differs among miRNA clusters. 
 
 




Similar results, as discussed in 5.4.2, were obtained when the stem loop of miR-25 
was targeted in the miR-106b~25 cluster (Figure 5.22 and Figure 5.23). Effective 
editing was observed with sg25, as determined by both the T7EI assay (20–27%, 
Figure 5.24C) and the disruption of the MfeI restriction digestion site (Figure 5.24D). 
Sanger sequencing demonstrated a mutation pattern of small indels (Figure 5.24E), 
while qPCR quantification showed a significant downregulation of miR-25 expression 
(49%, Figure 5.24F) with the levels of miR-93 and miR-106b not being affected. Off-
target mutagenesis assessment showed no editing for the miR-93 and miR-106b loci 
(Figure 5.25). The DNA sequence alterations led to a secondary structure of the miR-
25 stem loop with a disrupted terminal loop (Figure 5.26). 
 
Interestingly, interdependency in expression does not seem to be a common feature 
in all clustered miRNAs. Gene editing in mmu-miR-497~195 homo-cluster and mmu-
miR-143~145 hetero-cluster revealed that targeting of one of the hairpins of the 
cluster led to downregulation of both of the clustered miRNAs. Although 
overexpression of mmu-miR-195a did not result in enhanced levels of mature mmu-
miR-497a, suggesting no interdependency in the mmu-miR-497~195 cluster, in the 
case of mmu-miR-143~145 cluster the levels of mature mmu-miR-143 were affected 
by those of mmu-miR-145. 
 
However, targeting of miR-18a and mmu-miR-25 revealed that the expression of 
other miRNAs in the corresponding clusters are not affected by changes in the 
structure of the targeted hairpins. No compensatory increase of these miRNAs was 
observed in edited cells either. Thus, it seems that while coordinated expression of 
miRNAs in clusters is a shared feature, feed-forward and feedback loops are in place 
only when a synergistic effect and combined regulation of multiple pathways is 
required. 
 
Overall, it has been shown that despite the sequence diversity of pri-miRNAs, 
mutations can be well tolerated, provided that they do not disrupt critical elements 
such as stem length, bulge position and terminal loops. Furthermore, it was 
demonstrated that although miRNAs in a cluster form a co-transcriptional unit their 




In conclusion, these data confirmed that the CRISPR/Cas9 editing technology is 
extremely precise, since indels occurred only in the vicinity of the DSB while no 
mutations were identified in the regions encoding the cluster. All in all, CRISPR/Cas9 
emerged as a robust system for miRNA inhibition that is able of revealing novel 
regulatory mechanisms for clustered miRNA expression. 
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6 Chapter 6 ASSESSMENT OF THE LEVELS OF RBPS 




RBPs are important regulators of various steps in the expression of genes either co- 
or post-transcriptionally and they participate in multiple steps such as RNA splicing, 
capping, polyadenylation, export and translation7, 257.  Following the same recognition 
patterns, RBPs participate in the maturation process of the miRNAs by controlling 
their post-transcriptional processing, tightly and in various steps such as the primary 
transcript cleavage, the export, the pre-miRNA cleavage, the stability control and the 
loading to RISC complex. 
 
The regulation of the maturation of miRNAs is a multistep process that is controlled 
both by the rate and the efficiency of the recognition and the binding of the RNase III 
nucleases Drosha and Dicer. This efficiency is influenced by both structural and 
sequence characteristics of the miRNA precursors7. Further to this, RBPs are able of 
recognising specific sequence motifs in precursor miRNAs and regulate the 
maturation according to the cell type or exogenous signals258-260. In addition, RBPs 
have been shown to be capable of binding short single-stranded or double-stranded 
RNA1, 260-262. 
 
Only a small portion of the putative RBPs have been studied in eukaryotic cells with 
regards to their function with the reported results not being conclusive due to the 
diverse experimental approaches followed and the cell line specific RNA interactions 
that the RBPs showed221, 263.  Some of the discrepancies among the data reported 
cannot be conclusively explained but could be due to discrepancies between in vitro 
and in vivo conditions, different binding conditions, and/or the proteins per se 
analysed221. 
 
The cell type specific interactions between RBPs and miRNAs are an aspect of the 
proteins that restricts their study and the universal application of the conclusions 
drawn from the studies while some RBPs recognise multiple hairpin-forming RNAs, 
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indicating a wider range of interacting repertoire263. Nonetheless, in the latter case, 
the recognition was specific only to hairpin structures but not generic dsRNAs, 
implying that other co-factors, and not the secondary structure alone, are necessary 
for the recognition of the miRNAs. This duality that the RBPs present in their function 
suggests that they might have specific context or cofactor-dependent effects on their 
targets. 
 
Multiple RBPs have been implicated in the biogenesis of the miRNAs such as KSRP 
and TRIM25 in the regulation of let-755, 264, MSI1/2 in miR-7 processing265. However, 
an exhaustive approach to identify and describe RBPs that bind and regulate miRNAs 
during all the stages of their biogenesis and turnover has yet to be conducted. This 
would provide the needed information for a comprehensive picture of the dynamic 
interactome of pri-/pre-miRNAs to be drawn. Taken together, these data highlight the 
importance of the in vitro studies for the identification of the interactions between 
RBPs and miRNAs, although the limitations of the approach need to be also taken 
into consideration221.   
 
Although studies have reported data regarding recognition of specific RNA sequence 
motifs and secondary structures for various miRNAs during their maturation, namely 
miRNAs that participate in tumorigenesis, miR-195 is one of the least studied ones. 
In light of this, in the current chapter the project focused in establishing a workflow to 
identify the RBPs that bind the pri-miR-195a and participate in its maturation. 
Additionally, a comprehensive panel of RBPs that bind the mutant pri-miRNA was 





6.2 Experimental Design 
 
The scope of the current chapter was to establish the RBPs that recognise and bind either 
the WT or the mutant pri-miR-195a, and to compare the panels of the proteins that bound 
differentially on the two primary transcripts. The objective of this approach was to provide 
in vitro data for proteins that can participate in the maturation process of the primary 
transcript of the miRNA. Moreover, by using a mutant primary transcript, the goal of the 
study was to decipher the alterations in the processing of the transcript that can lead to 
differential expression. In order to do so, RNA molecules were in vitro transcribed.  
 
In more detail, DNA sequences of pri-miR-195a that corresponded to either the WT or a 
mutant sequence, the latter one harbouring a 16nt deletion upon editing with sg195m3, 
were in vitro transcribed as described in Chapter 3.18 and were labelled with biotin. Next, 
they were bound to streptavidin magnetic beads and they were used as baits to bind and 
pull-down proteins from mouse VSMC lysates, proteins that are capable of recognising 
and binding the two distinct RNA molecules. The eluted proteins were then analysed with 
Mass Spectrometry (MS) with the aim to be validated by an independent approach, like 
Western Blotting. These experiments were performed in collaboration with Prof Manuel 
Mayr and the hypothesis to be tested was that, since no editing of the genomic locus of 
the mmu-miR-497 was identified, the downregulation observed was the result of the 
differential processing of the whole primary transcript due to a new panel of RBPs that 
recognise and bind the mutant pri-miR-497~195 that either restrained its processing or 
led to its cleavage. 
 
It is the first time, to the best of my knowledge, that a pull-down experiment was conducted 
aiming to identify the network of RBPs that recognise the pri-miR-195a. According to the 
data received and analysed, a higher number of RBPs bound the mutant transcript, 
despite the shorter sequence and the decreased number of the putative sequence motifs 
that can potentially be recognised and bound. Lastly, analysis of the networks of the 
identified proteins, with the use of online tools, demonstrated that these proteins 








6.3.1 Differences in expression of RBPs  
 
The levels of a panel of 14 RBPs that have been previously identified to participate in the 
maturation process of miRNAs221, and share RNA binding motifs with the primary 
transcript of mmu-mir-195a, were tested. In more detail, three different edited sequences 
were expressed, with the use of pLKO.1 vector, that harboured 1nt, 4nt and 126nt 
deletions. VSMCs were infected with lentiviral particles with either an empty pLKO.1 
vector, a vector with the unedited sequence of the primary transcript or with vectors 
harbouring each of the edited sequence resulting in their overexpression. Assessment of 
the expression levels of the 14 RBPs without showing any statistically significant 
difference in their expression. The proteins with their corresponding RNA binding motifs 
are depicted in Supplementary Table 6. 
 
 
Figure 6.1 Assessment of the expression levels of a panel of RBPs. The level of 14 RBPs were 
quantified in VSMCs after transfection with pLKO.1 expressing mutants of mmu-miR-195a harbouring 




6.3.1.1 Validation of the Mass Spectrometry data using Western Blot 
 
 Titration of the Pull-down conditions 
 
Titration experiments were conducted to identify the optimal conditions for the RNA 
Pull-down assays. IVT RNA transcripts corresponding to the WT or the mutant pri-
miR-497~195 were tested in two individual Pull-down experiments. Blotting against 
human antigen R (HuR) showed that the two transcripts were able to bind to the 
protein and pull it down in the conditions tested. 
 
 
Figure 6.2. Western blot analysis for HuR. Two independent experiments were used to assess the 
ability of the IVT transcripts to recognise and pull-down HuR protein (lanes 1-2 and lanes 3-4, 
respectively). The negative and positive RNA controls that were provided with the kit were used as 
controls for the Pull-down. As negative control a poly(A)25 RNA and as positive control the 3´ 
untranslated-region of androgen receptor (UC-rich region) was used. WT: wild type transcript, mt: mutant 
transcript. 
 
In addition to the first set of titration experiments, further optimisation revealed that 
regardless of the amount of DNA used in the IVT, the efficiency of the Pull-down was 
not affected. This indicated that the IVT reaction was not affected by the amount of 
DNA. Furthermore, the streptavidin beads bound to the positive RNA control, 
following elution under the recommended conditions, were boiled with sample buffer 
containing SDS, and assessment of the eluted proteins, demonstrated that the initial 







Figure 6.3. Titration experiment for the RNA template of the Pull-down. Different amount of DNA 
was used for the IVT reaction, preceding the labelling and the Pull-down. An IVT RNA that corresponded 
to GFP was used as a negative control alongside the negative and positive RNA controls that were 
provided with the kit. Input was used as a control for the antibody together with the eluate from the 
streptavidin beads bound to the labelled positive or negative RNA controls.   
 
Further optimisation of the Pull-down assay reached the conclusion that there are no 
detectable differences in the efficiency of the Pull-down when either 25 or 50pmol 
were used while the absence of 30% PEG during the labelling reaction was 
detrimental for the assay (Figure 6.4). In addition, blotting with Dicer antibody showed 




Figure 6.4. Titration experiment for the amount of labelled RNA to be used for the Pull-down. 






Figure 6.5. Western blot analysis for Dicer. Different amounts of labelled RNA were tested to assess 





6.3.2 Proteomic Analysis of the RNA Pull-down proteins 
 
6.3.2.1  Mass Spectrometry analysis of the RNA Pull-down proteins 
 
The proteins that were pulled down using the IVT transcripts corresponding to the WT 
and mutant pri-miR-497~195 were analysed using MS. The eluted proteins were then 
injected onto the nano-LC-MS/MS system for data dependent analysis on a Q 
ExactiveTM Plus Quadrupole-Orbitrap MS. Overall, 766 proteins were detected. 
 
Protein abundance was measured using normalised TIC of MS/MS spectra in 
Scaffold (version 4.8.7). In the untargeted proteomics analysis, 139 proteins were 
considered quantifiable with the following criteria: the protein was present in a 
minimum of 2 samples in at least 1 group. Statistical analysis of the MS results 
revealed a number of proteins of which about 45% were RNA binding and 55% non-
RNA binding as annotated in Uniprot (Figure 6.6). Moreover, their localization was 
reviewed, with the majority of them being found in the nucleus (42% (Figure 6.7) as 





Figure 6.6. Distribution of RNA pulled down proteins. The proteins that were pulled down with either 






Figure 6.7. Chart for the localization of the RNA pulled down proteins. UNIPROT annotation was 

















Figure 6.8 Number of RBDs in the pulled down proteins. Of the proteins that were pulled down, the 
RBDs were grouped according to the number of the RBDs that they harbour as per UNIPROT 
annotation. 
 
Statistical analysis of the MS results revealed 5 proteins that are bound to the mutant 




Figure 6.9. Volcano plot analysis for the RNA pulled down proteins that were differentially bound 
on the two transcripts. Statistical analysis of the Mass Spectrometry data revealed 5 proteins that 




In addition, the proteins that bound exclusively to the mutant transcript were analysed 
and 12 proteins were identified to bind to RNA, 4 of which participate in the formation 
of complexes that are involved in the pre-mRNA splicing (Figure 6.10). 
 
 
Figure 6.10. Clusters of proteins that bind exclusively on the mutant transcript. UNIPROT 





6.3.2.2 In silico analysis of the interactions of the pulled down RBPs 
 
In silico analysis of the proteins that bound solely to the mutant IVT transcript of the 
pri-miR-497~195, with the use of STRING software, showed experimentally 





Figure 6.11. Analysis of the predicted protein-protein interactions for the protein Eri1. The protein-
protein interactions as returned by the STRING software are depicted. Protein Eri1 and Dicer1 are 
highlighted as two of the proteins that were identified by Mass Spectrometry analysis of the pulled down 
eluate. Magenta lines indicate experimentally confirmed interactions, dark lines co-expression and light 





Figure 6.12. Analysis of the predicted protein-protein interactions for the protein Luc7l3. The 
protein-protein interactions, as returned by the STRING software, show that proteins the identified Luc7l3 
and Prpf19 proteins (highlighted in red ovals) are experimentally determined to interact. Magenta lines 
indicate experimentally confirmed interactions, dark lines co-expression, light green text-mining 





Figure 6.13. Analysis of the predicted protein-protein interactions for the protein Tra2b. The 
protein-protein interactions, as returned by the STRING software, show the proteins Tra2b and Prpf19 
as identified by MS (highlighted in red ovals) are experimentally determined to interact. Magenta lines 
indicate experimentally confirmed interactions, dark lines co-expression, light green text-mining 




In silico analysis of the identified proteins in cluster revealed a less complex but more 
specific network for the proteins with most of them showing experimentally confirmed 
interactions. Of note, all of the proteins that participate in the processing of the pre-
mRNA (Figure 6.14, red oval) showed interactions with each other and with a part of 
the generically RNA binding proteins, such as Larp1 and Ddx21 (Figure 6.14). 
 
 
Figure 6.14. Analysis of the predicted protein-protein interactions for the cluster of proteins that 
bind only the mutant RNA transcript. Interactions of the cluster of proteins that bind only the mutant 
RNA transcript as returned by STRING. Highlighted in red oval shapes are the proteins that participate 






Further in silico analysis with STRING showed that the interactions among the 
identified proteins are mainly due to binding, with the new analysis revealing a subset 




Figure 6.15. Analysis of the molecular action for the predicted protein-protein interactions for the 
cluster of proteins that bind only the mutant RNA transcript. Assessment of the molecular action of 
the proteins that were pulled down. Blue lines indicate binding, black reaction, purple catalysis and grey 
unspecified interaction. No line indicates no action. Highlighted in red oval shapes are the proteins that 






The confidence for the predicted protein-protein interactions, as returned by the 
STRING, showed binding of high confidence for the cluster of the pre-mRNA binding 
and processing RBPs (Figure 6.16). 
 
 
Figure 6.16. Analysis of the confidence for the predicted protein-protein interactions for the 
cluster of proteins that bind only the mutant RNA transcript. Assessment of the confidence for the 
functional association of the proteins. The weight of the grey lines is indicative of the confidence level 
varying from high (0.9) to low (0.15), indicating the estimated likelihood that the depicted interaction is 
specific and meaningful. No grey line indicates no association. Highlighted in red oval shapes are the 
proteins that participate in the pre-mRNA splicing and in blue rectangular the ones that are RNA binding, 







To confirm the protein interactions indicated by STRING and to study the possible 
pathways that these proteins participate in, Reactome software was used. Except for 
Eri1 and Dicer1, that interact with each other but do not show to participate in any 
pathway that is shared by the other proteins, the rest of them display an interaction 
network. Tra2b, Prpf19 and Luc7l3 interact with each other and the first two with 
Ddx21 and Prpf31, respectively, proteins that form a different cluster with Larp1 and 
Sart3. Proteins Tra2b, Prpf19 and Prpf31, interact with each other and partake in an 
mRNA splicing pathway with a statistical significance of p<0.01. 
  
 
Figure 6.17. Cluster analysis of the identified proteins. Reactome was used to identify interactions 
between the pulled down proteins and the pathway they participate in. The different proteins, depicted 
in circles, are coloured according to the interacting groups they participate in. The black lines indicate 
interaction between proteins while the underlined proteins, according to the Reactome analysis, partake 







It is well established that the biogenesis of miRNAs is a multistep process that 
presents high complexity and is regulated by a number of RBPs21. They participate 
in every step of the maturation of the miRNAs, from recognition and cleavage of the 
primary transcript, to the export of the pre-miRNA hairpins to the cytoplasm, the 
further processing to a miRNA duplex and the loading to RISC263, 266-268. After these 
initial steps, the RISC complex binds the corresponding mRNA targets, via imperfect 
Watson and Crick complementarity between the mature miRNA and the targeted 
mRNAs and controls their expression1, 40, 221. 
 
Although they play a central role in the maturation of the miRNAs, only a small fraction 
(<5%) of these are characterised, contrary to RBPs that participate in the general 
processing of the miRNAs, such as Drosha and Dicer, that are very well described263, 
269, 270. Taking into consideration the plethora of the miRNAs, the complicated clusters 
they form, the interdependent regulation of their transcription and the complexity of 
the miRNA networks it becomes apparent that more RBPs than just Drosha and Dicer 
participate in a targeted way in the biogenesis of the miRNAs. Furthermore, studies 
report specific subsets of RBPs to interact with distinct miRNAs in specific cell types40, 
221, 263. As an example of the specific role that RBPs play in miRNA biogenesis, 
TRIM71/LIN41 has been shown to regulate the expression of miR-29a alone, in two 
different cell lines while the downregulation of the protein affects the levels of the miR-
29a targets in a functional approach that provides data regarding how RBPs can both 
affect directly the maturation of miRNAs and indirectly the silencing of the targeted 
mRNAs221. 
 
To gain deeper knowledge in regard to the processing of the miRNAs and how it gets 
affected by both sequence and tertiary changes in the pri-miRNAs, further 
identification of the RBPs that regulate the miRNA biogenesis is needed. To this end, 
in this chapter, the study focused on characterising the RBPs that interact with the 
WT pri-miR-195a and to elucidate the mechanism that result in the downregulation of 





6.4.1 Expression levels of RBPs 
 
As a first approach, a panel of RBPs that have been previously described221 to 
participate in the maturation process of miRNAs and share RNA binding domains that 
recognise sequence motifs located in the primary transcript of mmu-miR-195a was 
assessed upon miRNA overexpression with pLKO.1 (Figure 6.1). After editing the 
genomic locus of mmu-miR-195a, DNA sequences harbouring deletions of various 
lengths (1bp, 4bp and 126bp) were PCR amplified and cloned into pLKO.1 vectors. 
QPCR quantification did not show any significant changes in the expression levels of 
the RBPs when compared to the levels of the cells at baseline, infected with lentiviral 
particles with an empty vector. These results indicated that the differences of the 
levels of mature mmu-miR-497a and mmu-miR-195a upon editing were not due to 
the downregulation of the expression of certain RBPs but a result of the editing per 
se and the differential processing of the primary transcript. 
 
6.4.2 Proteomic Analysis 
 
MS is an unbiased screening technique for single protein analysis that offers a 
platform for the thorough examination of multiple proteins from tissue or cell lysates. 
An additional advantage that it presents is the unbiased detection of proteins since 
there is no need for antibodies designed to recognise specific epitopes to be 
employed.  
 
In the present study, MS was employed to identify differential binding of RBPs to the 
mutant primary transcript of mmu-miR-195a~497 cluster that result in the 
downregulation of the mmu-miR-497a expression levels, two miRNAs that reside on 
the same cluster and are transcribed as one primary transcript. Results already 
presented above in Chapter 5, have shown that no editing occurs within the genomic 
locus of mmu-miR-497a. 
  
To decipher the changes in the maturation process that led to the differential 
expression of the miRNAs, RNA Pull-down assays were conducted and the eluted 
proteins were analysed. As an initial step, the Western Blotting was tested using the 
conditions following the company’s recommendations. In more detail, two RNA 
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molecules are provided with the kit, a positive control, that corresponds to the 3’-
untranslated region androgen receptor RNA which is recognised and bound by HuR, 
and a negative control of a poly(A) sequence consisting of 25nt that are not 
recognised by the protein. In the initial experiment, the RNA transcripts biotin labelled 
together with the positive and negative RNA control and, following the pull-down, a 
HuR mouse monoclonal antibody was used to detect the protein (Figure 6.2). Results 
showed that, under the tested conditions, HuR is able to bind all the transcripts, even 
including the negative control although with significantly lower efficiency. Noteworthy, 
the mutant transcript in both of the two independent experiments presented, although 
bound by HuR, was bound with an efficiency almost as low as that of the negative 
control and notably lower than that of the WT. Interestingly, the 16nt deletion does 
not contain any AU element, which means that the difference in the binding efficiency 
that was observed was not due to the excision of any AU sequences but possibly due 
to a different tertiary structure that does not let the transcript to get accessed by the 
RBPs. These results contradict the previously presented MS results221, that showed 
that Tial1, that binds AU-rich elements, is enriched in the eluate of proteins pulled 
down with IVT mutant RNA, indicating that the recognition of the AU sequence motifs 
is not enough for the interaction between the transcripts and the RBPs. In more detail, 
the differential binding of the WT and mutant transcript by HuR cannot be attributed 
to sequence differences since the number of AU motifs in the sequence of the two 
transcripts are the same. Therefore, the differential binding can only be explained 
either by differences in the tertiary structure of the mutant transcript or the inability of 
other necessary co-factors to bind the transcript. 
 
Further titration experiments, concluded in that the amount of DNA, corresponding 
either to the WT or the mutant sequence, does not affect the efficiency of the in vitro 
transcription. As shown in Figure 6.3, regardless of the amount of DNA that was in 
vitro transcribed, blotting with HuR antibody did not demonstrate any differences in 
the amount of the RBP that was pulled down. Negative RNA control did not show any 
binding of the protein. Moreover, streptavidin magnetic beads that bound labelled 
positive RNA controls were incubated for a second time with sample buffer containing 
SDS, at 95°C, elution conditions that were more extreme than the recommended 
ones. Western blotting revealed a distinct, although diffuse band of HuR protein, 
results that showed that with elution under the recommended conditions, not the 
whole amount of proteins were eluted. The intensity of the band of the positive control, 
compared to the intensity of the band of the input, demonstrated that the pull-down, 
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although highly specific, did not enrich for the pulled down proteins. On top of that, 
the fact that we were able to detect pulling down of HuR with an artificial positive 
control transcript indicates that binding of RBPs to the bio-transcript does not mean 
RBP depletion of the sample. Further blotting with beta-actin revealed a distinct band 
only for the input, showing the specificity of the pull-down. Next, following labelling of 
the IVT RNA transcripts, different amounts of labelled transcripts were used for the 
pull-down with the results demonstrating that half of the amount of the recommended 
labelled RNA to be used had the same results while the use of smaller amount of 
labelled RNA improved the results. Absence of PEG in the labelling experiment 
showed detrimental results for the pull-down. PEG provides a hydrophobic 
environment to the RNA molecules improving the precipitation efficiency which in its 
absence decreases. Lastly, blotting with antibody against Dicer, showed that 
regardless of the amount of labelled RNA used, Dicer was pulled down only for the 
WT transcript (Figure 6.5). Although Dicer, according to the canonical pathway of the 
maturation of miRNAs binds to the pre-miRNA in the cytoplasm, the lack of cell 
compartmentalisation exposed the primary transcript to Dicer which resulted in its 
binding, contrary to the MS results that showed binding only of the mutant transcript 
by Dicer. Nonetheless, although these results revealed the binding of Dicer, they 
cannot provide any insight of the nature of interactions. More specifically, the binding 
could have been detected due to the physiological recognition of the pre-miRNA stem 
loop, as part of the primary transcript, by Dicer or due to the participation of the protein 
in a complex that bind the transcript. 
 
The proteomics data outlined in the current chapter, offer a unique description of the 
RBPs that interact with both the WT and the mutant transcript. In total, 766 proteins 
were identified of which only 141 were quantifiable according to quality control of the 
data (Supplementary Table 7). Of them, about 45% are annotated in UNIPROT 
database as RNA binding proteins (Figure 6.6). The relatively small percentage of the 
identified RBPs, compared to the total number of proteins that were pulled down, can 
be indicative either of innate limitations of the pull-down assay or of specific protein-
protein interactions between RBPs and other co-factors that led to non RBPs to be 
pulled down in complexes. More specifically, this assay was performed in vitro, and 
high activity of background binding was expected. Furthermore, it should be 
considered that the differences between conditions of the presented assay and the 
physiological conditions of the processing of the miRNAs are notably different. Firstly, 
during the maturation of the miRNAs, cell compartmentalisation plays a pivotal role 
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in the process, with primary transcript being exported from the nucleus to the 
cytoplasm after the initial cleavage by Drosha. In the case of the RNA Pull-down, the 
lack of compartmentalisation could have potentially led to different, non-physiological 
and not related interactions between RBPs and co-factors, thus hindering the ability 
of specific RBPs to freely recognise and bind the pri-miR-497~195, while resulting in 
more proteins being pulled down. Secondly, the concentration of the primary 
transcript, which is used for the pull-down, is significantly higher than under 
physiological condition. The transcription of the pri-miR-497~195 is tightly regulated, 
by various regulatory factors that expose the primary transcript to the maturation 
machinery in waves, thus its high, non-physiological concentration could affect its 
binding by RBPs and subsequently the proteins that are identified by MS, as it was 
previously described221, 260. 
 
Following these results, the identified RBPs were further analysed regarding their 
localisation as annotated by UNIPROT. Of the proteins identified, 50% are localised 
either in the nucleus or the cytosol while the vast majority of them (40%) are nuclear 
proteins, as expected (Figure 6.7). Under the physiological pathway of the maturation 
of miRNAs, the primary transcript is, in a first step, bound by the RBPs localised in 
the nucleus. With this in mind, it was expected that the primary transcript would be 
recognised by nuclear proteins even in the lack of cell compartmentalisation.  
 
Further statistical analysis of the data showed that despite the various changes that 
were noted between the proteins pulled down with the WT and the mutant primary 
transcript, only 5 of them were statistically significant (Figure 6.9), with the rest of the 
proteins either showing small differences between the two groups or no statistical 
significance, results that lead to the conclusion that these proteins bound the two 
transcripts at the same level . Noteworthy, all of the statistically significant proteins 
were bound with higher affinity to the mutant transcript, contrary to the expected 
results. It was thought that the 16nt deletion in the sequence of the mutant transcript 
would, on the one hand, result in the abolition of sequence motifs able to be 
recognised by the RBPs and, on the other hand, a non-physiological tertiary structure 
that would restrain the RBPs from approaching and binding the transcript. 
Furthermore, although not statistical significance was identified, a trend was observed 
for the majority of the pull-down proteins to bind the primary transcript with higher 
affinity when compared to the WT transcript (Figure 6.9, lower right panel). Of the 5 
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statistically significant proteins identified, 3 showed a smaller than a 2-fold increase. 
Tial1 is an RBP that has not been previously described in detail, with an AU-rich 
binding element, Ran is a GTP-ase that is involved in the nucleo-cytoplasmic 
transportation of proteins and RNA molecules and Apex1 is an endoribonuclease that 
recognises ssRNA molecules and exerts control on their metabolism. Moreover, 
proteins Sec63 and Copb2 showed a 2.5 and 4-fold increase, respectively, in their 
affinity to the mutant transcript. 
 
In fact, it has been proposed that Tial1 binds both to mRNA and ssDNA via its RRM 
domains (RRM1 and RRM2) located in its C terminus. It participates in the splicing 
regulation and translational repression of the mRNA, via the alteration of their half-
life, and transcription regulation of the DNA271-274. Nevertheless, the precise 
mechanisms that Tial1 employs to bind to and thereby repress the translation of 
specific target mRNAs has not been specified. Tial-1 has been shown to assist the 
aggregation of complexes, such as eIF2 and eIF5, in discrete cytoplasmic foci called 
stress granules that inhibit the translation of the bound mRNAs275. It is thought that 
via this interaction both the mRNA stability and the translation is regulated during 
stress the composition of mRNA RNPs and their subsequent binding and processing 
with the translation or degradation machineries276, 277. In our experiments, Tial1 was 
detected to bind a non-coding transcript therefore it is thought to partake in the 
degradation of the transcript. 
 
Ran is a predominantly nuclear GTPase protein, a member of the Ras superfamily278. 
It is associated with different proteins and depending on the binding of a Guanine 
(RanGTP or RanGDP) it is located either in the cytoplasm or the nucleus279. It 
regulates the nuclear trafficking and the translocation of mRNA280.  
 
Apex1 is a multifunctional protein that has been implicated in binding of ssDNA, 
DNA/RNA hybrids and ssRNA molecules and participates in the response to oxidative 
stress with its two functions being the DNA repair and regulation of transcriptional 
factors. Functions as an endodeoxyribonuclease in the DNA repair during oxidative 
stress. Apex1 is involved in the regulation of transcription by repressing it together 
with HNRNPL and partakes in the metabolism of ssRNA. It is associated with proteins 
non-sense mediated decay-1 (NMD1) and Y-box protein 1 (YBX1) that regulate the 




Furthermore, Sec63 has been implicated in the transport of proteins through the 
endoplasmatic reticulum (ER) while Copb2 participates in the transportation of 
proteins from the ER to the Golgi network in association with GTP-binding proteins283. 
 
Taken together these results indicate that the mutant transcript follows a different 
processing pathway.  Although further in silico analysis with STRING online software 
did not reveal any interaction between the identified proteins (data not shown), 
according to their annotation they can be organised in two groups. To be specific, 
Tial1 and Apex1 are RBPs that recognise specific motifs (AU-rich and UACA 
respectively) in ssRNA molecules and partake in their processing. Their function is 
indicative, although not conclusive, of how the editing of mmu-miR-497~195a locus, 
through a 16nt deletion in the mmu-miR-195a hairpin, can affect its processing. These 
proteins, being identified in higher abundance bound to the mutant transcript, could 
potentially be due to differential processing that leads to the clearance of the non-
physiological transcript. Furthermore, a second cluster, comprised of Ran, Sec63 and 
Copb2, regulates the identification and transportation of proteins to Golgi network. 
Although, these results seem not to be relevant to the processing of RNAs and 
miRNAs, they should be analysed under the light of both the presence of the non-
physiological pri-miRNA and the lack of compartmentalisation. The RBPs that bind 
the mutant transcript could form a complex that potentially attract a group of proteins 
that do not naturally bind the RBPs organised around the WT pri-miR-497~195 
transcript. Thus, these results could be suggestive of a pathway that does not reflect 
any canonical processing and is not followed under physiological conditions in cells. 
 
Interestingly, a set of proteins that bound only the mutant transcript was identified 
(Figure 6.10, Supplementary Table 7). Nonetheless, the possibility that the primary 
transcript forms a new structure, because of the different sequence, cannot be 
excluded. Of them, a small subset of 12 proteins were annotated to bind RNA 
molecules. More specifically, two subsets were identified according to UNIPROT 
annotation. A subset of 8 proteins that are generally RBPs, such as Dicer1 which 
binds primary transcripts and leads to specific cleavage, was identified and a subset 
of 4 proteins that is involved in the pre-mRNA splicing. The representative spectra of 
the identified proteins are shown in Supplementary Figure 1 and Supplementary 
Figure 2. Although these interactions could be due to new sequences being created, 
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analysis of the sequence of the mutant primary transcript did not show any known 
RNA binding motifs to be created. 
 
Further analysis of the associations of these proteins with online software, revealed 
functional interactions between the proteins and between the two clusters. STRING 
software, a free online database of known and predicted functional and physical 
protein-protein interactions284, was used for a preliminary analysis to highlight the 
functional relationship of the proteins. STRING uses experimental evidence, 
database information, text-mining from PubMed abstracts285, co-expression data284, 
neighbourhood, ortholog analysis and phylogenetic contribution genome-based 
prediction data286 to reveal interactions indicative of biological pathways. When 
proteins were analysed individually, interactions showed a group of proteins that have 
been experimentally shown to interact. More specifically, in the case of Eri1 (Figure 
6.11), the proteins it interacts with include Dicer1, a type III ribonuclease that plays a 
pivotal role in the maturation of miRNAs. Eri1 is an RNA exonuclease that has been 
shown to participate in the degradation of histone mRNA along with the 3’ overhangs 
of siRNAs. Additionally, Dicer1’s function of cleaving miRNAs, as double stranded 
RNAs that form short hairpin structures, is well described. Taken together, these data 
suggest that either the two proteins work together conferring similar functions or that 
Dicer’s activity supplements Eri1 with cleaving the RNA molecules that the latter 
recognises. Furthermore, Luc7-like 3 protein, that is involved in the RNA splicing has 
been experimentally shown to interact with Prpf19 (Figure 6.12), a core component 
of complexes participating in pre-mRNA splicing, while Tra2b, a sequence specific 
RBP that participate in pre-mRNA splicing, interacts with Prpf19 according to 
experimentally proved data (Figure 6.13). These results are suggestive of a possible 
interaction between two groups of proteins (Eri1-Dicer1 and Luc7l3-Prpf19-Tra2b) 
that recognise the mutant transcript and cleave it. 
 
Intriguingly, when the 12 RBPs that bind solely the mutant transcript, were input in 
the software together, a network of experimental validated protein-protein interactions 
was highlighted (Figure 6.14). The cluster analysis revealed that 7 of the input 
proteins form a network of interacting RBPs while the interaction between Eri1 and 
Dicer1 was confirmed. Additionally, a second clustering became apparent when they 
were grouped on the basis of their function. Proteins that participate in the pre-mRNA 
splicing (Figure 6.14 red oval) form a cluster of closer interacting members that show 
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an association through proteins Tra2b and Prpf31 with the second cluster of Larp1, 
Ddx21 and Prpf31 (Figure 6.14 red rectangular). Further analysis, with STRING 
software, demonstrated co-operative binding among the pre-mRNA splicing proteins 
indicating either an interdependent binding of the RBPs of the clusters to the mutant 
transcript or increased binding due to these interactions (Figure 6.15), with the 
confidence for these interactions being high for the core of the cluster among Tra2b, 
Prpf19 and Prpf31 (Figure 6.16). 
 
Further analysis was performed with Cytoscape, an open-source software platform 
for the analysis and visualisation of interactions of proteins and protein networks287. 
Cytoscape analysis of the 12 proteins that bound solely to the mutant transcript 
returned the same results as STRING software with the formation of 2 distinct clusters 
that interact with each other through binding between Tra2b-Ddx21 and Prpf19-
Prpf31 (Figure 6.17). Lastly, pathway analysis with Reactome, an online software for 
the detection of biological pathways288, indicated that these 3 proteins participated in 
a pathway of mRNA splicing with statistical significance (Figure 6.17, Supplementary 
Table 8). 
 
In light of these results, it becomes apparent that this set of proteins participate in a 
different than the canonical pathway of the processing of miRNAs. The newly 
identified interactions cannot be explained exclusively through the formation of new 
sequence motifs due to the 16nt deletion. Moreover, although according to UNIPROT 
annotation these pulled down proteins are RNA binding, the possibility of interactions 
with the mutant transcript due to association with other proteins that bind the mutant 
transcript because of a newly created tertiary structure, cannot be excluded. 
Furthermore, these possible binding interactions would explain the non-RBPs that 
were pulled down solely for the mutant transcript (Figure 6.10). In addition, results 
from two independent software showed that 3 proteins (Tra2b, Prpf19 and Prpf31) 
form a core of interactions with the transcript and pathway analysis implicated them 
with pre-mRNA splicing. 
 
In more detail, Tra2b has been implicated in mammals with the activation of 
nonsense-mediated decay splicing upon recognition of a GAA repeats although not 
specific mechanism has been identified289. Furthermore, Prpf19 protein has been 
shown to be a core component of PRP19C/Prp19 assembly, as part of the U4/U5/U6 
tri-snRNP spliceosomal complex, and partakes both in its assembly and activity of 
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the pre-mRNA splicing290, 291. Interestingly, complex PRP19C does not contain any 
known RNA binding proteins. This feature suggests that the complex interacts with 
the pre-mRNA through other RNA binding factors, a characteristic that comes in 
accordance with our results. Additionally, Prpf31 is another component of the 
spliceosome. 
 
Moreover, it seems that the mutant primary transcript gets processed through a 
different pathway. Indicative results from the in silico analysis of the interactions of 
the MS analysed proteins suggest that the mutant primary transcript takes part in a 
pathway that leads to its degradation and clearance from the cells. These results also 
explain the decrease in the levels of the mature miRNAs, mmu-miR-497a and mmu-
miR-195a, since clearance of the primary transcript would lead to a decrease of their 
levels. Nevertheless, although indicative, these results cannot be conclusive. The 
possibility of these interactions not reflecting the conditions in cells upon editing of 
the targeted locus cannot be ruled out. In more detail, as explained above, the 
conditions of the pull-down experiments do not represent physiological conditions, 
thus, although in silico and statistical analysis identified a set of proteins that 
potentially participate in a different processing pathway the possibility that these 
interactions came up as significant due to innate limitations of the assay cannot be 
excluded. In more detail, as already explained, firstly the presence of a mutant 
transcript, harbouring a 16nt deletion, does not occur in nature and secondly the 
conditions of the assay do not represent cellular conditions. This could mean that the 
showed interactions do not represent any specific pathway that is followed by the 
cells but artefact interactions that is the result of non-physiological binding of the 
identified proteins to the mutant transcript. 
 
Although MS is a sensitive technique that is employed for both the identification of 
new proteins and of a set of known proteins it still presents limitations. It is a semi-
quantitative technique that is capable of showing only the presence of proteins and 
not possible interactions between them. In addition, the need for the validation of the 
results with an independent technique led to the employment of Western Blotting to 
test for the proteins, as demonstrated by the analysis of MS data. To elucidate the 
pathway that lead to the downregulation of the mmu-miR-497a upon editing, the study 
focused, on the proteins that bind exclusively to the mutant transcript. The hypothesis 
to be tested was that the deletion changed the tertiary structure of the primary 
transcript in a way that it could not be processed by the maturation machinery either 
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due to its degradation, through a different pathway, or due to the binding of RBPs that 
hinder its recognition.  
 
The experiments that were conducted to identify the optimal conditions of blotting did 
not lead to successful results while more antibodies were tested against proteins 
Larp1, IGF2BP2, hnRNPE1, DHX9, EIF2AK2, ILF3 Tra2b (Table 2)  but did not allow 
quantification of the respective protein due to multiple nonspecific bands of multiple 
sizes being detected. 
 
In conclusion, MS analysis of RNA pull-down with WT and mutant transcripts of pri-
miR-497~195 revealed, for the first time, a set of proteins that bind the pri-miR-
497~195 as well as RBPs that bind only the mutant transcript. Although the results 
did not lead to any firm conclusions with regards to the interaction between the 
proteins and the transcript they imply that alternative pathways may lead to the 
downregulation of the levels of mature mmu-miR-497a and mmu-miR-195a. 
Furthermore, as analysis of the 3D structure of the edited transcript revealed, the 
RNA Pull-down results could also indicate ineffective processing of the transcript. As 
the different elements of the primary transcript are not easily accessible upon editing, 
due to its non-canonical conformation, the binding of the identified pulled-down 
proteins could, potentially, signify differential processing that can explain the lower 
levels of mmu-miR-497. However, the lack of validation of the MS identified proteins 
with Western Blot indicate that further analysis and validation is needed in order to 









The objective of the study was to specifically inhibit hsa-miR-195 in order to study its 
implication in aneurysm formation. To this end target the genomic locus of hsa-miR-
195 stem loop was edited with the precision offered by CRISPR/Cas9. When 
designing the guides the short length of the gene was taken into consideration and 
the guides were chosen based on the position of the site they targeted Three different 
strategies of delivery were studied. 
 
Plasmid delivery to HEK293T cells, was tested as an initial method because of the 
transient expression of Cas9 minimising the possibility of off-target editing. DNA 
sequencing of the edited cells showed that the editing occurred specifically in the 
targeted sites, as expected, resulting mainly in deletions. However, taking into 
consideration the high percentage of the transfection that was observed and the 
relatively modest percentage of the gene editing, the plasmid delivery did not appear 
as favourable for primary cells, cells that are difficult ot transfect. 
 
In order to address the low efficiency observed with plasmid delivery, lentiviral 
delivery of the CRISPR/Cas9 was chosen and tested in primary human cells 
(HUVECs). Results from three independent experiments suggested that infection with 
lentiviral particles resulted in almost complete editing of the gene that can be 
attributed to both the high proliferation rate of the cells as well as the efficacy of the 
delivery. 
 
In a third approach, the use of Cas9/RNPs appeared as an advantageous alternative 
to the previous strategies deployed because of its transient effects. The fact that, the 
editing efficiency was similar to the one observed after plasmid transfection with the 
same guide, lead to the conclusion that it was not possible to obtain a higher efficiency 




Next, after assessing the levels of miR-195 in human SMCs in prolonged cell culture 
conditions and because of their low levels we changed to mouse VSMCs. For the 
mouse VSMCs three guides were designed due to sequence differences. Lentiviral 
delivery of the system was tested based on the editing efficiency of the guides. Of 
interest is the fact that the pattern of the edited bands changed according to the 
guides used. The difference between the efficiency when targeting with different 
combination of guides and with each guide alone can possibly be explained by the 
relative position of the targeted sites influencing their accessibility by the Cas9/RNP 
complexes. Differences in the editing efficiency among the guides for mouse VSMCs 
and between the two species (human and mouse) SMCs can be explained by the fact 
that different guides were used.  
 
Although lentiviral delivery was highly effective, the continuous expression of Cas9 
together with the guides was deemed to be a non-favourable feature. Stably 
expressing Cas9 cells were generated by infecting mouse VSMCs with lentiviral 
particles harbouring only the gene for Cas9. Next, IVT sgRNAs were used to test their 
ability to form Cas9/RNP complexes showing a successful and almost complete 
digestion. By using this approach no off-target editing was expected to occur since 
the accumulation of the Cas9 was not expected to result in any off-target editing.  
 
Next, to address the limitation of the off-target mutagenesis, 7 possible off-target sites 
as returned by both CRISPR Online Tool and CRISPR Finder were tested. By using 
the potential off-target sites that were returned by both software we eliminated the 
chances of false positive sites being false. T7EI assay demonstrated that none of the 
guides induced any off-target mutagenesis. 
 
Next, to determine the effect of gene editing in a hetero-cluster the study focused on 
the mmu-miR-143~145 cluster, consisting of two miRNAs that do not share sequence 
similarities. Two sgRNAs targeting the mmu-miR-145a locus were designed with 
qPCR quantification showing that the gene editing had a robust effect on miRNA 
expression. Interestingly, despite the high levels of gene editing induced by the 
sgRNAm1 guide, the downregulation in mature mmu-miR-145a and mmu-miR-143 
expression was significant but lower than when guide sgRNA145m2 was used. These 





In order to determine whether mature miR-145a expression exerts transcriptional 
control on the miR-143~145 cluster, mmu-miR-145a was overexpressed in VSMCs 
using miRNA mimics. High levels of mmu-miR-145a led to increased miR-143 
expression as well as pri-miR-143 and miR-145a expression. Although not 
conclusive, these results are indicative of a disruption of a feed-forward loop due to 
miRNA editing as well as of the hindering of the processing of the primary transcript. 
 
Next, the study focused on a highly studied miRNA clusters in the mouse genome, 
the miR-17~92. Gene editing using sg18 was efficient and although the expression 
of miR-18a diminished significantly there was no impact on miR-17, miR-19a and 
miR-20a levels, miRNAs of the same cluster. Intriguingly, RNAfold did not show any 
significant secondary structure alterations upon editing. 
 
Next, the stem loop of miR-25 was targeted in the miR-106b~25 cluster with qPCR 
quantification showing a significant downregulation of miR-25 expression with the 
levels of miR-93 and miR-106b not being affected. 
 
These results show how editing with CRISPR/Cas9 can be employed for the 
downregulation of different miRNAs of the same cluster. Nonetheless, editing of the 
DNA sequence of clustered miRNAs showed that the maturation process differs 
among miRNA clusters with varying effect on the levels of the other miRNAs of the 
cluster. Additionally, these results showed that expression interdependency is not 
common in all clustered miRNAs. Gene editing of mmu-miR-497~195 and mmu-miR-
143~145 led to downregulation of both of the clustered miRNAs. However, targeting 
of miR-18a and mmu-miR-25 revealed that the expression of other clustered miRNAs 
are not affected by editing of the cluster sequence. 
 
In conclusion, these data confirmed that the CRISPR/Cas9 editing technology is 
extremely precise, since indels occurred only in the vicinity of the DSB while no 
mutations were identified in the regions encoding the cluster. All in all, CRISPR/Cas9 
emerged as a robust system for miRNA inhibition that is able of revealing novel 




Next, CRISPR/Cas9 was assessed as a tool to understand the maturation of 
clustered miRNAs. This is the first time, to the best of my knowledge, that the 
maturation process of the mmu-miR-195a is investigated. Following the preliminary 
results from editing the DNA sequence of the genomic locus of mmu-miR-195a and 
the unexpected downregulation of mmu-miR-497a, the study sought to elucidate the 
mechanism of this downregulation. In order to decipher whether the downregulation 
was either the direct result of the editing or of the impaired processing of the pri-
miRNA, guide sg195m2 was used in the new set of experiments. While no editing 
was detected in the genomic locus of mmu-miR-497a, overexpression of mmu-miR-
195a lead to no differences on the expression of the mature miR-497a suggesting 
that the mmu-miR-497a expression is not controlled by miR-195a. 
 
The tertiary structure of the primary miRNA transcripts can affect the accessibility of 
the stem loops by Drosha and Dicer affecting miRNA biogenesis. Therefore,  
computational analysis assessed if the structure of pri-miRNAs could influence the 
processing of the mutant pri-miRNAs. Software prediction programmes were used 
and all of them returned identical results with a 18nt deletion resulting in a wider apical 
loop and the abolition of a bulge in the stem of the hairpin. Although these results 
cannot safely lead to definitive conclusions about the mechanism, the possibility of 
impairing the maturation in a dual manner directly through sequence and structural 
alterations and disruptions cannot be excluded. 
 
Building on these results together with the alterations in the predicted tertiary 
structure of the edited primary transcript we postulated that these changes, as a result 
of the editing of the genomic locus with CRISPR/Cas9, led to differential processing. 
The biogenesis of miRNAs is a multistep and complex process regulated by a number 
of RBPs that participate in every step of the maturation. Nonetheless, only a small 
fraction are characterised. Given the plethora of miRNAs and the complicated 
clusters they form it becomes apparent that various RBPs partake in the miRNA 
biogenesis. 
 
It has been previously shown that certain RBPs interact with specific miRNAs to 
regulate their maturation, with the two most prominent examples being Drosha and 
Dicer. Although previously published studies had reported a panel of RBPs that 
participate in the maturation of the miRNAs, pri-miR-497~195 had not been studied 
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in detail. To elucidate these differences, RNA pull-down experiments were conducted 
comparing the RBPs that recognise and bind the WT and a mutant primary transcript 
harbouring a 16nt deletion. The latter transcript, produced with CRISPR/Cas9 editing, 
was missing both the sequence of the 5p arm of the mmu-miR-195a as well as that 
of a bulge upstream of the DSB. Secondary structure prediction confirmed the effects 
of the editing on the structure of the miRNA while the tertiary structure was highly 
different compared to the WT one. These changes were deemed detrimental for the 
maturation of the primary transcript by affecting the approach by RBPs. 
 
To gain deeper knowledge in the regulation of RBPs on the miRNA maturation this 
study focused on characterising the RBPs that interact with the WT pri-miR-195a. To 
this end, MS was employed to identify differential binding of RBPs to the mutant 
primary transcript of mmu-miR-195a~497.  
 
The MS data presented, offer a unique description of the RBPs that interact with both 
the WT and the mutant transcript. In total, 45% of the identified proteins are annotated 
in UNIPROT database as RNA binding proteins with the small number of the RBPs 
being suggestive either of innate limitations of the assay or of specific protein-protein 
interactions between RBPs and other co-factors. Furthermore, 50% of the proteins 
identified are localised either in the nucleus or the cytosol with the vast majority of 
them being nuclear proteins, as expected. Further analysis showed that only 5 of the 
identified proteins were statistically significant.  
 
Taken together these results indicate that the mutant transcript follows a different 
processing pathway.  Although further in silico analysis did not show any interaction 
between the identified proteins, they can be organised in two groups. Tial1 and Apex1 
are RBPs that recognise specific motifs in ssRNA molecules and help in their 
processing while Ran, Sec63 and Copb2, regulate the identification and 
transportation of proteins to Golgi network. 
 
In addition, 12 RBPs that bind solely the mutant transcript were identified and when 
analysed with STRING, a network of experimental validated protein-protein 
interactions was highlighted. The analysis revealed that 7 of the input proteins form a 
network of interacting RBPs while a second clustering became apparent when they 
194 
 
were grouped on the basis of their function. Proteins that partake in pre-mRNA 
splicing form a group of closer interacting members results that were confirmed when 
the identified proteins were analysed with Cytoscape. 
 
In light of these results, it becomes apparent that said proteins participate in a different 
than the canonical pathway of the processing of miRNAs. Moreover, results from the 
in silico analysis of the interactions of the MS analysed proteins suggest that the 
mutant primary transcript takes part in a pathway that leads to its degradation and 
clearance from the cells results that explain the decrease in the levels of both mmu-
miR-497a and mmu-miR-195a. 
 
In conclusion, MS analysis of RNA pull-down with WT and mutant transcripts of pri-
miR-497~195 revealed a set of proteins that bind the pri-miR-497~195 together with 
RBPs that bind only the mutant transcript. Although the results are only indicative 
they suggest that alternative processing pathways may lead to the downregulation of 
the levels of mature mmu-miR-497a and mmu-miR-195a. 
 
These results provide a helpful insight in the maturation process of the miRNAs in 
general and in that of pri-miR-497~195 specifically. They demonstrate that sequence 
changes lead to differential processing because the tertiary changes that they 
impose. This conclusion was drawn by the fact that firstly the RBPs that recognise 
the transcript seem to recognise specific structures and not sequence motifs and 
secondly no known motifs were created from the deletion. Moreover, pathway 
analysis of the proteins demonstrated that these proteins partake in the splicing step 
of miRNAs. This could mean that the structure of the mutant transcript hinders the 
recognition of the transcript from the miRNA processing machinery, resulting in the 
transcript not being recognising as a pre-miRNA leading to a new pathway getting 
triggered through which the mutant transcript gets degraded. However, these 
interactions that were described can be due to the non-physiological conditions of the 
assay, such as the lack of cell compartmentalisation, high concentration of primary 







The current study investigates the use of CRISPR/Cas9 as a gene editing technique 
for the specific inhibition of miRNAs. It is the first time it has been shown that 
CRISPR/Cas9 can be used in primary mammalian cells for the inhibition of miRNAs. 
Although a reliable and robust workflow is provided, with regards to inducing gene 
editing in mouse VSMCs to dissect the regulation and function of clustered miRNAs, 
there are limitations that have to be taken into consideration. 
 
An important limitation is the usage of mouse VSMCs and human SMCs cell line 
instead of human primary SMCs. The study focused on editing miRNA gene in human 
SMCs and, to that end, human SMCs cell lines were used for the initial experiments, 
since they were a limitless source of cells. Nonetheless, and despite the fact that the 
scope of the study was to examine the effects of editing miR-195 with CRISPR/Cas9 
in human primary VSMCs, the low expression of the miRNAs of the miR-15 family, 
after prolonged culture, conditions that were needed in our study, was an important 
issue. Prolonged culture of VSMCs was needed in order for the cells to reach 
senescence and a phenotype as close to AAA. Due to this, the focus of the study 
shifted from human to mouse VSMCs that expressed the studied miRNAs at 
satisfactory levels. Additionally, due to the differences of the miRNA gene sequences 
between the two organisms new guides had to be designed and tested, guides that, 
due to sequence limitations, cannot be useful for human studies. 
 
Moreover, the delivery of Cas9 to mouse VSMCs was an important step for the study, 
since they express all of the miRNAs that were evaluated. Although the approach that 
was finally undertaken resulted in engineering the genome of the cells and in the 
accumulation of Cas9 protein, that did not affect the phenotype or the proliferation 
rate (data not shown). Moreover, Cas9 was not expected to lead to any editing unless 
in complex with a sgRNA. In more detail, the binding between the endonuclease and 
the guide RNA is dependent on an interaction between the tracrRNA and the protein 
through a specific sequence. During the maturation process of the crRNA:tracrRNA, 
Cas9 recognises a sequence in the tracrRNA which binds and then uses the latter’s 
complementarity to crRNA to cleave it. The crRNA:tracrRNA duplex stays tethered to 
Cas9 with the help of tracRNA292. Since Cas9 is an exogenous protein of bacterial 
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origin it was expected that it would not get activated unless bound to a sgRNA 
introduced to the cells after transfection. Furthermore, the transient presence of the 
IVT sgRNA in the cells was thought to protect against potential off-target effects due 
to the high concentration of the Cas9. Indeed, no off-target effects were detected in 
any of the possible off-target sites, that were in silico predicted, for any of the guides 
tested. 
 
Delivery of the system is one of the major limitations, especially when it comes to in 
vivo models. In order to address these difficulties various groups have developed 
new, more elegant techniques over the last years that help the uptake of the RNPs 
by the cells114, 212. Regardless, the technique employed in the present study was 
deemed suitable for the purpose it was used as sufficient editing occurred with no off-
target effects in the 7 most likely targets, according to in silico analysis, and no other 
complications. Although the computationally predicted off-target sites that were 
tested, were confirmed by two software, the chances that the guides used could lead 
to non-identified editing in other sites still remains. Additionally, the list of the tested 
potential off-targets are by no means exhaustive. Hence, whole genome sequencing 
of edited compared to non-edited cells would possibly provide more convincing 
results. 
 
Nevertheless, following the generation of mouse VSMCs stably expressing Cas9, the 
effects of editing the genomic loci of 4 different clusters were assessed. The clusters 
were chosen based on their implication in cardiovascular disease and their 
organisation in homo-clusters or hetero-clusters. 
 
Editing of one of the miRNAs of the cluster led to unexpected downregulation of the 
second clustered miRNA in the case of the mmu-miR-497~195 and mmu-miR-
143~145 clusters, while editing of one miRNA stem loop did not show any differences 
in the regulation of clustered miRNAs in the case of mmu-miR-17~92 and mmu-miR-
106b~25. No off-target editing was detected in either case. Additionally, 
computational modelling suggests important changes in the structure of the primary 
transcript that was hypothesised to hinder its processing by the maturation 
machinery. The study concludes that the expression of the clustered miRNAs is not 
necessarily co-dependent as well as that clusters show strict tertiary structural 




Although the study underscores the power of CRISPR/Cas9 in the knocking down of 
miRNAs over conventional methods that can target multiple related paralogs, the 
approach remains rather imprecise both in the investigation of the editing and its 
outcome. In regards to the former, the T7EI assay was used for the calculation of the 
editing efficiency as a technique has innate limitations. Firstly, it can underestimate 
the final efficiency due to fact that it cannot recognise homodimers of edited strands 
resulting in those strands not being cut and quantified. Secondly, the technique is 
based on gel separation of the bands and their intensity after the electrophoresis 
depends on both their size and the electrophoresis settings. In detail, the smaller 
sized bands during the electrophoresis get diffused easier and furthermore appear 
less intense due to less staining dye being bound by smaller DNA strands while high 
voltage of electrophoresis leads to the gel developing high temperatures and higher 
diffuse rate. Although the way that the technique was designed accounted for these 
limitations i.e. the PCR primers were designed so that the predicted cut site was 
upstream of the middle of the amplicon but as close as possible to it, in order for the 
two resulting bands to differ as little as possible from each other in size, and the used 
calculating formula adjusted for these discrepancies, the limitations still remain and 
need to be taken into consideration. However, at the time of the assessment of the 
editing efficiency of these experiments, the T7EI assay was the gold standard assay. 
In order to overcome the aforementioned limitations new techniques have been 
developed e.g. TIDE/ICE analysis295 or analysis of Amplicon sequencing data with 
bioinformatic tools296. By employing the NHEJ pathway the formation of mutations, 
that result in the disruption of the miRNA sequence, is random, not only regarding the 
type (insertions or deletions) but also regarding the length and the exact position. 
Although an adequate number of colonies were picked and screened to reveal 
sequence changes upon induction of editing, these were but a small portion of the 
occurred alterations. A wider range of mutations was expected to have been induced. 
In the same line, the structure prediction models presented above are only indicative 
of a very small number of changes. However, these conclusions were based on a 
single 3D computational prediction, that of pri-miR-497~195, due to limitations of the 
software. The length of the cluster miR-143~145 is about 1400bp therefore it cannot 
be analysed using the currently available algorithms. In addition, changes in the 
secondary structure due to sequence motifs alterations could affect the expression of 




To address these limitations the study focused on mmu-miR-195a, the miRNA of 
interest, and sought to decipher how the editing affects the processing of pri-miR-
497~195. Proteins that bound to the WT and the mutant transcript were evaluated 
and analysed with MS. Analysis of the results showed a panel of proteins that bind 
preferentially to the mutant transcript. Further analysis revealed that the identified 
proteins bind RNA molecules based on their tertiary structure since, according to 
published data on their function, they do not recognise specific secondary structures 
or sequence motifs that were altered upon editing. These results indicate that the 
differential processing of the mutant transcript was due to changes in the tertiary and 
not the secondary structure or the abolition of any sequence motif. 
 
Nonetheless, it is likely that the proteins identified do not represent interactions that 
occur in the edited cells. This could be for a number of reasons. Firstly, it is an in vitro 
assay which means that its conditions under which the proteins, approach, interrogate 
and bind the primary transcript are different. Additionally, the transcripts that were 
used in the assay were in vitro transcribed which means that the transcripts were 
isolated from possible post-transcriptional processing that could affect its binding by 
the RBPs and, subsequently, its maturation221. In more detail, it has been shown that 
RNA-folding, especially for larger miRNA clusters, affects the accessibility of the 
processing machinery is important293, 294 therefore, isolating the primary transcripts 
from the cellular environment can result in differential folding and processing. The 
concentration of the transcripts was a lot higher than the one that occurs in vivo and 
the protein population of the cells get exposed to the transcript simultaneously which, 
together with the lack of cell compartmentalisation, means that the interactions 
between the proteins and the RNA transcripts are not necessarily canonical. 
 
Moreover, although MS is a highly sensitive technique that can identify a vast number 
of proteins, even in low concentration, it is semi-quantitative. It can only provide data 
with regards to the detection of proteins and their relative, but not absolute, 
abundance. Given the above, WB was employed to confirm the MS results and further 
elucidate the abundance of proteins. Nonetheless, the validation of the MS data failed 
therefore additional validation is required to experimentally test the concept that 




All in all, besides the limitations this study presents, it provides strong evidence of the 
suitability of the CRISPR/Cas9 editing to inhibit miRNAs, via permanent alterations of 
their genes, adds new concepts to the miRNA study and offers well-founded results 
regarding the processing of primary miRNA transcripts in primary mammalian cells. 
 
7.3 Future Outlook 
 
The current study offers an insightful groundwork on how editing with CRISPR/Cas9 
can be employed for the inhibition of miRNAs. The problem of delivering the system 
in high efficiency was resolved and no more titration is needed in that front. 
Additionally, off-target editing seemed not to be an issue in the 7 most likely off-target 
sites. However, in light of new studies that have shown that CRISPR/Cas9 can result 
in non-predicted, unintended editing in various, random sites193, 194, further scrutiny is 
needed. In more detail, whole genome sequencing has emerged as the method of 
choice for investigating possible off-target editing. Further investigation using whole 
genome sequencing would clarify the unintended editing and resolve the issue.  
 
The main aim of the study was to overcome the limitations of the traditional methods 
for inhibiting specific miRNAs. The results outlined above demonstrated that, 
although editing with CRISPR/Cas9 can lead to inhibiting miRNAs, the effects of 
editing differ according to the cluster that is targeted with certain clusters showing 
abolition of the expression of all the miRNAs that are co-transcribed. Clustered 
miRNAs have attracted intense interest in the biomedical research and the findings 
presented here on clustered miRNA regulation offer valuable insights. Secondary and 
tertiary structure prediction models have shown that the deletion of sequences of the 
hairpin of miRNAs result in different structures of the stem loop. However, given the 
small number of the edited sequences that were studied, the presented results can 
only be suggestive of the effects of the editing in the maturation of the miRNAs. 
Therefore, additional sequences harbouring deletions need to be analysed in silico 
with regards to how sequence alterations change the secondary and tertiary 
structures of the hairpin and the primary transcript. 
 
Proteins interact with RNA transcripts through recognition of specific binding motifs 
with these interactions being significantly influenced by the tertiary structure on the 
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RNA molecules. RNA pull-down assays are useful in studying these interactions by 
providing the possibility of extracting RBP–RNA complex for MS or western blotting 
by exploiting high affinity tags like biotin. Moreover, validation of the MS results with 
Western Blotting, as an independent method, was not possible since the antibodies 
used did not produce any conclusive results. Therefore, more titration experiments 
will resolve the issues raised and will provide a better understanding of the 
interactions of the identified proteins. In addition, given that this the first time that the 
maturation of the pri-miR-497~195 is being investigated, these results will provide a 
list of validated proteins that are important for the process. Quantification of the 
miRNA levels and MS analysis in experiments where these proteins will be knocked-
down, will offer a valuable insight in their effects on the process.  
 
Additionally, RNA pull-down assays and MS analysis of the eluted proteins 
demonstrated differential binding of certain RBPs. However, only one mutant 
sequence was analysed. New RNA pull-down assays with more mutant transcripts, 
harbouring deletions of various lengths and positions, excising various structural 
features of the hairpins need to be conducted to elucidate the contribution of each 
structural element in the recognition by RBPs. Thus, supplemental experiments are 
needed to decipher the mechanisms that affect the expression of the miRNAs 
especially since studies have shown that the secondary structure of the pri-miR-
17~92 influences the processing of the transcript by following a highly specific 
sequence of cleavage of the clustered stem loops. 
 
In general, the experimental approach outlined in the study can be proved to be useful 
for the clarification of the maturation of mmu-miR-195a, as well as other miRNAs, and 
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Supplementary Table 1. Details of mouse miRNA clusters. Data on miRNA clusters were obtained from the MiRBase database.  
miRNA miRNA Clusters Coordinates Sequence 
mir-15a 
miR-15 
chr14: 61632027-61632110 [-] UAGCAGCACAUAAUGGUUUGUG 
mir-15b chr3: 69009772-69009835 [+] UAGCAGCACAUCAUGGUUUACA 
mir-16-2 chr3: 69009902-69009996 [+] UAGCAGCACGUAAAUAUUGGCG 
mir-16-1 chr14: 61631880-61631972 [-] UAGCAGCACGUAAAUAUUGGCG 
mir-195 chr11: 70235042-70235135 [+] UAGCAGCACAGAAAUAUUGGC 
mir-497a chr11: 70234717-70234800 [+] CAGCAGCACACUGUGGUUUGUA 
    
mir-497b chr11: 70234692-70234816 [-] CACCACAGUGUGGUUUGGACGUGG 
    
mir-143 
miR-143-145 chr18: 61649196-61649258 [-] 
GGUGCAGUGCUGCAUCUCUGG 
mir-145 chr18: 61647825-61647894 [-] GUCCAGUUUUCCCAGGAAUCCCU 
    
mir-17 
miR-17~92 
chr14: 115043671-115043754 [+] CAAAGUGCUUACAGUGCAGGUAG 
mir-20a chr14: 115044157-115044263 [+] UAAAGUGCUUAUAGUGCAGGUAG 
mir-106b chr5: 138165737-138165818 [-] UAAAGUGCUGACAGUGCAGAU 
mir-93 chr5: 138165523-138165610 [-] CAAAGUGCUGUUCGUGCAGGUAG 
   
mir-92a1 chr14: 115044427-115044506 [+] AGGUUGGGAUUUGUCGCAAUGCU 
mir-25 chr5: 138165321-138165404 [-] AGGCGGAGACUUGGGCAAUUGC 
   
mir-19a chr14: 115044000-115044081 [+] UAGUUUUGCAUAGUUGCACUAC 
mir-19b-1 chr14: 115044305-115044391 [+] AGUUUUGCAGGUUUGCAUCCAGC 
   




Supplementary Table 2. IVT primers. Sequences of the primers used for the IVT of the guides along with the coordinates that they target in the mouse genome. 
Assay Primer Sequence (5' to 3') Coordinates 
IVT F 195G1 TAATACGACTCACTATAGTTGAGGCAGAACTTACTCCC chr17:7017580-7017600 IVT R 195G1 TTCTAGCTCTAAAACGGGAGTAAGTTCTGCCTCAA 
IVT F 195G2 TAATACGACTCACTATAGGGAAGCGAGTCTGCCAATAT chr17:7017672-7017692 IVT R 195G2 TTCTAGCTCTAAAACATATTGGCAGACTCGCTTCC 
IVT F 195m2 TAATACGACTCACTATAGGTGGAGCAGCACAGCCAATAT 
chr11:70236143-70236163 IVT R 195m2 TTCTAGCTCTAAAACATATTGGCTGTGCTGCTCCAC 
IVT F 195mA TAATACGACTCACTATAGATTTCTGTGCTGCTAGAGCC chr11:70048515-70048535 IVT R 195mA TTCTAGCTCTAAAACGGCTCTAGCAGCACAGAAAT 
IVT F 195m3 TAATACGACTCACTATAGCTCTAGCAGCACAGAAATAT chr11:70048561-700488581  IVT R 195m3 TTCTAGCTCTAAAACATATTTCTGTGCTGCTAGAG 
IVT F 145m1 TAATACGACTCACTATAGAGGGGCGTGGCACGTGCTGA 
chr18:61807217-61807237 IVT R 145m1 TTCTAGCTCTAAAACTCAGCACGTGCCACGCCCCT 
IVT F 145m2 TAATACGACTCACTATAGGATGCTAAGATGGGGATTCC 
chr18:61807220-61807240 IVT R 145m2 TTCTAGCTCTAAAACGGAATCCCCATCTTAGCATC 
IVT F 18a  TAATACGACTCACTATAGTTATGCCAGAAGGAGCACTT 
chr14:115443138-115443158 IVT R 18a  TTCTAGCTCTAAAACAAGTGCTCCTTCTGGCATAA 
IVT F 25 TAATACGACTCACTATAGGCGGAGACTTGGGCAATTGC 
chr5:138606184-138606204 IVT R 25 TTCTAGCTCTAAAACGCAATTGCCCAAGTCTCCGC 
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Supplementary Table 3. Table of primers. Primers that were used for genomic PCR, cloning in pLKO.1 vector and qPCR for gene expression with the corresponding coordinates 
of the amplified genomic loci. 
Assay Primer Sequence (5' to 3') Coordinates 
GENOMIC PCR hsa-mir-195 F GGGCCTTGTGACAAACTTCT chr17:7017431-7017863 GENOMIC PCR hsa-mir-195 R GCTATTCCCGCATAAGCATC 
GENOMIC PCR mmu-mir-195 F (P1) CACACACACACCGTCTAGGG 
chr11:70234880-70235407 GENOMIC PCR mmu-mir-195 R (P2) CTGAGCCTTCCACCTCTGAC 
GENOMIC PCR mmu-mir-497 F (P3) CCTGTGTCTTCCAGCATTTCTC 
chr11:70234360-70234977 GENOMIC PCR mmu-mir-497 R (P4) GTATCAGACAACCTGGGGGTT 
GENOMIC PCR mmu-mir-143 F (P5) GTGCTGCGTGCATAAAGAGA 
 chr18:61649137-61649567 GENOMIC PCR mmu-mir-143 R (P6) GCTATCCCATGCCAACACTT 
GENOMIC PCR mmu-mir-145 F (P7) CTTTCCAAGCCACTCAAAGC 
chr18:61647566-61648054 GENOMIC PCR mmu-mir-145 R (P8) GGAGCCGTCTCATAGTCTGG 
GENOMIC PCR mmu-mir-18 F (P9) CCTGGTCAATGTGAGGCTTT  chr14:115043309-
115044386 GENOMIC PCR mmu-mir-18 R (P10) CCACAGTCAGTTTTGCATGG 
GENOMIC PCR mmu-mir-25 F (P11) TTCTCCGACTTTCCACTGCT 
chr5:138164956-138165932 GENOMIC PCR mmu-mir-25 R (P12) GCCACAAACAGTAGCAGCAA 
pLKO.1 cloning miR-497~195 F GACCGGTTGCTGGTTCCTGATTGTTC 
chr11:70048081-70048911 pLKO.1 cloning miR-195 R GATGAATTCAAAAACTGAGCCTTCCACCTCTGAC 
Gene expression Carmn F AATAGACTGGGCCTCCACCT   
Gene expression Carmn R GTTCCTCTCTGGGGCTCTTC   
Gene expression Beta-actin F CACAACTGGGACGACATGGAG   





Supplementary Table 4. Table of restriction sites. The restriction sites, along with the digestion enzymes that are recognised by, for each miRNA and targeting guide used. 
miRNA sgRNA sgRNA sequence (5’-3’) Restriction site (5’-3’) Restriction enzyme 
mmu-miR-195a 
sg195m2 TGGAGCAGCACAGCCAATAT AATATT SspI 
sg195mA ATTTCTGTGCTGCTAGAGCC GCNNNNNNNGC MwoI 
mmu-miR-145 sg145m2 GATGCTAAGATGGGGATTCC GANTC HinfI 
mmu-miR-18 sg18 TTATGCCAGAAGGAGCAGTT GDGCHC Bsp1268I 





Supplementary Table 5. Table of possible off-target sites. The genomic loci that were possibly targeted by the guides used along with the mismatches (depicted in red), the 
primers used to study them and their coordinates.  
 
 






[1:9:10] OFT1 195M2 F 
GTGCTGGGATTACAGGCATT chr17:-3133199 
 







[1:8:17] OFT2 195M2 F 
GCCCCAGAGTGTGTGAAAGT chr8:-10246601 







[1:2:15] OFT3 195M2 F 
TCCACATGGACTGCAGTGTT chr14:-73777792 







[8:9:11] OFT4 195M2 F 
ATTCTCGGGGAAATTCCATC chrX:+72165663 
 






TGGAGCATCACAGCCAACAT 2MMs [8:17] 
OFT5 195M2 F 
TATCCTCTCGCCTTTGCACT chr2:+24952183 
 







[3:11:17] OFT6 195M2 F 
CGACTTGCAATGACATGGAG chr13:+35216456 
 






AGGATTAGCTCAGCCAATAT 4 MMs 
[1:5:6:17] OFT7 195M2 F 
AGTGCTGGGCATAGGACAAC chr2:-91834510 
 








CTGTAGCAACACAGAAATAT 2 MMs [3:9] 
OFT1 195M3 F 
TGGGTTTGAAGGTCCTGAAG chr1:-196773757 
 






CTCTAGCAGGACAGAAATAA 2 MMs 
[10:20] OFT2 195M3 F 
TCTGCCTCAGCTTTCCAAGT chr4:+62834971 
 






TTAAAGCAGCACAGAAATAT 3 MMs 
[1:3:4] OFT3 195M3 F 
TCCCCTGGACTTTGACATTC chr3:-154152635 






AGCTAGCAGCTCAGAAATAT 3 MMs 
[1:2:11] OFT4 195M3 F 
TGGAGAAGGAGGAGGTCTGA chr15:-76275971 






GTCTACCAGAACAGAAATAT 3 MMs 
[1:6:10] OFT5 195M3 F 
CCCATTTGCATGGAAAGATT chr:12+31442719 






CTCTGTCTGCACAGAAATAT 3 MMs 
[5:6:8] OFT6 195M3 F 
GGGAGACTATTGTGCATGATTTTATT chr9:-22593762 
 






Supplementary Table 6. RNA binding proteins with their corresponding RNA binding motifs. The panel of the RNA binding proteins with RNA binding motifs that could 
potentially bind the primary mmu-miR-195a transcript. 





















Supplementary Table 7. Statistical analysis of the MS identified proteins after RNA pull-down. The information from the statistical analysis of the MS data regarding the proteins 
that were identified. The proteins are presented in order, according to their p-values, following FDR correction, while the p-values for the statistically significant proteins are highlighted in 
bold. The RBPs that bound only the mutant transcript are highlighted in grey. 
PROTEIN NAME 
ACCESSION  













(Mean±SD) P VALUE 
FOLD 
CHANGE 
Coatomer subunit beta' OS=Mus musculus GN=Copb2 PE=1 SV=2 
O55029 COPB2_MOUSE 102.4 NA 1 1 2642550±1740339 10015250±2286433 
0.047545608 
3.79 
GTP-binding nuclear protein Ran OS=Mus musculus GN=Ran PE=1 SV=3 
P62827 RAN_MOUSE 24.4 29.6% 11 6 6014625±1700654 9125875± 1663758 
0.047545608 
1.52 
DNA-(apurinic or apyrimidinic site) lyase OS=Mus musculus GN=Apex1 PE=1 SV=2 
P28352 APEX1_MOUSE 35.5 28.7% 7 12 2130005±883254 4017175 ±936713 
0.047545608 
1.89 
Translocation protein SEC63 homolog OS=Mus musculus GN=Sec63 PE=1 SV=4 
Q8VHE0 SEC63_MOUSE 87.8 2.89% 2 2 636675±367811 1676175 ±516067 
0.047545608 
2.63 
Nucleolysin TIAR OS=Mus musculus GN=Tial1 PE=1 SV=1 
P70318 TIAL1_MOUSE 43.4 5.1% 3 3 4027650±694148 6402450±288123 
0.047545608 
1.59 
Interferon-induced, double-stranded RNA-activated protein kinase OS=Mus musculus GN=Eif2ak2 PE=1 SV=2 
Q03963 EIF2AK2_MOUSE 58.2 17.5% 7 8 52845750±9776039 20465475±13084972 
0.05 
0.39 
Serine/arginine-rich splicing factor 4 OS=Mus musculus GN=Srsf4 PE=2 SV=1 
Q8VE97 SRSF4_MOUSE 55.9 6.75% 5 2 21982750±3762952 40300500±2500749 
0.054097937 
1.83 
Non-POU domain-containing octamer-binding protein OS=Mus musculus GN=Nono PE=1 SV=3 
Q99K48 NONO_MOUSE 54.5 16.5% 9 10 4369675±1658070 8461950±1435566.244553 
0.054097937 
1.94 
Vigilin OS=Mus musculus GN=Hdlbp PE=1 SV=1 
Q8VDJ3 HDLBP_MOUSE 141.7 7.81% 8 9 25550250±8691150 42709500±7435685 
0.110222347 
1.67 
Muscleblind-like protein 3 OS=Mus musculus GN=Mbnl3 PE=2 SV=1 
Q8R003 MBNL3_MOUSE 37.5 5.56% 13 3 2875075±1047635 5155450±559199 
0.110222347 
1.79 
Replication factor C subunit 5 OS=Mus musculus GN=Rfc5 PE=1 SV=1 
Q9D0F6 RFC5_MOUSE 38.1 20% 5 9 2089900±1658585 6156800±490180 
0.11529996 
2.95 
DnaJ homolog subfamily C member 10 OS=Mus musculus GN=Dnajc10 PE=1 SV=2 
Q9DC23 DNAJC10_MOUSE 90.5 NA NA NA 770700±1125101 2960875±540379 
0.11529996 
3.84 
Radixin OS=Mus musculus GN=Rdx PE=1 SV=3 
P26043 RDX_MOUSE 68.5 19.4% 14 19 6109550±1617951 10591300±1681539 
0.117490648 
1.73 
Ezrin OS=Mus musculus GN=Ezr PE=1 SV=3 
P26040 EZR_MOUSE 69.4 16.6% 13 17 8582375±3232269 14253750±1295569 
0.117490648 
1.66 
Y-box-binding protein 3 OS=Mus musculus GN=Ybx3 PE=1 SV=2 
Q9JKB3 YBX3_MOUSE 38.8 44.3% 10 14 10120000±1038572 14558000±836357 
0.117490648 
1.44 
Cluster of Polyadenylate-binding protein 2 OS=Mus musculus GN=Pabpn1 PE=1 SV=3 (Polyadenylate-binding) 
Q8CCS6 PABPN1_MOUSE 32.2 11.9% 4 4 7896850±864314 14105500±2055670 
0.117490648 
1.79 
5'-3' exoribonuclease 1 OS=Mus musculus GN=Xrn1 PE=1 SV=1 
P97789 XRN1_MOUSE 194.2 9.19% 14 14 3337150±5604165 8627125±3290583 
0.117490648 
2.59 
RNA binding motif protein, X-linked-like-1 OS=Mus musculus GN=Rbmxl1 PE=1 SV=1 
Q91VM5 RBMXL1_MOUSE 42.1 9.28% 3 3 1089855±727860 2785825±819121 
0.117490648 
2.56 
Far upstream element-binding protein 1 OS=Mus musculus GN=Fubp1 PE=1 SV=1 
Q91WJ8 FUBP1_MOUSE 68.5 24.3% 12 28 25273500±10539068 40113500±4573025 
0.117490648 
1.59 
Ras GTPase-activating protein-binding protein 1 OS=Mus musculus GN=G3bp1 PE=1 SV=1 
P97855 G3BP1_MOUSE 51.8 2.37% 1 2 7735275±3728617 16154500±2456521 
0.117490648 
2.09 
U1 small nuclear ribonucleoprotein 70 kDa OS=Mus musculus GN=Snrnp70 PE=1 SV=2 
Q62376 SNRNP70_MOUSE 52 6.25% 2 2 1739742.5±1027569 5044400±1015501 
0.117490648 
2.90 
Regulator of nonsense transcripts 1 OS=Mus musculus GN=Upf1 PE=1 SV=2 




















(Mean±SD) P VALUE 
FOLD 
CHANGE 
Heterogeneous nuclear ribonucleoprotein D0 OS=Mus musculus GN=Hnrnpd PE=1 SV=2 
Q60668 HNRNPD_MOUSE 38.3 23.1% 7 15 324040000±117986121 409772500±93472172 
0.117490648 
1.26 
Fibronectin OS=Mus musculus GN=Fn1 PE=1 SV=4 
P11276 FN1_MOUSE 272.4 4.28% 8 8 1437215±1127426 2909650±638126 
0.117490648 
2.02 
ATP-binding cassette sub-family E member 1 OS=Mus musculus GN=Abce1 PE=1 SV=1 
P61222 ABCE1_MOUSE 67.3 3.51% 2 2 2608500±1718519 6178825±540335 
0.117490648 
2.37 
Lupus La protein homolog OS=Mus musculus GN=Ssb PE=1 SV=1 
P32067 SSB_MOUSE 47.7 6.99% 3 3 14736750±2837240 26222500±4450531 
0.117490648 
1.78 
Poly [ADP-ribose] polymerase 1 OS=Mus musculus GN=Parp1 PE=1 SV=3 
P11103 PARP1_MOUSE 113 10.4% 8 8 799347.5±1217644 2808225±632890 
0.117490648 
3.51 
Zinc finger protein 2 OS=Mus musculus GN=Znf2 PE=2 SV=1 
Q8BIQ3 ZNF2_MOUSE 96.6 60% 3 4 3595650±1017060 5628025±1556055 
0.117490648 
1.57 
Cytoplasmic dynein 1 light intermediate chain 2 OS=Mus musculus GN=Dync1li2 PE=1 SV=2 
Q6PDL0 DYNC1LI2_MOUSE 54.2 3.46% 1 1 4432860±5244229 11160275±3413432 
0.117490648 
2.52 
Moesin OS=Mus musculus GN=Msn PE=1 SV=3 
P26041 MSN_MOUSE 67.7 25.1% 15 27 7128275±2412050 13050725±1003194 
0.117490648 
1.83 
60S ribosomal protein L15 OS=Mus musculus GN=Rpl15 PE=2 SV=4 
Q9CZM2 RPL15_MOUSE 24.1 11.3% 2 3 141000000±26672696 221087500±15479498 
0.12191124 
1.57 
DNA topoisomerase 1 OS=Mus musculus GN=Top1 PE=1 SV=2 
Q04750 TOP1_MOUSE 90.8 10.6% 7 7 6548050±4261755 15203300±3234194 
0.125107744 
2.32 
Poly(U)-binding-splicing factor PUF60 OS=Mus musculus GN=Puf60 PE=1 SV=2 
Q3UEB3 PUF60_MOUSE 60.2 1.42% 1 1 3907900±4136619 7048650±3588780 
0.137147767 
1.80 
Small nuclear ribonucleoprotein Sm D2 OS=Mus musculus GN=Snrpd2 PE=1 SV=1 
P62317 SNRPD2_MOUSE 13.5 8.47% 1 1 1683775±430941 2776300±394620 
0.137147767 
1.65 
Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 OS=Mus musculus GN=Dhx15 PE=1 SV=2 
O35286 DHX15_MOUSE 90.9 9.81% 7 7 7680850±3219170 14339750±2329582 
0.144146871 
1.87 
Extended synaptotagmin-1 OS=Mus musculus GN=Esyt1 PE=1 SV=2 
Q3U7R1 ESYT1_MOUSE 121.5 21% 21 88 3627950±5629331 10550250±3222843.2917741 
0.144146871 
2.91 
High mobility group protein B1 OS=Mus musculus GN=Hmgb1 PE=1 SV=2 
P63158 HMGB1_MOUSE 24.9 36.3% 9 16 3350420±2648045 5613600±3554826 
0.144146871 
1.68 
Selenocysteine-specific elongation factor OS=Mus musculus GN=Eefsec PE=1 SV=2 
Q9JHW4 EEFSEC_MOUSE 63.5 13.9% 8 8 1089645±717847 2676850±765831 
0.144146871 
2.46 
Cell growth-regulating nucleolar protein OS=Mus musculus GN=Lyar PE=1 SV=2 
Q08288 LYAR_MOUSE 43.7 11.3% 3 3 3061125±1490567 5927950±1137195 
0.144146871 
1.94 
tRNA (cytosine(34)-C(5))-methyltransferase OS=Mus musculus GN=Nsun2 PE=1 SV=2 
Q1HFZ0 NSUN2_MOUSE 85.4 16.8% 11 13 1381100±2515198 5454075±126193 
0.144146871 
3.95 
Cluster of Transcription elongation factor B polypeptide 3 OS=Mus musculus GN=Tceb3 PE=1 SV=3 
(Transcription) 
Q8CB77 TCEB3_MOUSE 87.1 4% 3 7 1800550±3764890 6123150±1486485 
0.150795222 
3.40 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 OS=Mus musculus GN=Atp2a2 PE=1 SV=2 
O55143 ATP2A2_MOUSE 114.8 4.41% 4 4 1007357.5±429427 2442225±818034 
0.15911985 
2.42 
Peptidyl-prolyl cis-trans isomerase FKBP3 OS=Mus musculus GN=Fkbp3 PE=1 SV=2 
Q62446 FKBP3_MOUSE 25.1 4.91% 1 1 12152500±2585753 14972750±2475455 
0.159536494 
1.23 
X-ray repair cross-complementing protein 6 OS=Mus musculus GN=Xrcc6 PE=1 SV=5 
P23475 XRCC6_MOUSE 69.4 14.8% 7 8 2430825±823244 4157100±1448467 
0.159536494 
1.71 
Ribosomal L1 domain-containing protein 1 OS=Mus musculus GN=Rsl1d1 PE=1 SV=1 
Q8BVY0 RSL1D1_MOUSE 50.4 6.42% 2 3 775362.5 ±118701 1492500±557038 
0.159536494 
1.92 
Eukaryotic translation initiation factor 2A OS=Mus musculus GN=Eif2a PE=1 SV=2 
Q8BJW6 EIF2A_MOUSE 64.4 11.7% 5 6 24183000±8104034 38507000±7719760 
0.159536494 
1.59 
Nuclear RNA export factor 1 OS=Mus musculus GN=Nxf1 PE=1 SV=3 




















(Mean±SD) P VALUE 
FOLD 
CHANGE 
Glycylpeptide N-tetradecanoyltransferase 1 OS=Mus musculus GN=Nmt1 PE=1 SV=1 
O70310 NMT1_MOUSE 56.9 9.48% 5 5 1120880±993716 1984257.5±550122 
0.159536494 
1.77 
CDKN2A-interacting protein OS=Mus musculus GN=Cdkn2aip PE=1 SV=1 
Q8BI72 CDKN2AIP_MOUSE 59.7 7.64% 3 4 484522.5±645656 1166620±325712 
0.159536494 
2.41 
tRNA-splicing endonuclease subunit Sen34 OS=Mus musculus GN=Tsen34 PE=2 SV=2 
Q8BMZ5 TSEN34_MOUSE 34.2 12.3% 3 3 7459100±2698764 10597700±3094819 
0.16630515 
1.42 
Polyribonucleotide 5'-hydroxyl-kinase Clp1 OS=Mus musculus GN=Clp1 PE=1 SV=1 
Q99LI9 CLP1_MOUSE 47.7 6.35% 3 3 1192075±1234803 3176175±905991 
0.166594012 
2.66 
Glutamate dehydrogenase 1, mitochondrial OS=Mus musculus GN=Glud1 PE=1 SV=1 
P26443 GLUD1_MOUSE 61.3 14.5% 6 8 3927550±1206429 6165450±1870370 
0.170066424 
1.57 
Plasminogen activator inhibitor 1 RNA-binding protein OS=Mus musculus GN=Serbp1 PE=1 SV=2 
Q9CY58 SERBP1_MOUSE 44.7 1.97% 1 1 1161127.5±1337659 2331390±649525 
0.170066424 
2.01 
Exosome complex exonuclease RRP44 OS=Mus musculus GN=Dis3 PE=1 SV=4 
Q9CSH3 DIS3_MOUSE 108.8 3.44% 3 3 2704230±1595188 4132125±2150342 
0.174438825 
1.53 
U2 small nuclear ribonucleoprotein A' OS=Mus musculus GN=Snrpa1 PE=1 SV=2 
P57784 SNRPA1_MOUSE 28.3 5.49% 1 1 420462.5±639106 1284472.5±361454 
0.177750263 
3.05 
Nuclease-sensitive element-binding protein 1 OS=Mus musculus GN=Ybx1 PE=1 SV=3 
P62960 YBX1_MOUSE 35.7 59% 12 21 24221500±17321887 45234750±4829264 
0.177750263 
1.87 
CAD protein OS=Mus musculus GN=Cad PE=1 SV=1 
B2RQC6 CAD_MOUSE 243.1 2.74% 5 5 2048282.5±3095565 4526770±2070035 
0.177750263 
2.21 
Cold shock domain-containing protein E1 OS=Mus musculus GN=Csde1 PE=1 SV=1 
Q91W50 CSDE1_MOUSE 88.7 11.4% 8 8 2004912.5±1622819 4226925±934156 
0.177750263 
2.11 
Gem-associated protein 5 OS=Mus musculus GN=Gemin5 PE=1 SV=2 
Q8BX17 GEMIN5_MOUSE 166.5 1.26% 2 2 744720±1253023 1988962.5±525790 
0.180912864 
2.67 
Citrate synthase, mitochondrial OS=Mus musculus GN=Cs PE=1 SV=1 
Q9CZU6 CS_MOUSE 51.7 8.19% 3 3 3162525±1078201 3774250±697751 
0.180912864 
1.19 
Serine-threonine kinase receptor-associated protein OS=Mus musculus GN=Strap PE=1 SV=2 
Q9Z1Z2 STRAP_MOUSE 38.4 14% 4 4 227540±704776 938017.5±153694 
0.180912864 
4.12 
Uncharacterized protein C5orf52 homolog OS=Mus musculus PE=2 SV=1 
NA NA NA NA NA NA 792542.5±216262 1444850±611948 
0.1891091 
1.82 
Synaptic functional regulator FMR1 OS=Mus musculus GN=Fmr1 PE=1 SV=1 
P35922 FMR1_MOUSE 68.9 7.98% 4 4 561637.5±1509814 2765957.5±579941 
0.195375249 
4.92 
Constitutive coactivator of PPAR-gamma-like protein 1 OS=Mus musculus GN=FAM120A PE=1 SV=2 
Q6A0A9 FAM120A_MOUSE 121.6 0.809% 1 1 2043875±1474912 4328500±787991 
0.208285124 
2.12 
Asparagine--tRNA ligase, cytoplasmic OS=Mus musculus GN=Nars PE=1 SV=2 
Q8BP47 NARS_MOUSE 64.2 10.9% 5 5 1350312.5±1293492 2670775±1276295 
0.208285124 
1.98 
Double-stranded RNA-binding protein Staufen homolog 1 OS=Mus musculus GN=Stau1 PE=1 SV=1 
Q9Z108 STAU1_MOUSE 53.9 36% 16 72 9758700±3222532 13264000±4468473 
0.208285124 
1.36 
Bifunctional glutamate/proline--tRNA ligase OS=Mus musculus GN=Eprs PE=1 SV=4 
Q8CGC7 EPRS_MOUSE 170 11% 12 12 6020550±3003296 8958675±1339098 
0.208285124 
1.49 
T-complex protein 1 subunit gamma OS=Mus musculus GN=Cct3 PE=1 SV=1 
P80318 CCT3_MOUSE 60.6 24% 14 15 12193000±11058685 18662150±15340493 
0.213042051 
1.53 
Cluster of Myosin-9 OS=Mus musculus GN=Myh9 PE=1 SV=4 (MYH9_MOUSE) 
Q8VDD5 MYH9_MOUSE 226.3 2.5% 4 4 1923217.5±432517 3445325±1355486 
0.213042051 
1.79 
Prohibitin OS=Mus musculus GN=Phb PE=1 SV=1 
P67778 PHB_MOUSE 29.8 15.1% 4 4 1489715±1018543 2010352.5±798384 
0.218496364 
1.35 
40S ribosomal protein S5 OS=Mus musculus GN=Rps5 PE=1 SV=3 
P97461 RPS5_MOUSE 22.9 28.9% 7 17 126127500±14194326 151727500±16230954 
0.218496364 
1.20 
E3 ubiquitin/ISG15 ligase TRIM25 OS=Mus musculus GN=Trim25 PE=1 SV=2 




















(Mean±SD) P VALUE 
FOLD 
CHANGE 
Splicing factor, proline- and glutamine-rich OS=Mus musculus GN=Sfpq PE=1 SV=1 
Q8VIJ6 SFPQ_MOUSE 75.4 14% 10 13 15079500±11686019 27615500±2299843 
0.218496364 
1.83 
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha OS=Mus musculus GN=Pip5k1a PE=1 SV=2 
P70182 PIP5K1A_MOUSE 60.4 5.31% 3 3 487387.5±1101000 1585140±182319 
0.218496364 
3.25 
Putative ATP-dependent RNA helicase Pl10 OS=Mus musculus GN=D1Pas1 PE=1 SV=1 
NA D1PAS1_MOUSE NA NA NA NA 9920450±2617356 15889750±5177824 
0.218496364 
1.60 
SRA stem-loop-interacting RNA-binding protein, mitochondrial OS=Mus musculus GN=Slirp PE=1 SV=2 
Q9D8T7 SLIRP_MOUSE 12.6 52.7% 8 47 2135775±1118873 3447575±239464 
0.218496364 
1.61 
Cluster of ATP-dependent RNA helicase DDX3Y OS=Mus musculus GN=Ddx3y PE=1 SV=2 (ATP-dependent) 
Q62095 DDX3Y_MOUSE 73.4 NA NA NA 39693750±9857831 49679750±10883320 
0.218496364 
1.25 
DAZ-associated protein 1 OS=Mus musculus GN=Dazap1 PE=1 SV=2 
Q9JII5 DAZAP1_MOUSE 43.2 8.87% 3 5 790400±2638501 3463225±912937 
0.220382266 
4.38 
Microtubule-associated protein 4 OS=Mus musculus GN=Map4 PE=1 SV=3 
P27546 MAP4_MOUSE 117.4 2.49% 2 2 1777225±675728 2707050±631333 
0.225760101 
1.52 
Filamin-C OS=Mus musculus GN=Flnc PE=1 SV=3 
Q8VHX6 FLNC_MOUSE 290.9 1.65% 3 3 2592425±1813665 4140725±1857383 
0.225760101 
1.60 
Calumenin OS=Mus musculus GN=Calu PE=1 SV=1 
O35887 CALU_MOUSE 37 4.76% 1 1 1960400±870734 3055875±2015758 
0.225760101 
1.56 
Prolyl 4-hydroxylase subunit alpha-1 OS=Mus musculus GN=P4ha1 PE=1 SV=2 
Q60715 P4HA1_MOUSE 60.9 11.8% 5 5 2313500±1009508 3829400±1087413 
0.228450181 
1.66 
Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 OS=Mus musculus GN=Cmtr1 PE=1 SV=1 
Q9DBC3 CMTR1_MOUSE 95.6 14.6% 12 15 11128225±4946442 16583500±2442642 
0.228450181 
1.49 
Cluster of Sodium/potassium-transporting ATPase subunit alpha-2 OS=Mus musculus GN=Atp1a2 PE=1 SV=1 
(Sodium/potassium-transporting) 
Q6PIE5 ATP1A2_MOUSE 112.2 NA NA NA 2324925±871731 3300125±1004148 
0.24274262 
1.42 
Staphylococcal nuclease domain-containing protein 1 OS=Mus musculus GN=Snd1 PE=1 SV=1 
Q78PY7 SND1_MOUSE 102 31.5% 26 36 9929300±2833623 12503875±4476015 
0.247309751 
1.26 
Protein-glutamine gamma-glutamyltransferase E OS=Mus musculus GN=Tgm3 PE=1 SV=2 
Q08189 TGM3_MOUSE 77.3 1.88% 1 1 852855±821545 1951500±620857 
0.255693254 
2.29 
Polypyrimidine tract-binding protein 3 OS=Mus musculus GN=Ptbp3 PE=1 SV=1 
Q8BHD7 PTBP3_MOUSE 56.7 1.53% 1 1 62865500±96725099 136527000±22042633 
0.255693254 
2.17 
Drebrin OS=Mus musculus GN=Dbn1 PE=1 SV=4 
Q9QXS6 DBN1_MOUSE 77.2 15% 8 36 1036400±1790343 1655930 ±1055643 
0.265333671 
1.60 
Protein PRRC2C OS=Mus musculus GN=Prrc2c PE=1 SV=3 
Q3TLH4 PRRC2C_MOUSE 310.7 0.492% 1 1 30270500±17375339 41809000±15067524 
0.27983228 
1.38 
U6 snRNA-associated Sm-like protein LSm8 OS=Mus musculus GN=Lsm8 PE=1 SV=3 
Q6ZWM4 LSM8_MOUSE 10.4 10.4% 1 1 5365825±3689424 8027550±1327658 
0.289287835 
1.50 
Interferon-activable protein 204 OS=Mus musculus GN=Ifi204 PE=1 SV=1 
P0DOV2 IFI204_MOUSE 69.4 8.72% 5 5 2077400±880682 3080325±579356 
0.289287835 
1.48 
ATP-citrate synthase OS=Mus musculus GN=Acly PE=1 SV=1 
Q91V92 ACLY_MOUSE 119.7 9.44% 10 10 488112.5±738904 918090±538154 
0.300437115 
1.88 
Nucleolin OS=Mus musculus GN=Ncl PE=1 SV=2 
P09405 NCL_MOUSE 76.7 24.9% 20 47 25658750±8902516 29775250±5587866 
0.300437115 
1.16 
Collagen alpha-2(I) chain OS=Mus musculus GN=Col1a2 PE=1 SV=2 
Q01149 COL1A2_MOUSE 129.5 30.8% 24 33 36556250±19835242 45516000±8061173 
0.333951034 
1.25 
D-3-phosphoglycerate dehydrogenase OS=Mus musculus GN=Phgdh PE=1 SV=3 
Q61753 PHGDH_MOUSE 56.5 9.01% 4 4 2377830±2461929 3971475±2319231 
0.334710701 
1.67 
Matrin-3 OS=Mus musculus GN=Matr3 PE=1 SV=1 
Q8K310 MATR3_MOUSE 94.6 41% 32 175 9027775±3324674 10786575±3147813 
0.334710701 
1.19 
Importin subunit beta-1 OS=Mus musculus GN=Kpnb1 PE=1 SV=2 




















(Mean±SD) P VALUE 
FOLD 
CHANGE 
Tropomyosin alpha-3 chain OS=Mus musculus GN=Tpm3 PE=1 SV=3 
P21107 TPM3_MOUSE 32.9 3.51% 1 1 3975250±1370569 5148675±1381974 
0.338417651 
1.30 
Golgi apparatus protein 1 OS=Mus musculus GN=Glg1 PE=1 SV=1 
Q61543 GLG1_MOUSE 133.6 3.66% 4 4 1230442.5±1258375 2013830±320118 
0.338417651 
1.64 
Signal recognition particle 54 kDa protein OS=Mus musculus GN=Srp54 PE=1 SV=2 
P14576 SRP54_MOUSE 55.7 18.8% 8 8 4255675±1341165 5580800±1064537 
0.338417651 
1.31 
Spermatid perinuclear RNA-binding protein OS=Mus musculus GN=Strbp PE=1 SV=1 
Q91WM1 STRBP_MOUSE 73.7 3.42% 3 3 9562125±3739427 12641275±2395981 
0.338417651 
1.32 
Switch-associated protein 70 OS=Mus musculus GN=Swap70 PE=1 SV=2 
Q6A028 SWAP70_MOUSE 69 6.67% 4 4 1353410±466691 1936375±1121862 
0.341995489 
1.43 
Probable ribonuclease ZC3H12C OS=Mus musculus GN=Zc3h12c PE=1 SV=2 
Q5DTV4 ZC12C_MOUSE 99.4 NA NA NA 37968250±7452114 45292250±4965523 
0.341995489 
1.19 
Lysine--tRNA ligase OS=Mus musculus GN=Kars PE=1 SV=1 
Q99MN1 KARS_MOUSE 67.8 6.05% 3 3 4315350±2490945 5553350±981796 
0.341995489 
1.29 
Cleavage and polyadenylation specificity factor subunit 7 OS=Mus musculus GN=Cpsf7 PE=1 SV=2 
Q8BTV2 CPSF7_MOUSE 52 2.76% 1 1 4500825±1866643 6017375±3003352 
0.343837571 
1.34 
Transitional endoplasmic reticulum ATPase OS=Mus musculus GN=Vcp PE=1 SV=4 
Q01853 VCP_MOUSE 89.3 30% 20 108 2684565±1629636 396410 ±1416269 
0.371324854 
1.48 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 OS=Mus musculus GN=Rpn1 PE=1 
SV=1 
Q91YQ5 RPN1_MOUSE 68.5 5.76% 3 3 1563612.5±1671729 2536325±672515 
0.373058517 
1.62 
Phosphorylated adapter RNA export protein OS=Mus musculus GN=Phax PE=1 SV=1 
Q9JJT9 PHAX_MOUSE 43.2 21% 8 39 1633185±675636 2094875±1177060 
0.373233685 
1.28 
Serpin H1 OS=Mus musculus GN=Serpinh1 PE=1 SV=3 
P19324 SERPINH1_MOUSE 46.5 10.3% 4 7 9921575±4176038 13887200±6170504 
0.379619198 
1.40 
Procollagen galactosyltransferase 1 OS=Mus musculus GN=Colgalt1 PE=1 SV=2 
Q8K297 COLGALT1_MOUSE 71 7.46% 5 5 670372.5±892384 1287550±472404 
0.387195146 
1.92 
ATP synthase subunit alpha, mitochondrial OS=Mus musculus GN=Atp5a1 PE=1 SV=1 
Q03265 ATP5A1_MOUSE 59.7 9.04% 4 4 9428500±2881096 12031375±3208360 
0.387195146 
1.28 
RNA-binding protein FUS OS=Mus musculus GN=Fus PE=1 SV=1 
P56959 FUS_MOUSE 52.6 12.9% 5 9 25074750±8327819 30479250±6535074 
0.38962883 
1.22 
Filamin-A OS=Mus musculus GN=Flna PE=1 SV=5 
Q8BTM8 FLNA_MOUSE 281 8.65% 16 17 20070000±4023686 22572500±4087434 
0.38962883 
1.12 
Cluster of Keratin, type II cytoskeletal 5 OS=Mus musculus GN=Krt5 PE=1 SV=1 (Keratin,) 
Q922U2 K2C5_MOUSE 61.7 NA 43 22 959010000±365196601 336165000±251569289 0.38962883 0.35 
14-3-3 protein beta/alpha OS=Mus musculus GN=Ywhab PE=1 SV=3 
Q9CQV8 YWHAB_MOUSE 28.1 NA 2 2 20082500±4286450 8912875±7487941 
0.38962883 
0.44 
Junction plakoglobin OS=Mus musculus GN=Jup PE=1 SV=3 
Q02257 JUP_MOUSE 81.7 6.44% 4 4 15208075±4264665 4652400±6482450 
0.38962883 
0.31 
Interleukin enhancer-binding factor 3 OS=Mus musculus GN=Ilf3 PE=1 SV=2 
Q9Z1X4 ILF3_MOUSE 96 15.8% 12 14 58559000±9145458 47967000±16924078 
0.38962883 
0.82 
Desmoplakin OS=Mus musculus GN=Dsp PE=1 SV=1 
E9Q557 DSP_MOUSE 332.7 1.25% 4 4 14623900±6965103 5016095±6967817 0.38962883 0.34 
AMP deaminase 2 OS=Mus musculus GN=Ampd2 PE=1 SV=1 
Q9DBT5 AMPD2_MOUSE 92 NA 46 18 19893025±5571480 13332350±10528321 
0.38962883 
0.67 
Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 3 OS=Mus musculus GN=Agap3 PE=1 
SV=1 
Q8VHH5 AGAP3_MOUSE 97.9 3.85% 3 3 4143667.5±1183270 1588475±2462522 
0.38962883 
0.38 
Cluster of Ubiquitin-40S ribosomal protein S27a OS=Mus musculus GN=Rps27a PE=1 SV=2 (RS27A_MOUSE) 
P62983 RPS27A_MOUSE 17.9 30.1% 4 7 9635200±2025778 5217800±3756753 
0.38962883 
0.54 
Histone H4 OS=Mus musculus GN=Hist1h4a PE=1 SV=2 


















(Mean±SD) P VALUE 
FOLD 
CHANGE 
Brain acid soluble protein 1 OS=Mus musculus GN=Basp1 PE=1 SV=3 
Q91XV3 BASP1_MOUSE 22.1 6.19% 1 1 1560100±609232 777797.5±1155073 
0.38962883 
0.50 
Alpha-1-antitrypsin 1-1 OS=Mus musculus GN=Serpina1a PE=1 SV=4 
P07758 SERPINA1A_MOUSE 46 NA 3 3 1419560±386392 472207.5±1023676 
0.38962883 
0.33 
TAR DNA-binding protein 43 OS=Mus musculus GN=Tardbp PE=1 SV=1 
Q921F2 TARDBP_MOUSE 44.5 17.1% 7 10 8313450±1086648 6669325±1945379 
0.38962883 
0.80 
6-phosphogluconate dehydrogenase, decarboxylating OS=Mus musculus GN=Pgd PE=1 SV=3 
Q9DCD0 PGD_MOUSE 53.2 2.28% 1 1 1499482.5±675104 876217.5±1293204 0.38962883 0.58 
Fructose-bisphosphate aldolase A OS=Mus musculus GN=Aldoa PE=1 SV=2 
P05064 ALDOA_MOUSE 39.3 25% 8 10 8635075±5049243 7398400±5320273 
0.38962883 
0.86 
Serum albumin OS=Mus musculus GN=Alb PE=1 SV=3 
P07724 ALB_MOUSE 68.6 15.8% 8 8 34353600±7076873 12462125±39837680 0.38962883 0.36 
Ras-related protein Rab-8A OS=Mus musculus GN=Rab8a PE=1 SV=2 
P55258 RAB8A_MOUSE 23.6 NA 3 2 7860000±2373586 7041450 ±1348766 0.38962883 0.90 
Cluster of Actin, gamma-enteric smooth muscle OS=Mus musculus GN=Actg2 PE=1 SV=1 (Actin,) 
P63268 ACTG2_MOUSE 41.8 NA NA NA 22829500±9672418 20988250±7118405 0.38962883 0.92 
Rho guanine nucleotide exchange factor 15 OS=Mus musculus GN=Arhgef15 PE=1 SV=1 
 
ARHGEF15_MOUSE NA NA NA NA 
0 0 NA NA 
Actin-related protein 2/3 complex subunit 2 OS=Mus musculus GN=Arpc2 PE=1 SV=3 
 
ARPC2_MOUSE 34 7.67% 2 4 
0 0 NA NA 
Aspartyl/asparaginyl beta-hydroxylase OS=Mus musculus GN=Asph PE=1 SV=1 
 
ASPH_MOUSE 83 18.2% 11 33 
0 0 NA NA 
Ataxin-2-like protein OS=Mus musculus GN=Atxn2l PE=1 SV=1 
 
ATXN2L_MOUSE 111 21.9% 18 36 
0 0 NA NA 
Mitotic checkpoint serine/threonine-protein kinase BUB1 OS=Mus musculus GN=Bub1 PE=1 SV=1 
 
BUB1_MOUSE NA NA NA NA 
0 0 NA NA 
Cullin-associated NEDD8-dissociated protein 1 OS=Mus musculus GN=Cand1 PE=1 SV=2 
 
CAND1_MOUSE 136 3.33% 4 13 
0 0 NA NA 
Centrosomal protein of 170 kDa OS=Mus musculus GN=Cep170 PE=1 SV=2 
 
CEP170_MOUSE 175 7.75% 9 12 
0 0 NA NA 
Calponin-3 OS=Mus musculus GN=Cnn3 PE=1 SV=1 
 
CNN3_MOUSE 36 20.6% 5 27 
0 0 NA NA 
Src substrate cortactin OS=Mus musculus GN=Cttn PE=1 SV=2 
 
CTTN_MOUSE 61 16.8% 9 30 
0 0 NA NA 
EH domain-binding protein 1 OS=Mus musculus GN=Ehbp1 PE=1 SV=3 
 
EHBP1_MOUSE 139 1.06% 1 1 
0 0 NA NA 
Elongator complex protein 3 OS=Mus musculus GN=Elp3 PE=1 SV=1 
 
ELP3_MOUSE 62 8.04% 4 6 
0 0 NA NA 
Emerin OS=Mus musculus GN=Emd PE=1 SV=1 
 
EMD_MOUSE 29 30.1% 7 18 
0 0 NA NA 
Enhancer of rudimentary homolog OS=Mus musculus GN=Erh PE=1 SV=1 
 
ERH_MOUSE 12 42.3% 4 14 
0 0 NA NA 
Phenylalanine--tRNA ligase beta subunit OS=Mus musculus GN=Farsb PE=1 SV=2 
 
FARSB_MOUSE 66 13.6% 8 14 
0 0 NA NA 
Gelsolin OS=Mus musculus GN=Gsn PE=1 SV=3 
 
GSN_MOUSE 86 11.7% 6 18 
0 0 NA NA 
Host cell factor 1 OS=Mus musculus GN=Hcfc1 PE=1 SV=2 
 
HCFC1_MOUSE 210 2.2% 4 15 


















(Mean±SD) P VALUE 
FOLD 
CHANGE 
Heterochromatin protein 1-binding protein 3 OS=Mus musculus GN=Hp1bp3 PE=1 SV=1 
 
HP1BP3_MOUSE 61 14.4% 7 12 
0 0 NA NA 
Peroxisomal multifunctional enzyme type 2 OS=Mus musculus GN=Hsd17b4 PE=1 SV=3 
 
HSD17B4_MOUSE 79 9.12% 6 15 
0 0 NA NA 
Lamin-B receptor OS=Mus musculus GN=Lbr PE=1 SV=2 
 
LBR_MOUSE 71 10.5% 7 35 
0 0 NA NA 
Lipoma-preferred partner homolog OS=Mus musculus GN=Lpp PE=1 SV=1 
 
LPP_MOUSE 66 23.2% 8 25 
0 0 NA NA 
Magnesium transporter protein 1 OS=Mus musculus GN=Magt1 PE=1 SV=1 
 
MAGT1_MOUSE 38 11% 4 12 
0 0 NA NA 
Monofunctional C1-tetrahydrofolate synthase, mitochondrial OS=Mus musculus GN=Mthfd1l PE=1 SV=2 
 
MTHFD1L_MOUSE 106 15.4% 12 25 
0 0 NA NA 
Phosphoenolpyruvate carboxykinase [GTP], mitochondrial OS=Mus musculus GN=Pck2 PE=1 SV=1 
 
PCK2_MOUSE 71 16.7% 10 22 
0 0 NA NA 
Pleckstrin homology-like domain family B member 2 OS=Mus musculus GN=Phldb2 PE=1 SV=2 
 
PHLDB2_MOUSE 141 19.6% 19 33 
0 0 NA NA 
Proline synthase co-transcribed bacterial homolog protein OS=Mus musculus GN=Prosc PE=1 SV=1 
 
PROSC_MOUSE 30 23.4% 6 21 
0 0 NA NA 
Recombining binding protein suppressor of hairless OS=Mus musculus GN=Rbpj PE=1 SV=1 
 
RBPJ_MOUSE 59 16.3% 7 16 
0 0 NA NA 
RuvB-like 1 OS=Mus musculus GN=Ruvbl1 PE=1 SV=1 
 
RUVBL1_MOUSE 50 14.5% 5 13 
0 0 NA NA 
Serine/threonine-protein kinase Sgk2 OS=Mus musculus GN=Sgk2 PE=1 SV=1 
 
SGK2_MOUSE NA 0% 1 5 
0 0 NA NA 
Na(+)/H(+) exchange regulatory cofactor NHE-RF1 OS=Mus musculus GN=Slc9a3r1 PE=1 SV=3 
 
SLC9A3R1_MOUSE 39 21.7% 6 22 
0 0 NA NA 
Transmembrane emp24 domain-containing protein 2 OS=Mus musculus GN=Tmed2 PE=1 SV=1 
 
TMED2_MOUSE 23 4.48% 1 5 
0 0 NA NA 
WD repeat and SOCS box-containing protein 2 OS=Mus musculus GN=Wsb2 PE=2 SV=2 
 
WSB2_MOUSE 50 33.6% 10 33 
0 0 NA NA 
Lamina-associated polypeptide 2, isoforms beta/delta/epsilon/gamma OS=Mus musculus GN=Tmpo PE=1 SV=4 
 
TMPO_MOUSE NA NA NA NA 
0 0 NA NA 
Endoribonuclease Dicer OS=Mus musculus GN=Dicer1 PE=1 SV=3 
 
DICER1_MOUSE 217 6.21% 9 14 
0 0 NA NA 
28 kDa heat- and acid-stable phosphoprotein OS=Mus musculus GN=Pdap1 PE=1 SV=1 
 
PDAP1_MOUSE 21 31.5% 5 26 
0 0 NA NA 
mRNA cap guanine-N7 methyltransferase OS=Mus musculus GN=Rnmt PE=1 SV=1 
 
RNMT_MOUSE 53 9.25% 4 7 
0 0 NA NA 
THUMP domain-containing protein 2 OS=Mus musculus GN=Thumpd2 PE=2 SV=3 
 
THUMPD2_MOUSE 58 15.7% 6 17 
0 0 NA NA 
Transformer-2 protein homolog beta OS=Mus musculus GN=Tra2b PE=1 SV=1 
 
TRA2B_MOUSE 34 8.68% 2 12 
0 0 NA NA 
3'-5' exoribonuclease 1 OS=Mus musculus GN=Eri1 PE=1 SV=2 
 
ERI1_MOUSE 39 20.9% 5 17 
0 0 NA NA 
La-related protein 1 OS=Mus musculus GN=Larp1 PE=1 SV=3 
 
LARP1_MOUSE 121 36.5% 24 63 
0 0 NA NA 
Pre-mRNA-processing factor 19 OS=Mus musculus GN=Prpf19 PE=1 SV=1 
 
PRPF19_MOUSE 55 8.53% 4 11 
0 0 NA NA 
U4/U6 small nuclear ribonucleoprotein Prp31 OS=Mus musculus GN=Prpf31 PE=1 SV=3 
 
PRPF31_MOUSE 55 14.2% 5 10 


















(Mean±SD) P VALUE 
FOLD 
CHANGE 
Squamous cell carcinoma antigen recognized by T-cells 3 OS=Mus musculus GN=Sart3 PE=1 SV=1 
 
SART3_MOUSE 110 13.9% 11 41 
0 0 NA NA 
GTP:AMP phosphotransferase AK3, mitochondrial OS=Mus musculus GN=Ak3 PE=1 SV=3 
 
AK3_MOUSE 25 35.7% 7 22 
0 0 NA NA 
Apoptosis inhibitor 5 OS=Mus musculus GN=Api5 PE=1 SV=2 
 
API5_MOUSE 57 10.9% 5 20 
0 0 NA NA 
Caseinolytic peptidase B protein homolog OS=Mus musculus GN=Clpb PE=1 SV=1 
 
CLPB_MOUSE 76 11.5% 6 25 
0 0 NA NA 
Calponin-2 OS=Mus musculus GN=Cnn2 PE=1 SV=1 
 
CNN2_MOUSE 33 29.2% 8 36 
0 0 NA NA 
Cysteine and glycine-rich protein 1 OS=Mus musculus GN=Csrp1 PE=1 SV=3 
 
CSRP1_MOUSE 21 28% 4 22 
0 0 NA NA 
Cluster of Cullin-4B OS=Mus musculus GN=Cul4b PE=1 SV=1 (CUL4B_MOUSE) 
 
CUL4B_MOUSE 111 11.4% 12 39 
0 0 NA NA 
Endothelial differentiation-related factor 1 OS=Mus musculus GN=Edf1 PE=1 SV=1 
 
EDF1_MOUSE 16 30.4% 4 21 
0 0 NA NA 
Band 4.1-like protein 2 OS=Mus musculus GN=Epb41l2 PE=1 SV=2 
 
EPB41L2_MOUSE 110 12.3% 10 25 
0 0 NA NA 
Leucine--tRNA ligase, cytoplasmic OS=Mus musculus GN=Lars PE=1 SV=2 
 
LARS_MOUSE 134 15.4% 15 36 
0 0 NA NA 
Methionine aminopeptidase 2 OS=Mus musculus GN=Metap2 PE=1 SV=1 
 
METAP2_MOUSE 53 22% 8 29 
0 0 NA NA 
[F-actin]-methionine sulfoxide oxidase MICAL3 OS=Mus musculus GN=Mical3 PE=1 SV=2 
 
MICAL3_MOUSE NA NA NA NA 
0 0 NA NA 
Calcium uptake protein 1, mitochondrial OS=Mus musculus GN=Micu1 PE=1 SV=1 
 
MICU1_MOUSE 54 6.92% 3 7 
0 0 NA NA 
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 OS=Mus musculus GN=Plcb3 PE=1 SV=2 
 
PLCB3_MOUSE 139 6.89% 9 24 
0 0 NA NA 
DNA-directed RNA polymerases I, II, and III subunit RPABC1 OS=Mus musculus GN=Polr2e PE=1 SV=1 
 
POLR2E_MOUSE 25 19% 4 14 
0 0 NA NA 
Sphingosine-1-phosphate lyase 1 OS=Mus musculus GN=Sgpl1 PE=1 SV=1 
 
SGPL1_MOUSE 64 15.8% 8 28 
0 0 NA NA 
UDP-glucuronosyltransferase 1-7C OS=Mus musculus GN=Ugt1a7c PE=1 SV=1 
 
UGT1A7C_MOUSE 60 14.3% 7 23 
0 0 NA NA 
Nucleolar RNA helicase 2 OS=Mus musculus GN=Ddx21 PE=1 SV=3 
 
DDX21_MOUSE 94 35.1% 27 59 
0 0 NA NA 
Luc7-like protein 3 OS=Mus musculus GN=Luc7l3 PE=1 SV=1 
 
LUC7L3_MOUSE 51 10.4% 4 22 





Supplementary Table 8. Table of the pathways as returned by Reactome online software sorted according to the p-values of the identified interactions. The top six 
pathways, with a p-value<0.05 are highlighted in grey background while the ones with meaningful interactions are highlighted in bold.  





















Submitted entities  
found Mapped entities 
R-HSA-72163 mRNA Splicing - Major Pathway 3 180 6 633 0.016249887 0.00998423 0.608763792 8 9 7.93E-04 Tra2b;Prpf31;Prpf19 Q9UMS4;Q8WWY3;P62995 
R-HSA-72172 mRNA Splicing 3 188 6 636 0.016972104 0.010720796 0.608763792 9 14 0.001233154 Tra2b;Prpf31;Prpf19 Q9UMS4;Q8WWY3;P62995 
R-HSA-9017802 Noncanonical activation of NOTCH3 0 8 2 49 7.22E-04 0.015435875 0.608763792 1 2 1.76E-04   
R-HSA-159236 
Transport of Mature mRNA derived from an Intron-Containing 
Transcript 0 76 3 110 0.006861063 0.020624516 0.608763792 1 4 3.52E-04   
R-HSA-72203 Processing of Capped Intron-Containing Pre-mRNA 3 243 6 725 0.021937348 0.023863478 0.608763792 11 32 0.002818638 Tra2b;Prpf31;Prpf19 Q9UMS4;Q8WWY3;P62995 
R-HSA-426486 Small interfering RNA (siRNA) biogenesis 1 9 0 0 8.12E-04 0.029827035 0.608763792 3 5 4.40E-04 Dicer1 Q9UPY3 
R-HSA-77588 
SLBP Dependent Processing of Replication-Dependent Histone 
Pre-mRNAs 0 11 1 2 9.93E-04 0.042801649 0.608763792 1 3 2.64E-04   
R-HSA-72202 Transport of Mature Transcript to Cytoplasm 0 85 3 228 0.007673558 0.071750476 0.608763792 1 13 0.001145072   
R-HSA-169131 Inhibition of PKR 0 2 1 22 1.81E-04 0.074497975 0.608763792 1 2 1.76E-04   
R-HSA-203927 MicroRNA (miRNA) biogenesis 1 24 0 1 0.002166652 0.080712522 0.608763792 3 8 7.05E-04 Dicer1 Q9UPY3 
R-HSA-9013507 NOTCH3 Activation and Transmission of Signal to the Nucleus 0 25 2 120 0.002256929 0.083786527 0.608763792 1 15 0.001321237   
R-HSA-73980 RNA Polymerase III Transcription Termination 0 23 1 5 0.002076374 0.08995765 0.608763792 1 2 1.76E-04   
R-HSA-75067 Processing of Capped Intronless Pre-mRNA 0 28 1 6 0.00252776 0.10817507 0.608763792 1 10 8.81E-04   
R-HSA-450604 KSRP (KHSRP) binds and destabilizes mRNA 0 17 2 170 0.001534712 0.128531956 0.608763792 1 5 4.40E-04   
R-HSA-167160 
RNA Pol II CTD phosphorylation and interaction with CE during 
HIV infection 1 27 0 19 0.002437483 0.137745438 0.608763792 1 5 4.40E-04 Rnmt O43148 
R-HSA-77075 RNA Pol II CTD phosphorylation and interaction with CE 1 27 0 19 0.002437483 0.137745438 0.608763792 1 5 4.40E-04 Rnmt O43148 
R-HSA-749476 RNA Polymerase III Abortive And Retractive Initiation 0 41 1 5 0.003701363 0.143543004 0.608763792 1 13 0.001145072   
R-HSA-4570464 SUMOylation of RNA binding proteins 0 49 2 168 0.00442358 0.159675152 0.608763792 3 4 3.52E-04   
R-HSA-8851805 MET activates RAS signaling 0 11 1 49 9.93E-04 0.171962005 0.608763792 1 10 8.81E-04   
R-HSA-9012852 Signaling by NOTCH3 0 49 2 183 0.00442358 0.177542788 0.608763792 1 37 0.00325905   
R-HSA-72086 mRNA Capping 1 29 0 34 0.002618037 0.180305812 0.608763792 7 11 9.69E-04 Rnmt O43148 





R-HSA-6782210 Gap-filling DNA repair synthesis and ligation in TC-NER 1 64 0 0 0.005777738 0.194029204 0.608763792 2 2 1.76E-04 Prpf19 Q9UMS4 
R-HSA-5632987 Defective Mismatch Repair Associated With PMS2 0 2 1 67 1.81E-04 0.204845386 0.608763792 1 1 8.81E-05   
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Submitted entities  
found Mapped entities 
R-HSA-74158 RNA Polymerase III Transcription 0 41 1 28 0.003701363 0.207527101 0.608763792 1 25 0.002202061   
R-HSA-168276 NS1 Mediated Effects on Host Pathways 0 44 1 31 0.003972195 0.220803139 0.608763792 1 6 5.28E-04   
R-HSA-6782135 Dual incision in TC-NER 1 65 0 22 0.005868015 0.24159224 0.608763792 6 6 5.28E-04 Prpf19 Q9UMS4 
R-HSA-5423599 Diseases of Mismatch Repair (MMR) 0 5 1 82 4.51E-04 0.24159224 0.608763792 1 6 5.28E-04   
R-HSA-512988 Interleukin-3, Interleukin-5 and GM-CSF signaling 0 48 2 257 0.004333303 0.246379564 0.608763792 1 38 0.003347133   
R-HSA-5693548 Sensing of DNA Double Strand Breaks 0 6 1 84 5.42E-04 0.251781733 0.608763792 2 8 7.05E-04   
R-HSA-194441 Metabolism of non-coding RNA 0 55 1 45 0.004965243 0.254308046 0.608763792 1 6 5.28E-04   
R-HSA-191859 snRNP Assembly 0 55 1 45 0.004965243 0.254308046 0.608763792 1 6 5.28E-04   
R-HSA-4608870 Asymmetric localization of PCP proteins 0 64 1 25 0.005777738 0.25933559 0.608763792 2 7 6.17E-04   
R-HSA-168253 Host Interactions with Influenza Factors 0 48 1 43 0.004333303 0.261836876 0.608763792 1 8 7.05E-04   
R-HSA-72165 mRNA Splicing - Minor Pathway 0 52 1 41 0.004694412 0.264329873 0.608763792 1 5 4.40E-04   
R-HSA-5358565 Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) 0 14 1 82 0.00126388 0.264329873 0.608763792 1 10 8.81E-04   
R-HSA-5358508 Mismatch Repair 0 15 1 83 0.001354157 0.264329873 0.608763792 1 17 0.001497402   
R-HSA-8931987 RUNX1 regulates estrogen receptor mediated transcription 0 6 1 91 5.42E-04 0.274219518 0.608763792 1 8 7.05E-04   
R-HSA-450341 Activation of the AP-1 family of transcription factors 0 10 1 103 9.03E-04 0.303112357 0.608763792 3 5 4.40E-04   
R-HSA-170984 ARMS-mediated activation 0 7 1 105 6.32E-04 0.310157384 0.608763792 1 5 4.40E-04   
R-HSA-8849468 PTK6 Regulates Proteins Involved in RNA Processing 0 5 1 119 4.51E-04 0.330875841 0.608763792 2 7 6.17E-04   
R-HSA-6781823 Formation of TC-NER Pre-Incision Complex 1 53 0 75 0.004784689 0.342121002 0.608763792 2 7 6.17E-04 Prpf19 Q9UMS4 
R-HSA-211000 Gene Silencing by RNA 1 108 0 22 0.009749932 0.346566964 0.608763792 6 36 0.003170968 Dicer1 Q9UPY3 
R-HSA-5099900 WNT5A-dependent internalization of FZD4 0 15 1 116 0.001354157 0.353180686 0.608763792 1 5 4.40E-04   
R-HSA-5620924 Intraflagellar transport 0 53 1 101 0.004784689 0.3575533 0.608763792 2 12 0.001056989   
R-HSA-167172 Transcription of the HIV genome 1 74 0 66 0.006680509 0.359728718 0.608763792 1 45 0.00396371 Rnmt O43148 
R-HSA-169893 Prolonged ERK activation events 0 12 1 131 0.001083326 0.372630265 0.608763792 1 11 9.69E-04   
R-HSA-4641258 Degradation of DVL 0 57 1 93 0.005145798 0.385276652 0.608763792 1 7 6.17E-04   
R-HSA-3769402 Deactivation of the beta-catenin transactivating complex 0 42 2 372 0.00379164 0.385943196 0.608763792 1 14 0.001233154   
R-HSA-450513 Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA 0 17 1 134 0.001534712 0.391505711 0.608763792 1 4 3.52E-04   
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Submitted entities  
found Mapped entities 
R-HSA-6781827 Transcription-Coupled Nucleotide Excision Repair (TC-NER) 1 78 0 80 0.007041618 0.39767283 0.608763792 11 16 0.001409319 Prpf19 Q9UMS4 
R-HSA-8943724 Regulation of PTEN gene transcription 0 60 1 97 0.005416629 0.405800346 0.608763792 1 15 0.001321237   
R-HSA-450282 MAPK targets/ Nuclear events mediated by MAP kinases 0 31 1 137 0.002798592 0.411825276 0.608763792 3 16 0.001409319   
R-HSA-187687 Signalling to ERKs 0 32 1 133 0.002888869 0.415808555 0.608763792 1 24 0.002113979   
R-HSA-6796648 TP53 Regulates Transcription of DNA Repair Genes 0 65 1 104 0.005868015 0.421733896 0.608763792 1 17 0.001497402   
R-HSA-450385 Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA 0 17 1 173 0.001534712 0.467061134 0.608763792 2 6 5.28E-04   
R-HSA-1912408 Pre-NOTCH Transcription and Translation 0 62 1 133 0.005597183 0.474268873 0.608763792 1 27 0.002378226   
R-HSA-2028269 Signaling by Hippo 0 20 1 182 0.001805543 0.474268873 0.608763792 1 30 0.002642473   
R-HSA-450531 
Regulation of mRNA stability by proteins that bind AU-rich 
elements 0 88 2 409 0.007944389 0.484997109 0.608763792 4 26 0.002290144   
R-HSA-450294 MAP kinase activation 0 63 1 167 0.005687461 0.508897248 0.608763792 3 32 0.002818638   
R-HSA-6791226 Major pathway of rRNA processing in the nucleolus and cytosol 2 183 0 359 0.016520719 0.51410522 0.608763792 2 7 6.17E-04 Eri1;Ddx21 Q8IV48;Q9NR30 
R-HSA-448424 Interleukin-17 signaling 0 71 1 167 0.006409678 0.522113042 0.608763792 3 35 0.003082886   
R-HSA-8868773 rRNA processing in the nucleus and cytosol 2 193 0 361 0.01742349 0.526703315 0.608763792 2 15 0.001321237 Eri1;Ddx21 Q8IV48;Q9NR30 
R-HSA-4615885 SUMOylation of DNA replication proteins 0 48 1 186 0.004333303 0.530195051 0.608763792 1 8 7.05E-04   
R-HSA-4641265 Repression of WNT target genes 0 12 1 214 0.001083326 0.534979725 0.608763792 1 7 6.17E-04   
R-HSA-1912422 Pre-NOTCH Expression and Processing 0 78 1 153 0.007041618 0.534979725 0.608763792 1 37 0.00325905   
R-HSA-5250924 B-WICH complex positively regulates rRNA expression 1 60 0 174 0.005416629 0.536563967 0.608763792 3 3 2.64E-04 Ddx21 Q9NR30 
R-HSA-452723 Transcriptional regulation of pluripotent stem cells 0 36 1 211 0.003249977 0.56269983 0.608763792 1 35 0.003082886   
R-HSA-977225 Amyloid fiber formation 0 71 1 193 0.006409678 0.575945273 0.608763792 1 28 0.002466308   
R-HSA-72312 rRNA processing 2 203 0 402 0.018326262 0.576860524 0.608763792 2 21 0.001849731 Eri1;Ddx21 Q8IV48;Q9NR30 
R-HSA-4086400 PCP/CE pathway 0 92 1 184 0.008305498 0.599899166 0.608763792 3 24 0.002113979   
R-HSA-912446 Meiotic recombination 0 56 1 231 0.00505552 0.599899166 0.608763792 1 9 7.93E-04   
R-HSA-2871796 FCERI mediated MAPK activation 0 118 1 162 0.010652704 0.603986251 0.608763792 2 20 0.001761649   
R-HSA-6807070 PTEN Regulation 0 139 2 485 0.012548524 0.608763792 0.608763792 3 56 0.004932617   
R-HSA-5696398 Nucleotide Excision Repair 1 110 0 199 0.009930487 0.626384249 0.626384249 11 36 0.003170968 Prpf19 Q9UMS4 
R-HSA-5250913 Positive epigenetic regulation of rRNA expression 1 75 0 241 0.006770786 0.637733895 0.637733895 3 7 6.17E-04 Ddx21 Q9NR30 
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Submitted entities  
found Mapped entities 
R-HSA-165159 mTOR signalling 0 40 1 284 0.003611086 0.637733895 0.637733895 1 28 0.002466308   
R-HSA-5689896 Ovarian tumor domain proteases 0 38 1 274 0.003430532 0.641441401 0.641441401 1 14 0.001233154   
R-HSA-2559580 Oxidative Stress Induced Senescence 0 94 1 229 0.008486052 0.641441401 0.641441401 2 39 0.003435215   
R-HSA-6806834 Signaling by MET 0 79 1 250 0.007131895 0.652341973 0.652341973 1 49 0.00431604   
R-HSA-201681 TCF dependent signaling in response to WNT 0 202 3 907 0.018235984 0.692086216 0.692086216 2 71 0.006253854   
R-HSA-3858494 Beta-catenin independent WNT signaling 0 143 1 218 0.012909633 0.695938789 0.695938789 3 51 0.004492205   
R-HSA-416993 Trafficking of GluR2-containing AMPA receptors 0 17 1 336 0.001534712 0.696982995 0.696982995 3 3 2.64E-04   
R-HSA-73894 DNA Repair 1 296 2 880 0.026722037 0.697125809 0.697125809 14 308 0.027129393 Prpf19 Q9UMS4 
R-HSA-373752 Netrin-1 signaling 0 50 1 322 0.004513858 0.705210945 0.705210945 1 37 0.00325905   
R-HSA-162599 Late Phase of HIV Life Cycle 1 150 0 240 0.013541573 0.715188147 0.715188147 1 74 0.006518101 Rnmt O43148 
R-HSA-975138 
TRAF6 mediated induction of NFkB and MAP kinases upon 
TLR7/8 or 9 activation 0 91 1 312 0.008215221 0.716167453 0.716167453 3 47 0.004139875   
R-HSA-975871 MyD88 cascade initiated on plasma membrane 0 85 1 335 0.007673558 0.728601707 0.728601707 3 57 0.005020699   
R-HSA-168142 Toll Like Receptor 10 (TLR10) Cascade 0 85 1 335 0.007673558 0.728601707 0.728601707 3 58 0.005108782   
R-HSA-168176 Toll Like Receptor 5 (TLR5) Cascade 0 85 1 336 0.007673558 0.72953574 0.72953574 3 58 0.005108782   
R-HSA-5687128 MAPK6/MAPK4 signaling 0 89 1 315 0.008034666 0.731394352 0.731394352 1 40 0.003523298   
R-HSA-5693606 DNA Double Strand Break Response 0 60 1 354 0.005416629 0.735074061 0.735074061 2 43 0.003787545   
R-HSA-399719 Trafficking of AMPA receptors 0 31 1 362 0.002798592 0.735986233 0.735986233 3 4 3.52E-04   
R-HSA-399721 
Glutamate binding, activation of AMPA receptors and synaptic 
plasticity 0 31 1 362 0.002798592 0.735986233 0.735986233 3 9 7.93E-04   
R-HSA-168254 Influenza Infection 0 169 1 245 0.015256838 0.7387043 0.7387043 1 59 0.005196864   
R-HSA-975155 MyD88 dependent cascade initiated on endosome 0 92 1 344 0.008305498 0.742285719 0.742285719 3 62 0.005461112   
R-HSA-168181 Toll Like Receptor 7/8 (TLR7/8) Cascade 0 92 1 344 0.008305498 0.742285719 0.742285719 3 63 0.005549194   
R-HSA-162587 HIV Life Cycle 1 163 0 260 0.014715176 0.742285719 0.742285719 1 112 0.009865234 Rnmt O43148 
R-HSA-8866910 
TFAP2 (AP-2) family regulates transcription of growth factors and 
their receptors 0 13 1 397 0.001173603 0.74756772 0.74756772 2 18 0.001585484   
R-HSA-168138 Toll Like Receptor 9 (TLR9) Cascade 0 96 1 347 0.008666606 0.748437666 0.748437666 3 66 0.005813441   
R-HSA-8862803 
Deregulated CDK5 triggers multiple neurodegenerative pathways 
in Alzheimer's disease models 0 23 2 777 0.002076374 0.750740025 0.750740025 2 22 0.001937814   
R-HSA-8863678 Neurodegenerative Diseases 0 23 2 777 0.002076374 0.750740025 0.750740025 2 22 0.001937814   
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Submitted entities  
found Mapped entities 
R-HSA-8948751 Regulation of PTEN stability and activity 0 69 1 347 0.006229123 0.751029892 0.751029892 2 13 0.001145072   
R-HSA-187037 Signaling by NTRK1 (TRKA) 0 79 1 359 0.007131895 0.753595906 0.753595906 1 55 0.004844534   
R-HSA-166058 MyD88:Mal cascade initiated on plasma membrane 0 95 1 360 0.008576329 0.755292148 0.755292148 3 63 0.005549194   
R-HSA-157118 Signaling by NOTCH 0 205 2 634 0.018506816 0.755798049 0.755798049 2 151 0.013300449   
R-HSA-168928 DDX58/IFIH1-mediated induction of interferon-alpha/beta 0 77 1 357 0.006951341 0.756976932 0.756976932 1 46 0.004051792   
R-HSA-168179 Toll Like Receptor TLR1:TLR2 Cascade 0 98 1 361 0.008847161 0.758650333 0.758650333 3 65 0.005725359   
R-HSA-168188 Toll Like Receptor TLR6:TLR2 Cascade 0 95 1 364 0.008576329 0.758650333 0.758650333 3 65 0.005725359   
R-HSA-181438 Toll Like Receptor 2 (TLR2) Cascade 0 98 1 364 0.008847161 0.761139259 0.761139259 3 67 0.005901524   
R-HSA-168164 Toll Like Receptor 3 (TLR3) Cascade 0 97 1 372 0.008756884 0.762784534 0.762784534 3 60 0.005284947   
R-HSA-9018519 Estrogen-dependent gene expression 0 120 2 742 0.010833258 0.775759024 0.775759024 2 64 0.005637276   
R-HSA-8939211 ESR-mediated signaling 0 126 2 742 0.011374921 0.777502995 0.777502995 2 69 0.006077689   
R-HSA-937061 TRIF(TICAM1)-mediated TLR4 signaling  0 98 1 401 0.008847161 0.786908873 0.786908873 3 57 0.005020699   
R-HSA-166166 MyD88-independent TLR4 cascade  0 98 1 401 0.008847161 0.786908873 0.786908873 3 59 0.005196864   
R-HSA-195253 Degradation of beta-catenin by the destruction complex 0 82 1 388 0.007402726 0.789840766 0.789840766 1 22 0.001937814   
R-HSA-2454202 Fc epsilon receptor (FCERI) signaling 0 217 1 291 0.019590142 0.800487033 0.800487033 2 63 0.005549194   
R-HSA-9006931 Signaling by Nuclear Receptors 0 169 2 746 0.015256838 0.801779989 0.801779989 2 90 0.00792742   
R-HSA-6798695 Neutrophil degranulation 1 480 0 0 0.043333032 0.805946799 0.805946799 1 10 8.81E-04 Pdap1 Q13442 
R-HSA-1257604 PIP3 activates AKT signaling 0 269 2 667 0.024284554 0.809009401 0.809009401 3 85 0.007487008   
R-HSA-4090294 SUMOylation of intracellular receptors 0 31 1 474 0.002798592 0.813862661 0.813862661 1 25 0.002202061   
R-HSA-212165 Epigenetic regulation of gene expression 1 117 0 418 0.010562427 0.816430198 0.816430198 3 33 0.002906721 Ddx21 Q9NR30 
R-HSA-1500620 Meiosis 0 88 1 447 0.007944389 0.823313097 0.823313097 1 15 0.001321237   
R-HSA-5617833 Cilium Assembly 0 201 1 383 0.018145707 0.828755675 0.828755675 2 50 0.004404122   
R-HSA-9006925 Intracellular signaling by second messengers 0 300 2 704 0.027083145 0.838335654 0.838335654 3 104 0.009160574   
R-HSA-195721 Signaling by WNT 0 297 3 1123 0.026812314 0.840270443 0.840270443 6 156 0.013740861   
R-HSA-1474165 Reproduction 0 114 1 452 0.010291595 0.841376749 0.841376749 1 24 0.002113979   
R-HSA-8848021 Signaling by PTK6 0 57 1 513 0.005145798 0.846807459 0.846807459 2 52 0.004580287   
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Submitted entities  
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R-HSA-9006927 Signaling by Non-Receptor Tyrosine Kinases 0 57 1 513 0.005145798 0.846807459 0.846807459 2 52 0.004580287   
R-HSA-166016 Toll Like Receptor 4 (TLR4) Cascade 0 129 1 479 0.011645752 0.847871501 0.847871501 3 94 0.00827975   
R-HSA-112314 Neurotransmitter receptors and postsynaptic signal transmission 0 152 1 457 0.013722127 0.870437722 0.870437722 3 56 0.004932617   
R-HSA-2559583 Cellular Senescence 0 164 1 494 0.014805453 0.874890166 0.874890166 2 88 0.007751255   
R-HSA-168898 Toll-Like Receptors Cascades 0 155 1 527 0.013992958 0.881703694 0.881703694 3 180 0.01585484   
R-HSA-166520 Signaling by NTRKs 0 103 1 572 0.009298547 0.888152779 0.888152779 1 117 0.010305646   
R-HSA-5693532 DNA Double-Strand Break Repair 0 148 1 566 0.013361018 0.891246676 0.891246676 2 106 0.009336739   
R-HSA-5683057 MAPK family signaling cascades 0 302 1 440 0.0272637 0.906820061 0.906820061 1 86 0.00757509   
R-HSA-5619507 Activation of HOX genes during differentiation 0 91 1 619 0.008215221 0.908766466 0.908766466 1 43 0.003787545   
R-HSA-5617472 
Activation of anterior HOX genes in hindbrain development during 
early embryogenesis 0 91 1 619 0.008215221 0.908766466 0.908766466 1 43 0.003787545   
R-HSA-373760 L1CAM interactions 0 120 1 617 0.010833258 0.91556792 0.91556792 1 54 0.004756452   
R-HSA-5688426 Deubiquitination 0 282 1 570 0.025458157 0.927456162 0.927456162 1 77 0.006782348   
R-HSA-8864260 
Transcriptional regulation by the AP-2 (TFAP2) family of 
transcription factors 0 37 1 762 0.003340255 0.932886858 0.932886858 2 44 0.003875628   
R-HSA-202733 Cell surface interactions at the vascular wall 0 245 1 584 0.022117902 0.938356704 0.938356704 1 64 0.005637276   
R-HSA-162906 HIV Infection 1 246 0 649 0.022208179 0.946135197 0.946135197 1 155 0.013652779 Rnmt O43148 
R-HSA-1852241 Organelle biogenesis and maintenance 0 297 1 646 0.026812314 0.947084126 0.947084126 2 86 0.00757509   
R-HSA-5663205 Infectious disease 1 460 1 998 0.041527489 0.950522601 0.950522601 2 320 0.028186382 Rnmt O43148 
R-HSA-8878171 Transcriptional regulation by RUNX1 0 208 1 734 0.018777647 0.955557201 0.955557201 1 132 0.011626883   
R-HSA-112315 Transmission across Chemical Synapses 0 223 1 730 0.020131805 0.960638723 0.960638723 3 104 0.009160574   
R-HSA-449147 Signaling by Interleukins 0 457 3 1650 0.041256658 0.963667754 0.963667754 4 491 0.043248481   
R-HSA-3108232 SUMO E3 ligases SUMOylate target proteins 0 172 2 1440 0.01552767 0.969586635 0.969586635 5 130 0.011450718   
R-HSA-2990846 SUMOylation 0 178 2 1475 0.016069333 0.972728873 0.972728873 5 139 0.01224346   
R-HSA-2262752 Cellular responses to stress 0 405 1 822 0.036562246 0.980699978 0.980699978 2 181 0.015942923   
R-HSA-112316 Neuronal System 0 370 1 799 0.033402546 0.981387061 0.981387061 3 157 0.013828944   
R-HSA-9006934 Signaling by Receptor Tyrosine Kinases 0 471 2 1404 0.042520538 0.98309169 0.98309169 2 628 0.055315776   
R-HSA-8953897 Cellular responses to external stimuli 0 482 1 879 0.043513587 0.987111399 0.987111399 2 251 0.022108694   
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Submitted entities  
found Mapped entities 
R-HSA-1643685 Disease 1 1148 4 2413 0.103638169 0.991627006 0.991627006 5 930 0.081916674 Rnmt O43148 
R-HSA-168249 Innate Immune System 1 1180 2 1539 0.106527038 0.993340332 0.993340332 5 643 0.056637012 Pdap1 Q13442 
R-HSA-1280215 Cytokine Signaling in Immune system 0 771 3 2042 0.069603683 0.994416838 0.994416838 4 624 0.054963446   
R-HSA-3700989 Transcriptional Regulation by TP53 0 367 1 1307 0.033131714 0.995925754 0.995925754 1 258 0.022725271   
R-HSA-422475 Axon guidance 0 556 1 1279 0.050194096 0.997765002 0.997765002 2 296 0.026072404   
R-HSA-1640170 Cell Cycle 0 621 1 1400 0.056062111 0.998218763 0.998218763 1 423 0.037258874   
R-HSA-109582 Hemostasis 0 723 1 1294 0.06527038 0.998880525 0.998880525 1 327 0.02880296   
R-HSA-74160 Gene expression (Transcription) 3 1416 3 3112 0.127832446 0.999127233 0.999127233 15 817 0.071963358 Rnmt;Dicer1;Ddx21 O43148;Q9NR30;Q9UPY3 
R-HSA-73857 RNA Polymerase II Transcription 1 1274 3 2921 0.11501309 0.999524899 0.999524899 5 707 0.062274289 Rnmt O43148 
R-HSA-212436 Generic Transcription Pathway 0 1152 3 2813 0.103999278 0.999842063 0.999842063 4 648 0.057077424   
R-HSA-1266738 Developmental Biology 0 1053 2 2298 0.09506184 0.999850138 0.999850138 4 483 0.042543821   
R-HSA-168256 Immune System 1 2226 4 3053 0.200956938 0.999894313 0.999894313 6 1461 0.128688452 Pdap1 Q13442 
R-HSA-597592 Post-translational protein modification 0 1415 2 2339 0.127742168 0.999962946 0.999962946 6 509 0.044833965   
R-HSA-162582 Signal Transduction 0 2738 5 4507 0.247178839 0.999999929 0.999999929 20 2086 0.183739981   









Supplementary Figure 2. Representative MS/MS spectra for the proteins binding only the mutant transcript. 
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APPENDIX 
